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ABSTRACT OF DISSERTATION
MULTIFUNCTIONAL POTENTIAL THERAPEUTICS TOWARDS OXIDATIVE
STRESS MEDIATED NEURODEGENERATIVE DISORDERS AND MODELS
THEREOF
The studies described in this dissertation were performed with the goal of understanding
the function of antioxidant compounds delivered in vivo to rodents and the implication of the
results towards oxidative stress (OS)-related neurodegenerative disorders with particular
emphasis on Alzheimer’s disease (AD). OS has been implicated in AD and is characterized by
extensive oxidative damage to protein, lipids and DNA. A major thrust of this dissertation work
was to gain insight into antioxidant properties of compounds used in the following studies and
their efficacy as potential therapeutics for treatment of OS-related disorders.
D609, a glutathione (GSH) mimetic is known to trap OH. Radicals, scavenge H2O2 and
reduce the Aβ (1-42)-induced OS and cytotoxicity in neurons. The present dissertation study
showed in vivo protective effect of D609 in synaptosomes and mitochondria isolated from
gerbils against OS mediated by Fe2+/H2O2, AAPH, and Aβ (1-42). Upon intraperitonial (i.p.)
injection of gerbils, D609 showed protection of subsequently isolated brain moieties against OS.
In vivo administration of D609 also modulates brain GSH levels and increases the activity of key
GSH-related enzymes, thereby likely provides a protection against OS.
Adriamycin (ADR), a quinone-containing chemotherapeutic, is known to produce ROS in
heart. Patients under treatment with ADR often show persistent changes in cognitive function
(effect called as chemobrain by patients). Upon i.p. injection, ADR causes OS, increases
expression of multidrug resistant protein-1 (MRP-1) in brain and alters GSH levels and its
related enzyme activities. γ-Glutamyl cysteinyl ethyl ester (GCEE) is known to increase GSH
levels in brain, in vivo. Research reported in this dissertation shows that in vivo GCEE reverses
the ADR-mediated OS in mice brain.
N-acetylcysteine (NAC), a GSH precursor provides the limiting substrate cysteine in
GSH synthesis. Previously, our laboratory showed increased GSH levels post i.p. injection of
NAC and reduces OS in synaptosomes treated with acrolein. The present study showed that
NAC given in drinking water to APP/PS-1 mice, a model of AD can significantly reduce OS.
These results provide a potential therapeutic intervention by antioxidants that can modulate
GSH in OS-mediated neurodegenerative disorders.
KEYWORDS: Oxidative stress, Free radicals, Glutathione, Antioxidants, Alzheimer’s disease.
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Chapter 1
Introduction
The studies presented in this dissertation were completed with the goal of
understanding the role of oxidative stress in various neurodegenerative condition,
specifically focusing on Alzheimer’s disease (AD) and finding efficient therapeutic
towards reducing oxidative stress in these neurodegenerative conditions. Oxidative stress
plays a key role in cause or consequence of various neurodegenerative disorders
including AD (Hensley, Hall et al., 1995; Markesbery and Lovell, 1998; Butterfield,
Drake et al., 2001; Butterfield and Lauderback, 2002), which affects more that 4 million
American and is one of the leading causes of death in United States. There is no efficient
therapy towards treatment of this dreaded disease as of now. Pathologically, AD is
characterized by presence of senile plaques comprising aggregated amyloid β-peptide
(Aβ), neurofibrillary tangles consisting of hyperphosphorylated tau, and synapse loss
(Katzman and Saitoh, 1991; Bosetti, Brizzi et al., 2002). Etiologically, the free radicalmediated oxidative stress hypothesis in AD has gained considerable importance in recent
times (Butterfield, Drake et al., 2001). In AD brain, oxidative stress leads to significant
protein oxidation (Butterfield and Lauderback, 2002), DNA and RNA oxidation
(Mecocci, MacGarvey et al., 1993; Lovell, Gabbita et al., 1999; Nunomura, Perry et al.,
1999; Wang, Xiong et al., 2005), lipid peroxidation (Markesbery and Lovell, 1998), and
neuronal dysfunction or death. Increased production of ROS and RNS along with
depletion in antioxidant capacity is observed in AD and other neurodegenerative
disorders [reviewed in (Beckman and Ames, 1998)], and, consistent with this
observation, α-tocopherol (vitamin E) administration in AD patients delayed its

1

progression when compared to placebo treated control (Sano, Ernesto et al., 1997),
suggesting that oxidative stress-mediated AD pathogenesis can be altered by antioxidant
therapy. In contrast, recent studies with mild cognitive impairment (MCI), arguably the
earliest form of AD, do not support this view (Petersen, Thomas et al., 2005).
Mitochondrial electron transport is a potential source of ROS production (Ide,
Tsutsui et al., 1999). It is now well known that ROS such as superoxide radical anion (O2), hydroxyl radical (OH.), hydrogen peroxide (H2O2), and peroxynitrite (ONOO-)
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contribute to neurodegeneration (Zhang, Dawson et al., 1994; Cadenas and Davies, 2000;
Rego and Oliveira, 2003; Ansari, Ahmad et al., 2004; Tangpong, Cole et al., 2006a;
Tangpong, Cole et al., 2006b). Mitochondrial membrane potential depolarization induces
cytochrome-c release into the cytoplasm and elevates the activity of caspase-3,
suggesting a role for mtDNA-derived mitochondrial dysfunction in AD degeneration
(Bosetti, Brizzi et al., 2002).
Protein oxidation either by ROS or lipid peroxidation products such as 4-hydroxy
2- nonenal results in altered protein structure or loss of protein function, which may lead
to neuronal degeneration (Stadtman and Berlett, 1997). Protein oxidation markers such as
introduction of carbonyl functionality or nitration of tyrosine residues on proteins often
lead to conformation changes in proteins (Subramaniam, Roediger et al., 1997)that often
leads to protein dysfunction (Butterfield and Stadtman, 1997). As a part of this
dissertation, we have used four different oxidants, Fe2+/H2O2 (hydroxyl radical producer)
or 2,2- Azobis (2-amidino-propane) dihydrochloride (AAPH) (alkoxyl and peroxyl
radical producers), Aβ (1-42) and adriamycin (ADR). All these oxidants are known to
cause protein oxidation and lipid peroxidation.
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Major pathological hallmarks of AD include loss of synapses and the presence of
senile plaques and neurofibrillary tangles (Katzman and Saitoh, 1991). The major protein
component of the core of senile plaques is Aβ. The mechanisms involved in the Aβmediated neurotoxicity are unknown, but there is evidence suggesting that oxidative
stress plays a key role (Butterfield, Drake et al., 2001; Butterfield and Lauderback, 2002;
Canevari, Abramov et al., 2004; Butterfield and Boyd-Kimball, 2005). Increased
production of reactive oxygen and nitrogen species such as superoxide and nitric oxide
together with imbalance of antioxidant defenses was observed in neuronal systems after
Aβ(1-42) treatment (Keller, Pang et al., 1997; Yatin, Varadarajan et al., 1999;
Varadarajan, Yatin et al., 2000; Butterfield, 2002). Previous studies from our laboratory
and others reported that Aβ(1-42) induces reactive oxygen species (ROS) production, in
vitro and in vivo protein oxidation, DNA and RNA oxidation and lipid peroxidation
(Keller, Lauderback et al., 2000; Butterfield, 2002; Boyd-Kimball, Castegna et al., 2005).
ADR, a cancer chemotherapeutic drug used to treat solid tumors, is known to
cause side effects in heart and brain (Steinherz, Steinherz et al., 1991; Joshi, Sultana et
al., 2005b; Tangpong, Cole et al., 2006a; Tangpong, Cole et al., 2006b). Cardiomyocytes
treated with ADR have elevated levels of protein oxidation and lipid peroxidation
(DeAtley, Aksenov et al., 1998). Free radical scavengers are known to protect
cardiomyocytes from this effect (DeAtley, Aksenov et al., 1999). Brain isolated from
mice treated peripherally with ADR shows evidence of oxidative damage and
mitochondrial dysfunction (Joshi, Sultana et al., 2005b; Tangpong, Cole et al., 2006a;
Tangpong, Cole et al., 2006b). Patients under long-term treatment with ADR for breast
and lung cancer have shown symptoms of cognitive dysfunction such as lack of
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concentration, forgetfulness inability to multi-task, short term memory impairment and
dizziness, often lasting years after cessation of therapy (Meyers, 2000; Schagen,
Hamburger et al., 2001; Freeman and Broshek, 2002). The side effects in heart limit the
use of ADR in chemotherapy, while the side effects in brain limit the quality of life of
patients undergoing chemotherapy.
Recently, proteomics along with advances in bioinformatics tools have lead to the
identification, characterization and sequencing of proteins in various organisms,
including humans. Using redox proteomics (Dalle-Donne, Scaloni et al., 2006) our
laboratory has shown many key proteins that are oxidized or differentially expressed in
various neurodegenerative conditions or models thereof, such as Alzheimer’s disease
(AD) (Butterfield and Boyd-Kimball, 2004), ageing (Poon, Calabrese et al., 2006),
amylotropic lateral sclerosis (ALS) (Perluigi, Fai Poon et al., 2005; Poon, Hensley et al.,
2005), Parkinson’s disease (PD) (Poon, Frasier et al., 2005), mild cognitive impairment
(MCI) (Butterfield, Poon et al., 2006) and Huntington’s disease (Perluigi, Poon et al.,
2005). Although it is clear from the dissertation research described below that in vivo
ADR increases protein oxidation in brain, it is not clear which specific brain proteins
show increased oxidative damage. We used 2-dimensional gel electrophoresis (2DE)
coupled with mass spectrometric analysis (expression proteomics) to identify proteins
that are differentially expressed and 2DE followed by Western blot coupled with mass
spectrometric analysis (redox proteomics) to identify proteins that are oxidized in brain
isolated from mice injected i.p. with ADR as a part of this dissertation.
Glutathione (GSH) is the most abundant endogenous nonenzymatic antioxidant
present in brain and is found in millimolar concentrations. GSH is an oxyradical
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scavenger, thereby protecting against oxidative damage by free radicals and inhibits lipid
peroxidation and DNA damage (Meister, 1995; Darley-Usmar and Halliwell, 1996; Sies,
1999; Schulz, Lindenau et al., 2000; Hansen, Go et al., 2006). GSH has been implicated
in a wide range of metabolic processes, including cell division, DNA repair, regulation of
enzyme activity, activation of transcription factors, cellular homeostasis and protection
against oxidative damage (Meister and Anderson, 1983). The nervous system is
particularly susceptible to oxidative insults, and dependent on its glutathione defense.
Due to the involvement of oxidative stress-mediated toxicity in neurodegenerative
events and neuronal cell death (Good, Werner et al., 1996; Moreira, Smith et al., 2005),
various experimental approaches for effective protection by antioxidants have emerged.
In addition, antioxidant therapy is being discussed for Parkinson’s disease (Ebadi,
Srinivasan et al., 1996; Prasad, Cole et al., 1999), ischemia (Marczin, El-Habashi et al.,
2003) as well as for AD (Grundman and Delaney, 2002; Gilgun-Sherki, Melamed et al.,
2003) and other age-related disorders (Ames, 2004). Numerous potential free-radical
scavengers have been tested in different experimental paradigms of oxidative stressinduced cell death, such as Vitamin E (Behl, Davis et al., 1992), Vitamin C, melatonin
(Pappolla, Sos et al., 1997), ginko biloba (Smith and Luo, 2003), steroid hormones
(Goodman, Bruce et al., 1996; Behl, Skutella et al., 1997), N-acetylcysteine (Adair,
Knoefel et al., 2001), etc. However, many clinical trials are still unsuccessful because
most of the antioxidants tested are poorly active in crossing the blood brain barrier
(BBB).
Depletion of GSH is known to be involved in several neurodegenerative disorders
(Benzi and Moretti, 1995b; Markesbery, 1997; Butterfield, Castegna et al., 2002a). Many
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attempts have been made to develop antioxidant compounds that can act as precursor of
GSH or mimic GSH as scavenger of reactive oxygen species (ROS) and to maintain the
intracellular redox state. Increase in endogenous GSH levels by dietary or
pharmacological intake of GSH precursor or GSH mimetic protects brain against
oxidative stress (Anderson and Luo, 1998; Butterfield, Drake et al., 2001; Halliwell,
2001). Considering the importance of developing new antioxidant compounds and the
relevance of their application in the treatment of neurodegenerative diseases, in this
dissertation research we focused our attention on glutathione mimetic, tricyclodecan-9-ylxanthogenate (D609), the glutathione precursor, N-acetylcysteine (NAC), and γ-glutamyl
cysteine ethyl ester (GCEE).
In summary, this dissertation research has used synaptosomes, mitochondria and
brain homogenates to address the following hypothesis:
1.

Adriamycin-mediated oxidative stress leads to significant protein

oxidation, lipid peroxidation and alteration in glutathione levels and GSH related enzyme
activities.
2.

γ-Glutamyl cysteine ethyl ester (GCEE), in vivo, increases the GSH level

and reduces the protein oxidation and lipid peroxidation in brain isolated from mice that
were previously injected with GCEE followed by ADR injection when compared to brain
isolated from mice that are previously injected with saline followed by ADR injection.
3.

D609 prevents oxidative stress-mediated by Fe2+/H2O2, AAPH and Aβ(1-

42) in synaptosomes and mitochondria isolated from brain of gerbils previously injected
with D609.
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4.

NAC, delivered via drinking water, decreases oxidative stress, in vivo,

mediated by Aβ(1-42) in the APP/PS-1 mouse, a model of AD.

Copyright © Gururaj Joshi 2006
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Chapter 2
Background
2.1. Oxidative Stress and Neurodegeneration
2.1.1. Overview of oxidative stress
Free radical-mediated oxidative stress has been implicated in numerous disorders,
particularly in neurodegenerative disorders. However, the term “oxidative stress” is often
misinterpreted since the processes involved are poorly understood. A free radical is a
species that contains one or more unpaired electrons. Generally, free radicals are highly
reactive and are known to react vigorously with other less reactive non-radical species to
produce new free radicals in a chain reaction. It is these chain reactions that can lead to
formation of ROS (e.g., superoxide radical O2-. or hydrogen peroxide H2O2) and RNS
(e.g. nitric Oxide radical NO. or dinitrogen tetroxide N2O4) that can further damage
biomolecules such as proteins and lipids (Halliwell, 2001). Reactive species are found
both intracellularly and extracellularly. The source of free radicals could be exogenous
environmental factors such as ionizing radiation, photochemical reactions, among others
or endogenous biochemical and enzymatic processes. Figure 2.1 shows some of the
reactions that lead to the formation of ROS/RNS.
Various antioxidant systems are operational in the human body that inhibits the
activity of ROS/RNS. Some of the examples of antioxidant systems are antioxidant
enzymes (e.g., superoxide dismutase and glutathione peroxidase), antioxidant proteins
(e.g., thioredoxin) and antioxidant molecules (e.g., lipoic acid, GSH, vitamin E), among
others. During disease conditions, either the level of ROS/RNS goes up or antioxidant
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capacity is decreased or both occur at the same time (Halliwell, 2001). This condition is
often described as oxidative stress.
2.1.2. Free radical theory in neurodegeneration
Free radicals in biological systems are produced by metal catalyzed reactions
called Fenton reaction (Hensley, Carney et al., 1994) as shown in Figure 2.1. The
hydroxyl radicals are particularly damaging to proteins, lipids and nearby DNA, reacting
at diffusion-limited rates. O2 is the terminal acceptor of electrons in the electron transport
chain of oxidative phosphorylation processes in mitochondria and forms superoxide
radicals (O2-.). O2-. is relatively stable and being a free radical itself leads to formation of
other ROS. O2 undergoes a four electron reduction process in its conversion to water
(Fridovich, 1978a). Approximately 2% of O2 is leaked out of mitochondria as toxic
intermediates before its conversion to water [reviewed in (Beckman and Ames, 1998)].
Trace amount of iron present in cell reacts with the O2 to form highly toxic hydroxyl
radicals.
O2-.

1.

O2 + 1e- →

2.

O2-. + H2O2

→

3.

Fe2+ + H2O2

→

4.

O2-. + H+

→

5.

O2-. + NO.

→

6.

ONOO- + H+

OH. + O2 + H2O

(Fenton reaction, catalyzed by

Fe2+)
Fe3+ + OH. + OH- (Haber-Weiss reaction)
.

OOH

→

ONOOONOOH

Figure 2.1: Reaction leading to formation of ROS/RNS
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ADR is a quinone-containing anthracyclin drug (Figure 2.2) used in treating
breast cancer and various solid tumors. ADR is known to generate superoxide radical (O2.

) (Deres, Halmosi et al., 2005). A free radical-mediated mechanism of toxicity of ADR is

widely accepted. The quinone in ADR undergoes one electron reduction to generate
semiquinone, which is a free radical, and in the presence of oxygen converts back to
quinone producing O2-., a process known as redox cycling. ADR dependent redox cycling
is likely activated by nitric oxide synthase and cytochrome P 450 (Gutierrez, 2000;
Deres, Halmosi et al., 2005). Toxicity mediated by ADR is known to target mitochondria,
and NADH dehydrogenase, a mitochondrial enzyme, stimulates ADR to form
semiquinone radical and O2-. (Doroshow and Davies, 1986). O2-. radicals are converted to
hydrogen peroxide (H2O2) enzymatically by superoxide dismutase (Fridovich, 1978b).
Superoxide radical can react with H2O2 and other reactive species to generate various
other ROS/RNS (Halliwell and Gutteridge, 1999). All these reactive species target nearby
protein, lipids and other biomolecules leading to neurodegeneration.

Figure 2.2: Adriamycin
The free radical theory of aging proposed by Denham Harman in 1956 (Harman,
1956) states that oxyradicals or ROS, produced during aerobic respiration results in
cumulative damage leading to aging and eventual death. The brain is particularly
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vulnerable to free radical damage and oxidative stress because of following reasons: the
brain has high amount of polyunsaturated fatty acids (PUFA) that are easily oxidizable by
ROS; there is a significant amount of trace metal ions such as iron (II) and copper (I) that
can catalyze various redox reactions to produce ROS; the brain consumes relatively more
oxygen when compared to the other organs; the brain has relatively low antioxidant
levels; the terminally differentiated mature neurons in brain are incapable of dividing and
hence, once damaged are lost leading to neurodegeneration.
2.1.3. Targets of Oxidation
2.1.3.1.

Proteins

Proteins are one of the most important classes of biomolecules that are involved
in almost all physiological and biochemical functions. The genetic message from DNA is
expressed in the form of proteins. Twenty different amino acids form the building block
of proteins, which are composed of amino acids linked to each other by a peptide bond.
An amino acid sequence in the polypeptide chain provides the information of its primary
structure. The tertiary or quaternary structure of proteins can provide important clues
about their respective function. Among others, the important function of some proteins is
biocatalysis as enzymes, cellular functions, such as cell signaling and ligand transport and
as structural proteins. Being one of the most important biomolecules, it is important to
study protein oxidation, its cause and consequences and any modification or degradation
following oxidation.
Proteins are highly sensitive to ROS/RNS-mediated oxidative modifications.
Proteins can also be modified by reactive alkenals produced during ROS-mediated
oxidation of lipids (Esterbauer, Schaur et al., 1991) and glycated proteins (Nagaraj and
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Monnier, 1995). The site of oxidation in proteins is basically amino acid residue side
chains that can lead to fragmentation of the polypeptide chain, and the formation of
protein-protein cross-linked aggregates that often changes the conformation, including
protein unfolding of functional protein and thereby render a protein inactive [Reviewed in
(Butterfield and Stadtman, 1997; Stadtman and Berlett, 1997)]. Possible consequences of
such changes usually increase the exposure of hydrophobic residues of proteins and thus
modify the intrinsic capacity of protein function, such as binding to receptor or ligands,
and interaction with membrane lipid bilayer. Among other consequences, protein
oxidation also leads to trigger the synthesis of certain “stress proteins”, such as heat
shock proteins (HSPs) (Welch, 1992) and/or increases in susceptibility towards
proteolytic degradation that is often preceded by their post translational modification,
such as ubiquitinylation (Davies, Lin et al., 1987).
The two most important oxidative modifications of proteins are formation of
protein carbonyls and nitration of tyrosine residues on protein to form 3-nitrotyrosine
(3NT). The carbonyl functionality can be introduced in proteins by mechanisms, such as
β-scission and peptide bond cleavage following reaction of OH. radical, formed by metal
catalyzed cleavage of H2O2, with any amino acid residue on a protein [reviewed in
(Stadtman and Berlett, 1997)].
The metal ion-catalyzed oxidation of some amino acid residues on proteins leads
to the formation of protein carbonyl derivatives (Levine, Williams et al., 1994). Some of
the examples of protein carbonyl derivatives are formation of glutamic semialdehyde
derivatives of the protein following metal-catalyzed oxidation of proline and arginine
residues of proteins, formation of adipic semialdehyde derivatives following oxidation of
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lysine residues (Amici, Levine et al., 1989; Daneshvar, Frandsen et al., 1997; Requena,
Chao et al., 2001), oxohystidine, etc. Since the formation of protein carbonyl groups is
highly pronounced when compared to other oxidative modifications, determining the
level of protein carbonyl groups become the most important marker of protein oxidation
during various neurodegenerative disorder conditions including Alzheimer’s disease
(AD) (Stadtman and Berlett, 1997).
Nitric oxide (NO.), produced in the metabolism of arginine, reacts rapidly with
O2-. to form the highly reactive peroxynitrite (ONOO-) (Ischiropoulos, Zhu et al., 1992).
A key oxidative stress marker of peroxynitrite (ONOO-)-mediated nitration of tyrosine
residues on proteins is 3NT. CO2 is known to stimulate the (ONOO-)-dependent nitration
of tyrosine residues (Denicola, Freeman et al., 1996). Nitration of tyrosine may prevent
phophorylation of tyrosine thereby preventing various signaling pathway that can have
profound consequences in rendering protein inactive (Ischiropoulos, Zhu et al., 1992).
Elevated levels of 3NT have been found in various neurodegenerative disorders, such as
AD when compared to normal subjects (Hensley, Maidt et al., 1998; Castegna,
Thongboonkerd et al., 2003; Sultana, Poon et al., 2006a). It has also been shown that
several key proteins in AD brain are nitrated when compared to age-matched controls
(Castegna, Thongboonkerd et al., 2003). Nitrated tyrosine residues are also found in
degenerating motor neurons of amyotrophic lateral sclerosis (ALS) subjects (Abe, Pan et
al., 1995) and vulnerable neurons of Parkinson’s disease (PD) (Good, Hsu et al., 1998).
Hence, detection of 3NT may illustrate an important role in pathogenesis of various
neurodegenerative disorders.
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2.1.3.2.

Lipids

Unlike proteins, lipids are non-polymeric biomolecules, which are relatively small
when compared to proteins. Lipids consist of a hydrophilic polar “head” and a
hydrophobic “tail” consisting of acyl chains of variable length. As amphipathic
molecules, lipids tend to aggregate with their hydrophilic head exposed at the lipid-water
interface and their hydrophobic tails sequestered from the aqueous medium. Lipids are
the major component of cell membranes and arranged in a bilayer. The formation of lipid
bilayers is spontaneous and the increased entropy of the aqueous medium serves as the
driving force for this kind of arrangement. This kind of arrangement results in formation
of a hydrophobic domain that limits the permeability of polar species.
Glycerophospholipids are major the class of lipids that make the important part of
cell membrane. These glycerophospholipids consist of glycerol backbone that is
derivatized at the three alcohol functionalities (Figure 2.3). A1 and A2 are acyl chains
derived from fatty acids. Fatty acids can be saturated (palmitic and stearic acid) or
unsaturated (oleic acid, for example). An acyl chain with more than one unsaturation is
known as a polyunsaturated fatty acid (PUFA). Lipids are more susceptible to oxidation
if they have more unsaturation in there fatty acid β-chain and high solubility of nonpolar,
paramagnetic oxygen in bilayer (Esterbauer and Ramos, 1996). High content of PUFA
makes brain more vulnerable to oxidative damage.
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Figure 2.3: Glycerophospholipids. Adapted from (Garrett and Grisham, 1995)
with slight modification.
Lipids undergo peroxidation upon attack by a free radical. The cascades of events
that follow are shown below (Eqn A to D). From the unsaturated sites of lipids, hydrogen
is abstracted that results in formation of carbon-centered lipid radical (L.). L. reacts with
readily available paramagnetic O2 to form a lipid peroxyl radical (LOO.). These peroxyl
radicals propagate the chain reaction by reacting with nearby lipids to form lipid
hydroperoxide (LOOH) and another carbon-centered lipid radical. The chain reaction is
terminated by reaction between two peroxyl radical to form a non radical species and O2.
•

LH + X.

•

L. + O2

•

LOO. + LH

•

LOO. + LOO. →

→
→
→

L. + XH

(Eqn A)

LOO.

(Eqn B)

LOOH + L.

(Eqn C)

Non-radical + O2

(Eqn D)

Adapted from (Esterbauer and Ramos, 1996)
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Lipid peroxidation often leads to formation of toxic reactive alkenal species, such
as 4-hydroxy 2- nonenal (HNE), acrolein (2-propane 1-al) and malenaldehyde. These
alkenals binds to the protein by Michael addition to form covalent adducts with cysteine,
lysine or histidine residues (Figure 2.4) and render them inactive (Butterfield and
Stadtman, 1997). Antioxidant defense systems involving glutathione and its dependent
enzyme glutathione-S-transferase help in clearing these lipids peroxidation products with
the help of a detoxification protein, the multi drug resistance protein-1 (MRP1) (Sultana
and Butterfield, 2004). Growing number of evidences suggest increased lipid
peroxidation in various neurodegenerative disorders, including AD. HNE and acrolein are
known to be increased in AD brain (Markesbery and Lovell, 1998; Lovell, Xie et al.,
2001). Likewise, isoprostanes and neuroprostanes (markers of lipid peroxidation) levels
are increased in AD brain (Montine, Neely et al., 2002). Lipid oxidation can also be
reduced by lipid soluble antioxidants, such as α-tocopherol (Esterbauer and Ramos,
1996).

P1-NH2
1
P1-NH2
1

Free
P1-NH2

Lipid
peroxidation
product

1

Figure 2.4: Reaction of reactive alkenals with histidine, cysteine and lysine to
form Michael adducts. P1 refers to another protein. Figure also shows formation of crosslinked derivatives between proteins. Adapted from (Stadtman and Berlett, 1997).
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2.2.

Alzheimer’s Disease

2.2.1. Overview
AD is an age-associated progressive neurodegenerative disorder characterized by
memory loss, cognitive dysfunction and is the most common form of dementia in elderly
population. More than 4 million Americans are affected by this disease out of which 7-10
% fall in the age group of 65-74 and more 80% are over 85 years of age (Price, Sisodia et
al., 1998). Pathological hallmarks of AD includes brain atrophy due to neuronal and
synapse loss, senile plaques predominantly consisting of fibrillar amyloid β-peptide and
neurofibrillary tangles (NFT) made up of hyperphosphorylated tau, a cytoskeletal protein
(Van Uden, Sagara et al., 2000). Some of the major risk factors for AD are unhealthy
aging in sporadic AD cases, the presence of ApoE-4 alleles in both sporadic and familial
AD (FAD) (Namba, Tomonaga et al., 1991) and genetic factors, such as mutation in
amyloid precursor protein (APP) and presenilin-1 in FAD (Lee, Borchelt et al., 1997)
among others. Growing evidence shows that AD brain is under tremendous oxidative
stress. There is increased protein oxidation [reviewed in (Markesbery, 1997; Butterfield,
Drake et al., 2001)] and lipid peroxidation (Markesbery and Lovell, 1998; Lauderback,
Hackett et al., 2001; Lovell, Xie et al., 2001) in AD brain when compared to aged
matched control, and antioxidant therapy, known to slow progress of AD (Sano, Ernesto
et al., 1997), may reduce this effect.
2.2.2. Aβ(1-42)-mediated oxidative stress in AD
The major protein component of senile plaques is amyloid β-peptide (Aβ). Aβ is
formed upon proteolytic processing (Figure 2.5) by β- and γ-secretases (Haass and De
Strooper, 1999) of the 695 amino acid APP, a ubiquitously expressed transmembrane
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glycoprotein (Glenner and Wong, 1984; Glenner, Eanes et al., 1988). The 40 or 42 amino
acid Aβ peptide is the major component of senile plaques and are toxic to neuronal cells
in culture (Yankner, Duffy et al., 1990). Another secretase involved in APP processing is
α-secretase, the product of which is a large soluble fragment (sAPPα), which is possibly
involved in preventing excitotoxicity by regulating intracellular calcium levels (Mattson,
Cheng et al., 1993). The amyloid β-cascade hypothesis, suitably updated, postulates that
Aβ is likely central to the pathogenesis of AD (Hardy and Allsop, 1991; Smith, Chen et
al., 1999; Selkoe, 2001). The mechanisms involved in the Aβ-mediated neurotoxicity are
unknown, but there is evidence suggesting that oxidative stress plays a key role
(Butterfield, Drake et al., 2001; Butterfield and Lauderback, 2002; Canevari, Abramov et
al., 2004). Growing attention has been focused to investigate the oxidative mechanism of
Aβ toxicity and as well in the search for novel neuroprotective agents. Previous studies
from our laboratory and others reported that Aβ peptide induces in vitro reactive oxygen
species production, protein oxidation, DNA and RNA oxidation and lipid peroxidation
(Butterfield, 2002). Aβ disrupts Ca2+ homeostasis in neurons (Mattson, Barger et al.,
1993), and increased intracellular Ca2+ level can increase sphingomylinase activity to
produce ceramide (Di Paola, Zaccagnino et al., 2004). Activation of the apoptogenic
sphingomyelin-dependent signaling pathway is mediated by ceramide (Di Paola,
Zaccagnino et al., 2004) during oxidative stress to play role in the pathogenesis of
neuronal disease (Michel, Lambeng et al., 1999). Increased production of ROS/RNS,
such as superoxide and nitric oxide together with imbalance of antioxidant defenses was
observed in neuronal systems after Aβ(1-42) treatment (Keller, Pang et al., 1997; Yatin,
Varadarajan et al., 1999; Varadarajan, Yatin et al., 2000; Butterfield, 2002). Recently, our
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laboratory showed the critical role of methionine at the 35th position in Alzheimer’s
Aβ(1-42)-mediated oxidative stress and toxicity [reviewed in (Butterfield and BoydKimball, 2005)]. In addition, Aβ(1-42) leads to oxidative stress in vivo (Yatin,
Varadarajan et al., 1999; Drake, Link et al., 2003; Mohmmad Abdul, Sultana et al.,
2006).

Figure 2.5: Aβ(1-42) generation by APP processing. Adapted from (Butterfield
and Boyd-Kimball, 2005)

2.2.3. APP/PS-1 human double mutant knock-in mice as an AD model
Among the genetic risk factors for AD are included mutations in the presenilin 1
(PS1) gene on chromosome 14 (Sherrington, Rogaev et al., 1995), the presenilin 2 (PS2)
gene on chromosome 1 (Rogaev, Sherrington et al., 1995), or the APP gene on
chromosome 21 (Chartier-Harlin, Crawford et al., 1991). Around 30% FAD cases have
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mutations in PS1 (Schellenberg, 1995). PS1 is part of the γ-secretase complex that
cleaves APP to release Aβ(1-42). Mutations in PS1 has been shown to alter APP
processing to enhance the generation of Aβ(1–42) peptides (Jarrett, Berger et al., 1993).
Synaptosomal proteins from PS-1 mutant mice showed increased oxidative stress and
alteration in synaptosomal protein structure when compared to wild type (LaFontaine,
Mattson et al., 2002).
Several lines of evidence show that Aβ(1–42) plays a central role in AD
pathogenesis and is well documented. Hence, a mouse model was developed by Borchelt
et al., which had FAD mutant human PS1-A246E and a chimeric mouse/human (Mo/Hu)
APP695 harboring a Hu Aβ domain and mutations (K595N, M596L) linked to Swedish
FAD (APP swe) co-expressed (APP/PS-1 human knock-in mouse) (Borchelt, Ratovitski
et al., 1997). The APP/PS-1 mice showed increased Aβ production and accelerated
amyloid deposition in the brain (Borchelt, Ratovitski et al., 1997). Previous studies from
our laboratory have shown that neurons from APP/PS1 have increased basal protein
oxidation and lipid peroxidation, and are more vulnerable to oxidation by various
exogenous oxidants when compared to wild type (Mohmmad Abdul, Sultana et al.,
2006). All these studies suggest that APP/PS1 mice can be used as a model of FAD,
which is characterized Aβ(1–42)-mediated oxidative stress. Indeed, recently completed
initial redox proteomics studies demonstrated elevated oxidized protein in FAD brain
(Butterfield, Perluigi et al., 2006).
2.3.

Synaptosomes

Synaptosomes are membrane bound sac-like structures that contain synaptic
vesicles and mitochondria and nerve terminals isolated from the synapse of neurons.
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During brain tissue homogenization, the synaptosomes break away from axon terminal
under controlled conditions. Synaptosomes were first isolated by Hebb and Whittaker in
1957. The process of isolation of synaptosomes from detached synapses involves
ultracentrifugation and use of a discontinuous sucrose gradient. Synaptosomes are often
used for studies involving synaptic transmission because they have machinery similar to a
functional synapse. They have functional pumps and channels, synaptic protein and
receptors, respond to depolarization, can translocate metabolite and ions and can respire
due to the presence of mitochondria (Whittaker, 1993).
In AD, synaptic membranes are known to show increased oxidative stress
(Hensley, Carney et al., 1994; Hensley, Hall et al., 1995). Synaptosomes were selected
for some of the studies discussed in this dissertation for the following reasons. Synaptic
membranes have receptors for glutamate, which mediate increased intracellular Ca2+ and
exitotoxicity and cause production of ROS/RNS that lead to subsequent protein oxidation
and lipid peroxidation (Hensley, Carney et al., 1994; Mattson, 1996). Elevation in Ca2+
levels also causes changes in mitochondrial potential and lead to production of
superoxide ion radicals. Due to more energy usage in the synaptic region of neuron,
mitochondria are concentrated in these areas of cell. Hence, the synaptic region of
neurons becomes more vulnerable to oxidative stress. Synaptosomes virtually “mimic” a
functional neuron and are easy to isolate.
2.4.

Mitochondria

Mitochondria, often described as the “cellular power plant” and one of the most
important intracellular organelles, occupies up to 25% of the cellular cytoplasm. The
main function of mitochondria is to convert organic material into energy in the form of
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ATP by a process called oxidative phosphorylation. Mitochondria are bound by an inner
and an outer membrane with distinct functions. The mitochondrial matrix, which is the
space enclosed by the inner membrane, has various metabolic enzymes involved in
electron transport and energy metabolism, mitochondrial DNA (mtDNA) among others
(Fig 2.6). The mtDNA is non chromosomal and encodes 13 mitochondrial peptides.
Unlike nuclear DNA, mtDNA lacks histones, hence mtDNA becomes more vulnerable to
ROS-mediated

oxidative

damage

(Cadenas

and

Davies,

2000).

Figure 2.6: Diagram of human mitochondrion (Adapted from wikipedia)
Although it is reported that heart mitochondria contain catalase (Radi, Turrens et
al., 1991), an enzyme that converts toxic H2O2 to water, brain mitochondria lacks
catalase. Also, mitochondria lack the enzyme to synthesize GSH; hence, mitochondrial
GSH depends on dicarboxylate and 2-oxoglutarate carriers, which aid in uptake of GSH
(Chen and Lash, 1998). Mitochondria not only generate energy but are also a source of
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free radicals and ROS/RNS. This, combined with factors described above, makes
mitochondrial protein and lipids more prone to oxidative insult.
Apart from ATP production, the mitochondrion is also involved in variety of
functions, such as regulation of cellular redox state, glutamate-mediated exitotoxicity and
apoptosis. Cytochrome C release from an opened mitochondrial permeability transition
pore upon oxidative insult or compromise in cellular redox state may initiate apoptosis or
programmed cell death. Cytochrome C released into the cytosol forms a complex with
caspase-9 and APAF-1 called an apoptosome, which activates caspase-3. Caspase-3
activation leads to apoptosis (Michel, Lambeng et al., 1999; Adrain and Martin, 2001). In
this dissertation research, mitochondria were used to study the in vivo protective effect of
GSH mimetic, D609, from various oxidants.
2.5.

Glutathione

2.5.1. GSH metabolism and biosynthesis
GSH is a tripeptide, γ-glutamyl-cysteinyl-glycine (IUPAC name: 2-amino-5-[2[(carboxymethyl) amino]- 1-(mercaptomethyl)-2-oxoethyl]amino-5-oxopentanoic acid),
is the most abundant low molecuar weight thiol expressed ubiquitously. Glutathione is
widely recognized as an endogenous nonenzymatic antioxidant, an oxyradical scavenger,
thereby useful in protecting cells against oxidative damage by free radicals and inhibiting
lipid peroxidation and DNA damage (Meister, 1995; Darley-Usmar and Halliwell, 1996;
Sies, 1999; Schulz, Lindenau et al., 2000; Hansen, Go et al., 2006). Glutathione has been
implicated in a wide range of metabolic processes, including cell division, DNA repair,
regulation of enzyme activity, activation of transcription factors, modulation of anion and
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cation homeostasis and protection against oxidative damage (Meister and Anderson,
1983).
The synthesis of GSH from glutamate, cysteine, and glycine is catalyzed by two
cytosolic enzymes, γ-glutamylcysteine ligase (GCL) and GSH synthatase (GS). It is a two
step process and both the steps need ATP as cofactor. The first step involves ligation of
γ-glutamate to cysteine to form γ-glutamylcysteine and the reaction is catalyzed by GCL.
This step is the rate-limiting step. Cysteine generally is present in micromolar
concentration in brain, while glutamate and glycine are present at millimolar levels
(Cooper, 1997). GCL is feedback inhibited by GSH itself. GS catalyzes the addition of
glycine to the limiting substrate γ-glutamylcysteine (Figure 2.7).
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Figure 2.7: GSH synthesis
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2.5.2. GSH and Oxidative stress
GSH is present in 1-3mM concentration throughout the brain (Cooper, 1997),
acting as a high capacity detoxification agent. GSH maintains the cellular redox balance
depending upon the pH of the cellular compartment and is involved in various
biosynthetic processes as well (Schulz, Lindenau et al., 2000). The level of GSH is
reduced in specific regions of the central nervous system in various neurodegenerative
disorders and concomitant increase in oxidized glutathione (GSSG) levels contributes to
the oxidative stress-mediated neuronal cell dysfunction and/or loss in these disorders
(Benzi and Moretti, 1995a; Cooper, 1997). GSH, in conjugation with glutathione
reductase (GR), glutathione peroxidase (GPx), glutathione-S-transferase (GST) and
NADPH provide protection against various toxic electrophiles and hydrogen peroxide
(Watson, Chen et al., 2003) (fig 2.8).
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Usually the ratio of GSH to GSSG is maintained towards more reducing state.
The GSH/GSSG ratio toward the oxidizing state activates several signaling pathways
including protein kinase B, calcineurin, nuclear factor κB, and mitogen- activated protein
kinase (Wu, Fang et al., 2004). Hence, the GSH/GSSG ratio is the important indicator of
cellular redox state. Apart from its function as ROS scavenger, GSH reacts with various
electrophiles, physiological metabolites and xenobiotics and helps clear the toxic
substances. GSH conjugates with NO to form an S-nitrosoglutathione adduct, which is
cleaved by the thioredoxin system to release GSH and NO.
2.5.3. Glutathione Peroxidase
GPx (EC 1.11.1.9) is the enzyme that helps in detoxification by catalyzing the
conversion of H2O2 to H2O and O2 (Figure 2.8). Different GPx isoforms also detoxify
lipid peroxides and alkyl peroxides. The reducing electron comes from GSH. There are
various isoforms of GPx and is present in both cytosol and mitochondria. Since
mitochondria lacks catalase, GPx becomes particularly important in H2O2 clearance.
H2O2, if not cleared, can produce hydroxyl radicals in the presence of Fe2+ or Cu+.
2.5.4. Glutathione Reductase
GR (EC 1.6.4.2) is the enzyme that keeps the GSSG concentration low compared
to GSH and hence helps maintain the redox balance of the cell. GR catalyzes the
conversion of GSSG to GSH with the aid of NADPH as cofactor (Figure 2.8). NADPH
comes from the pentose phosphate pathway. GR is localized in both brain cytosol and
mitochondrial matrix.
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2.5.5. Glutathione-S-Transferase
GST (EC 2.5.1.18) is the key detoxification enzyme that catalyzes the conjugation
of various electrophiles, reactive alkenals, such as 4-hydroxynonenal (HNE) and acrolein,
and xenobiotics to GSH. These GSH-S-conjugates are removed from cells by the
multidrug resistant protein-1 (MRP-1) (Figure 2.9), an ATP binding cassette (ABC)
family protein (Renes, de Vries et al., 2000; Sultana and Butterfield, 2004). MRP-1 is an
integral plasma membrane protein that exports glutathione-S conjugates out of the cell in
an ATP-dependent manner (Nies, Jedlitschky et al., 2004; Conseil, Deeley et al., 2005).
Studies have shown reduced GST activity in brain and ventricular fluids in AD (Lovell,
Xie et al., 1998). Increased expression of GST leads to increased resistance towards
oxidative stress in neuroblastoma cells and provides protection against HNE mediated
toxicity in neuronal cell culture (Lovell, Xie et al., 1998).

GSH

GS –
Conjugate

GST

Alkylating
Xenobiotics,
Electrophiles,
Reactive Alkenals

MRP - 1

Cell

Figure 2.9: Detoxification process involving GST and MRP-1 to remove GSconjugates out of the cell.
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2.6

Superoxide Dismutase

SOD (EC 1.15.1.1) converts superoxide radicals to hydrogen peroxide and
oxygen, the former subsequently is converted to water and oxygen by action of GPx
and/or catalase. SOD has various isoforms depending upon their reaction center, but in
eukaryotes, two isoforms are predominantly found, Cu/ZnSOD in cytosol and MnSOD in
mitochondria. SOD has one of the fastest turn-over numbers among any known enzymes.
Mutation in SOD 1 has been linked with familial ALS. Increased expression of certain
SODs has shown to be protective against oxidative stress in many disease models (Yen,
Oberley et al., 1999). A typical reaction of CuSOD looks like those shown in equations 1
and 2 below:
•

Cu1+-SOD + O2-. + 2H+ → Cu2+-SOD + H2O2

(Eqn 2)

•

Cu2+-SOD + O2-. → Cu1+-SOD + O2

(Eqn 1)

2.7.

Proteomics

Proteomics can be broadly defined as the large-scale study of structure, function
and localization of proteins. This term was coined to make an analogy with genomics,
which is study of genome by gene sequencing. While the genome is static, the proteome
is dynamic and more complex, differing from cell to cell and through biochemical
interaction contantly keeps changing. The proteome can be defined as an entire protein
complement of a biological system at any given time. Protein expression of any organism
or cell differs in different parts of body, at different stages of the life cycle and in
different environmental conditions. With the completion of he human genome, many
researchers are tryng to solve the problem related to biological information that cannot be
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obtained from genenome alone and now examine gene and protein interaction to form
other proteins.
We now know that there are far fewer protein coding genes in the human genome
(Approximately 20 – 30 K genes) than the actual number of protein in human proteome
(> 400 K proteins). Due to this discrepancy, gene expression analysis alone cannot be
used to characterize its protein complement. A major diversity in proteins is due to posttranslational modification. Proteomics plays an important role in characterizing a
particular protein in tissue or organism. Collection of such information offers opportunity
to study mechanisms of disease, is instrumental in discovery of biomarker, such as
markers that indicate a particular disease and often help in elucidating the pathological
events involved in a particular disease condition for therapeutic intervention.
With the technological advances in seperation of complex mixture of protein and
identification by using soft ionization techniques such as matrix assisted laser disorption
and ionization (MALDI) and electrospray ionization (ESI) coupled mass spectrometry,
and advances in bioinformatic tools, it has become possible today to meet proteomic
demand. Protein expression is dynamically regulated in response to internal and external
disturbance

under

various

physiological,

pathological,

developmental

and

pharmacological conditions, thereby resulting in the formation of various posttranslational modifications. ROS/RNS-mediated oxidative stress leads to the most
common post-translational modification, carbonylation. The branch of proteomics that
deals with identification of specifically oxidized protein under a given oxidative stress or
diseased condition is called “Redox Proteomics”. Oxidative stress has been implicated in
many neurodegenerative disorders, including AD. Our laboratory has successfully used
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redox proteomics approaches towards identifying specifically oxidized, nitrated and HNE
bound proteins in various neurodegenerative disorder condition [reviewed in (Butterfield
and Castegna, 2003; Butterfield, 2004; Butterfield, Perluigi et al., 2006; Butterfield, Poon
et al., 2006)]. In this dissertation research, the redox proteomics expertise of our
laboratory was used to identify specifically oxidized and differentially expressed proteins
in brains isolated from mice injected i.p. with ADR.

Copyright © Gururaj Joshi 2006
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Chapter 3
Experimental Procedure
3.1.

Synaptosome Isolation

As previously described in Chapter 2, a series of ultracentrifugation on a
discontinuous sucrose gradient was used for synaptosome isolation. For all the studies
with synaptosomes, male Mongolian gerbils (2-3 months of age), approximately 60-70 g
in size, housed in the University of Kentucky Central Animal Facility in 12-h light/dark
conditions and fed standard Purina rodent laboratory chow ad libitum, were used. The
animal protocols were approved by the University of Kentucky Animal Care and Use
Committee.
Gerbils were decapitated during the light phase and the cortex was isolated on ice.
The synaptosomal isolation procedure has been described elsewhere (Whittaker, 1993).
The isolated cortex was placed in ice-cold 0.32M sucrose isolation buffer containing
4μg/ml leupeptin, 4μg/ml pepstatin, 5 μg/ml aprotinin, 2mM ethylenediaminetetraacetic
acid (EDTA), 2mM ethylene glycol-bistetraacetic acid (EGTA) and 20mM 4-(2hydroxyethyl)-1-piperazine-ethanesulfonic acid (HEPES), 20μg/ml trypsin inhibitor and
0.2mM phenylmethanesulfonyl fluoride (PMSF), pH 7.4. The cortex was homogenized
by 20 passes with a Wheaton tissue homogenizer. The homogenate was centrifuged at
1500 g for 10 min. The pellet was discarded and the supernatant was retained and
centrifuged at 20000 g for 10 min. The resulting pellet was resuspended in approximately
1ml of 0.32M sucrose isolation buffer and layered over discontinuous sucrose gradient
(0.85M pH 8.0, 1.0M pH8.0, 1.18M pH8.5 sucrose solutions each containing 2mM
EDTA, 2mM EGTA and 10mM HEPES) and spun at 82500g for 1h at 4o C. The purified
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synaptosomes were collected from the sucrose gradient interface at the 1.0/1.18M (Fig
3.1) and washed with phosphate buffered saline containing 0.01% (w/v) sodium azide
and 0.2% (v/v) Tween 20 (PBS), twice and centrifuged at 32000 g.

Figure 3.1: Sucrose density gradient for isolation of purified synaptosome

3.2.

Mitochondria Isolation

As discussed in Chapter 2, mitochondria are major source of ROS. The brain
mitochondria were isolated according to the procedure of Sims et al. (Sims, 1990) with
minor modifications. Gerbils were decapitated in light phase and the whole brain was
isolated on ice. Whole brain was homogenized in ice-cold isolation buffer (250 mM
sucrose, 10 mM HEPES, and 1 mM potassium EDTA, pH 7.2, 4 μg/ml leupeptin, 4
μg/ml pepstatin, 5 μg/ml aprotinin 20 μg/ml trypsin inhibitor) with 6 passes of a Wheaton
tissue homogenizer. The homogenate was centrifuged for 3 min at 1,330× g at 4°C, and
the resulting pellet was resuspended in isolation buffer and centrifuged at 1,330× g for 3
min. The supernatants from both spins were combined and spun at 21,200x g for 10 min
at 4°C. The pellet was resuspended in 15% Percoll solution (v/v in isolation buffer) and
layered onto discontinuous Percoll gradients of 23 and 40% Percoll (v/v in isolation
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buffer). Gradients were centrifuged at 30,700× g for 5 min at 4°C. At the 23-40% Percoll
interface, mitochondria were isolated and resuspended in respiration buffer (250 mM
sucrose, 2 mM magnesium chloride, 20 mM HEPES, and 2.5 mM phosphate buffer, pH
7.2) and centrifuged at 16,700× g for 10 min at 4°C. The pellet was resuspended in
respiration buffer, centrifuged at 6,900× g for 10 min at 4°C, and the resulting pellet was
washed in PBS at 6,900× g for 10 min at 4°C.
3.3.

Protein Concentration

The subsequently isolated synaptosomes and mitochondria were assayed for
protein concentration by Pierce BCA method (Bradford, 1976). The principle behind this
assay is to measure the absorbance of Cu1+ complex with bicinchoninic acid (BCA) at
562 nm in a spectrophotometer. The protein-mediated reduction of Cu2+ to Cu1+ in
alkaline solution complexes with BCA to give bluish purple color that has strong
absorbance at 562 nm. Bovine serum albumin (BSA) was used as standard for all the
protein concentration determination studies as a part of this dissertation. Beers law was
used to calculate the concentration of unknown samples.
3.4.

DCF Fluorescence

Oxidative stress and its implication in neurodegenerative disorders can be
understood

by

studying

the

levels

of

intracellular

ROS

generation.

The

dichlorofluorescein (DCF) assay is useful in understanding the intracellular ROS
generation by various oxidants and can be used to test the efficacy of an antioxidant
compound as ROS scavenger. As a part of this dissertation research, DCF assay was used
to study the antioxidant properties of D609 and FAEE as ROS scavenger.
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DCF is sensitive to many oxidative stress-inducing compounds including
hydroxyl radical, ONOO-, AAPH and Aβ (Wang and Joseph, 1999; Keller, Lauderback
et al., 2000; Lauderback, Kanski et al., 2002). Dichlorofluorescine diacetate (DCFH-DA)
is a membrane permeable non-fluorescent compound that crosses the membrane and is
acted upon the intracellular esterases to form dichlorofluorescine (DCFH). DCFH then
reacts with intracellular ROS to form a fluorescent DCF which is measured by
spectrofluorometer (Fig 3.2). To ensure that ester cleavage or efflux of the DCFH, prior
to the reaction with ROS, was not contributing to changes in fluorescence, the oxidationinsensitive dye (C369) was used in similar studies and was used as control.
In this assay, 10 μM DCFH-DA was incubated with synaptosomes (1mg/ml) for
30 minutes at 37o C. Intracellular esterases convert DCFH-DA into anionic DCFH, which
because of its negative charge is trapped in the synaptosomes. Upon oxidation with ROS,
DCFH is converted to DCF, a fluorescent compound. Synaptosomes were spun at 3000 g
in a tabletop Eppendorf centrifuge for 5 minutes at 4o C. Synaptosomes were resuspended
in 500 μl of PBS and loaded in triplicate (100 μl per well) in a black microtiter plate and
fluorescence was measured in a Spectramax microtiter plate reader (λex = 495nm, λem =
530nm) and quantified using softPro max software. To verify that ester cleavage and
efflux of the dye were not contributing to changes in fluorescence, similar studies were
done with an oxidation-insensitive dye carboxy-DCFH-DA (C369).
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3.5.

Protein oxidation (Slot blot)

As discussed in Chapter 2, free radical mediated oxidative stress causes protein
oxidation. Also discussed were the consequences of protein oxidation. The two markers
of protein oxidation are formation of protein carbonyl and nitration of tyrosine residues
on protein by ONOO-.
3.5.1. Protein carbonyl
Levels of protein carbonyl can be estimated by immunochemical method. 2, 4dinitrophenylhydrazine reacts with the carbonyl groups on protein to form a hydrazone
adduct (Schiff base) (Fig 3.3). By using a specific antibody for hydrazone, the carbonyl
level can be estimated. Briefly, sample (5 μl) (normalized to 4mg/ml), 5μl of 12% sodium
dodecyl sulfate (SDS) and 10μl of 10 times diluted 2,4-dinitrophenylhydrazine (DNPH)
from 200mM stock were incubated at room temperature for 20 min. Samples were
neutralized with 7.5μl neutralization solution (2M Tris in 30% glycerol). The resulting
solution was solution was loaded in each well on nitrocellulose membrane under vacuum
using a slot blot apparatus.
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Figure 3.3: Derivatization of protein by DNPH
The assembly of the slot blot apparatus is shown below (fig 3.4). The membrane
was blocked in blocking buffer (3% bovine serum albumin) in phosphate buffered saline
containing 0.01% (w/v) sodium azide and 0.2% (v/v) Tween 20 (PBS) for 1 h and
incubated with a 1:100 dilution of anti DNP polyclonal antibody in phosphate buffered
saline containing 0.01% (w/v) sodium azide and 0.2% (v/v) Tween 20 (PBS) for 1h. The
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membrane was washed three times in PBS and was incubated for 1 h with an anti-rabbit
IgG alkaline phosphatase secondary antibody diluted in PBS in a 1:8000 ratio. The
membrane was washed for three times in PBS for 5 min and developed in Sigma fast
tablets (BCIP/NBT substrate). Blots were dried, scanned with Adobe Photoshop, and
quantified with Scion Image (PC version of Macintosh compatible NIH image).

Sealing
screws
Sample template
Nitrocellulose membrane
Filter paper (3)

Gasket
Supporting plate
Vacuum manifold
Flow valve
Tubing

Figure 3.4: Slot blot apparatus assembly.

3.5.2. 3-Nitrotyrosine
As described in chapter 2, 3NT is a hallmark of ONOO- - mediated protein
damage. The 3NT levels were measured in both synaptosomal and mitochondrial
suspension. A slot blot technique similar to protein carbonyl was employed to
immunochemically detect the levels of 3NT.
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The suspended synaptosomes or mitochondria samples (5 μl) (normalized to
4mg/ml), 5μl of 12% sodium dodecyl sulfate (SDS) and 5μl of modified Laemmli buffer
containing 0.125 M tris base pH 6.8, 4% (v/v) SDS, and 20% (v/v) glycerol were
incubated for 20 minutes at room temperature. Sample (250 ng) was loaded in each well
on nitrocellulose membrane in slot blot apparatus under vacuum. The membrane was
blocked in blocking buffer (3% bovine serum albumin) in phosphate buffered saline
containing 0.01% (w/v) sodium azide and 0.2% (v/v) Tween 20 (PBS) for 1 hr and
incubated with a 1: 2000 dilution of anti-3-nitrotyrosine (3NT) polyclonal antibody in
PBS for 1 h 30 min. The membrane was washed in PBS for 5 min three times after
incubation. The membrane was incubated for 1 h, following washing, with an anti-rabbit
IgG alkaline phosphatase secondary antibody diluted in PBS in 1:8000 ratio. The
membrane was washed for three times in PBS for 5 minutes and developed in Sigma fast
tablets. Blots were dried, scanned with Adobe Photoshop, and quantified with Scion
Image as above.
3.6.

Lipid peroxidation (Slot blot)

As discussed in chapter 2 that lipid peroxidation often leads to formation of
byproduct, such as HNE and acrolein. These reactive alkenals bind to the protein by
Michael addition and inactivates them. A reaction of HNE with cysteine residues on
protein to form a Michael adduct is shown in figure 3.5. Hence, estimating the levels of
protein bound lipid peroxidation product can gives the extent of lipid peroxidation. As a
part of this dissertation research, protein-bound HNE levels were measured to quantify
the extent of lipid peroxidation. The protein-bound HNE levels were measured in both
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synaptosomal and mitochondrial suspension. A slot blot technique similar to protein
carbonyl was employed to immunochemically detect the levels of protein bound HNE.
Sample (5 μl) (normalized to 4mg/ml), 5μl of 12% sodium dodecyl sulfate (SDS)
and 5μl of modified Laemmli buffer containing 0.125 M tris base pH 6.8, 4% (v/v) SDS,
and 20% (v/v) glycerol were incubated for 20 minutes at room temperature. Sample (250
ng) was loaded in each well on nitrocellulose membrane in slot blot apparatus under
vacuum. The membrane was blocked in blocking buffer (3% bovine serum albumin) in
phosphate buffered saline containing 0.01% (w/v) sodium azide and 0.2% (v/v) Tween 20
(PBS) for 1 hr and incubated with a 1: 5000 dilution of anti-HNE polyclonal antibody in
PBS for 1 h 30 min. The membrane was washed in PBS for 5 min three times after
incubation. The membrane was incubated for 1 h, following washing, with an anti-rabbit
IgG alkaline phosphatase secondary antibody diluted in PBS in 1:8000 ratio. The
membrane was washed three times in PBS for 5 min and developed in Sigma fast tablets
(BCIP/NBT substrate). Blots were dried, scanned with Adobe Photoshop, and quantified
with Scion Image as above.
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3.7.

GSH and GSSG assays

As described in Chapter 2, GSH is the most abundant antioxidant present in
millimolar concentration in brain that helps protecting cells against oxidative stress.
Hence, it becomes important to study the levels of GSH during neurodegenerative
disorder conditions involving oxidative stress. As a part of this dissertation research the
GSH and GSSG levels were measured to look for the effect of D609 or GCEE as
modulator of GSH, either by mimicking its property or by increasing its levels.
GSH levels were measured by procedure described by Griffith et al., 1980
(Griffith, 1980). 5, 5’-Dithiobis (2-nitrobenzoic acid) (DTNB) is used for detecting
sulfhydryl groups. The principle behind this assay is enzymatic recycling method, using
GR, for quantification of GSH. GSH reacts with DTNB to form a mixed disulfide and
produces a yellow colored 5-thio-2-nitrobenzoic acid (TNB) that has absorbance at 414
nm in spectrophotometer. The GSTNB complex is reduced by GR to form more TNB
(Fig 3.6). The rate of formation of TNB is directly proportional to concentration of GSH
in the sample. A kit working on this principle was used as a part of some of the
dissertation research. Briefly, the cytosolic fraction isolated from brain homogenates was
precipitated with 10% (w/v) metaphosphoric acid and then centrifuged for 5 min at
5,000g. The supernatants were neutralized with 4M triethanolamine and then analyzed
according to manufacturer instructions. GSH concentration in the samples was calculated
using the kinetic method by measuring the absorbance at 405 nm with a Bio-Tek
Powerwave X Microtiter Plate Reader (Bio, Inc.). A plot of the corrected absorbance vs
the concentration of GSH standards (μM) was utilized to calculate the average
concentration of GSH present in the samples.
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A fluorescence method was also used to measure the level of GSH in one of the
part of this dissertation research. This method is dependent on measuring the floroscence
of GSH complex with O—phthaldehyde (OPT). Determination of GSH was performed
by the method of Hissin and Hilf (Hissin and Hilf, 1976). The reaction mixture
containing 0.1 M sodium phosphate buffer (pH-8.0), 5.0 mM EDTA, 10 μl OPT (1.0
mg/ml) and 10 μl of sample. After incubation for 15 min at room temperature,
fluorescence at emission 420 nm was recorded by excitation at 350nm. For assaying
levels of GSSG, same method was used. Briefly, the samples were incubated first with
0.04 M N-ethyleimide (NEM) for 30 min to interact with GSH present in sample. The
reaction mixture containing 0.1 N NaOH, 5.0 mM EDTA, 10 μl O-phthaldehyde (1.0
mg/ml) and 10 μl of sample. After incubation for 15 min at room temperature,
fluorescence at emission 420 nm was recorded by excitation at 350nm.
3.8.

Enzyme Activities

3.8.1. Glutathione peroxidase

As described in Chapter 2, GPx is the enzyme that converts H2O2 to H2O and O2.
It gets the reducing electrons from the GSH which is converted to GSSG. GPx (EC
1.11.1.9) activity was measured in a 96-well plate reader at 37 °C by a coupled assay
system (Wheeler, Salzman et al., 1990). The reaction mixture consisted of 0.2 mM H2O2,
1.0 mM GSH, 0.14 U of GR, 1.5 mM NADPH, 1.0 mM sodium azide and 0.1M
phosphate buffer (pH 7.4) and 10 μl PMS in a total volume of 200 μl. The enzyme
activity was calculated as nmol NADPH oxidized min− 1 mg− 1 protein.
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3.8.2. Glutathione reductase

GR is the enzyme that catalyzes conversion of GSSG to GSH as described in
Chapter 2. The cofactor for this enzymatic reaction is NADPH. The assay system to
estimate GR (EC 1.6.4.2) activity consisted of 0.1 M phosphate buffer (pH 7.6), 0.5 mM
EDTA, 1.0 mM oxidized glutathione, 0.1 mM NADPH and 10 μl PMS in a total volume
of 200 μl (Carlberg and Mannervik, 1985). The enzyme activity was assayed in a 96-well
plate reader by measuring the disappearance of NADPH at 340 nm and was calculated as
nmol NADPH oxidized min− 1 mg− 1 protein.
3.8.3. Glutathione-S-transferase

GST catalyzes the conjugation of GSH to various reactive alkenals, electrophiles,
and xenobiotics to remove them out of cell. In other word, GST is a detoxification
enzyme and functions as described earlier in Chapter 2. GST (EC 2.5.1.18) activity was
measured in a 96-well plate reader, with the reaction mixture consisting of 0.1 M
phosphate buffer (pH 6.5), 1.0 mM reduced glutathione, 1.0 mM CDNB and 0.1 μl of
PMS in a total volume of 200 μl(Habig, Pabst et al., 1974). The changes in absorbance
were recorded at 340 nm, and the enzymatic activity was calculated as nmol CDNB
conjugate formed min− 1 mg− 1 protein.
3.8.4. Total superoxide dismutase

SOD (EC 1.15.1.1) activity assay reaction consisted of 50 mmol/l glycine buffer,
pH 10.4, and 1mg/ml supernatant protein. The reaction was initiated by the addition of 20
mg/ml solution of (–)-epinephrine and absorbance was measured at 480 nm (Stevens,
Obrosova et al., 2000). SOD activity was expressed as nmol of (–)-epinephrine protected
from oxidation min− 1 mg− 1 protein.
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3.9.

Western blot

This method was used as a part of dissertation research to investigate the
expression

levels

of

various

proteins

involved

in

oxidative

stress-mediated

neurodegenerative disorders. In particular, the GSH and its related enzyme expression
levels were looked at in brain isolated from ADR injected mice. The principle behind this
method is to separate a mixture of protein based on there molecular weight at a specific
voltage on a sodium dodecyl sulfate-polyacrylamid gel (SDS-PAGE). Briefly, Samples
(100 μg) were incubated with sample loading buffer, and protein samples were denatured
and electrophoresed on a 12.5% SDS-PAGE. Proteins were transferred to a nitrocellulose
membrane at 90 mA/gel for 2 h. The blots were blocked for 1h in fresh wash buffer (10
mM Tris-HCl, pH7.5), 150 mM NaCl, 0.05% Tween 20, pH 7.4, containing 3% bovine
serum albumin) and incubated with a 1:1000 dilution of the respective monoclonal
antibody in phosphate buffered saline containing 0.01% (w/v) sodium azide and 0.2%
(v/v) Tween 20 (PBS) for 1h. The membrane was washed three times in PBS and was
incubated for 1 h with an anti-rabbit IgG alkaline phosphatase secondary antibody diluted
in PBS in 1:8000 ratio. The membrane was washed for three times in PBS for 5 min and
developed in Sigma fast tablets (BCIP/NBT substrate).
In all cases non-specific background labeling by secondary antibody was
negligible.
3.10.

Proteomics

2D-PAGE followed by 2D Western blot, coupled with mass spectrometry analysis
of the biological sample in single detectable protein spots, has been widely used to
identify complex protein mixtures. Recent advances in proteomics have improved result
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in identification techniques (Dalle-Donne, Scaloni et al., 2006). As a part of this
dissertation research, this method was used to identify specifically expressed protein and
differentially oxidized protein in brain samples obtained from ADR-injected mice.
3.10.1. Iso-electric focusing (First dimension)

The first dimensional separation of proteins id based on there isoelectric point
(IP). IP is the pH at which the net charge on a protein is zero. The protein samples are
loaded on an immobilized pH gradient (IPG) strip and a potential is supplied. The protein
starts moving on the strip and pH gradient allows the migration of protein to a point until
the net negative charge is balanced by the same amount of positive charge. At this point
the protein becomes neutral and is focused at a particular pH. Due to the neutral charge
proteins does not respond to the applied potential. This process is called isoelectric
focusing. In IEF, protein solubalization in the sample is very important step because the
higher gel friction coefficient might cause protein precipitation if not solubalized. The
sample buffer for IEF consist of urea, which is an effective chaotropic agent, dithiotreitol
(DTT) that is a reducing agent along with non-ionic detergents, such as Triton X and
CHAPS. The voltage applied depends on nature of sample, solubility of protein and
number of IPG strips. Following IEF, the strips are equilibrated with DTT that reduces
disulfide bind and iodoacetamide that derivatizes the cysteine residues.
3.10.2. SDS-PAGE (Second dimension)

Gel electrophoresis on polyacrylamide matrix is an analytical technique that
provides separation of proteins according to the size under applied potential difference.
The technique had been described earlier in this chapter. The only difference being that
instead of protein sample, the IPG strips on which proteins that are previously separated
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based on IP is mounted on top of the gel following equilibration. The separation occurs in
presence of detergent, SDS, that solubalizes and denatures the proteins. Due to presence
of SDS the protein lose their three-dimensional structure and assume a net negative
charge. Hence, unlike IEF the separation is purely based on the molecular migration rate
of a denatured protein on a polyacrylamide gel, which is based on size of a protein. Once
the proteins are separated into single spot on two different dimensions, the gels are
stained with sypro ruby. The result of 2D map provides various information, important
one being comparison between different sample to identify difference in protein
expression (Tilleman, Stevens et al., 2002). The 2D-PAGE can resolve thousand of
protein at once and provide clues even on posttranslational modification. The schematic
representation of 2D-PAGE is shown in Figure 3.7.
The overall process of 2D-PAGE follows the method as described. Samples of the
proteins from brain homogenate were prepared as previously described (Poon, Castegna
et al., 2004). Briefly, for isoelectric focusing, 200μg of protein were applied to a pH 3–10
ReadyStrip™ IPG strip (Bio-Rad), and Linear Gradient (8– 16%) Precast criterion TrisHCl gels (Bio-Rad) were used to separate proteins according to their molecular migration
rate (MrW). Sypro ruby stain was used to stain the gel for ~ 1 h, after which the gels were
placed overnight in deionized water for destaining.
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3.10.3. 2D Western blots

Redox proteomics is the branch of proteomics that is used to identify specifically
oxidized protein in a sample mixture. Our laboratory has used the redox proteomics
method to identify specifically carbonated, nitrated and HNE-bound protein in various
neurodegenerative disorders, including AD [reviewed in (Butterfield, Poon et al., 2006;
Sultana, Perluigi et al., 2006). As described in Chapter 2, ROS/RNS-mediated oxidative
stress leads to the most common post-translational modification, carbonylation. As a part
of this dissertation research, redox proteomics approach was used to identify
differentially carbonylated protein that index protein oxidation in brain protein samples
isolated from ADR-injected mice and were compared with respective control to identify
specifically oxidized protein. Briefly, the proteins are derivatized with DNPH and are
separated on 2D-PAGE as described in earlier section. The proteins separated on 2D gels
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are then transferred on a nitrocellulose membrane (western blotting) and developed
immunochemically. Western blotting for 2D-PAGE was performed as previously
described (Poon, Castegna et al., 2004). Briefly, 200μg of the brain protein were
incubated with 10 mM DNPH solution in 2 N HCl at room temperature (37°C) for 20
min. The gels were prepared in the same manner as for 2DE. The proteins from gels
following the second dimension electrophoresis were transferred onto nitrocellulose
paper (Bio-Rad) using a Transblot-Blot® SD semi-dry Transfer Cell (Bio-Rad) at 15V
for 2 h. The derivatized carbonyl adduct of the brain proteins were detected
immunochemically (Butterfield, 2004).
3.10.4. PD-Quest analysis

Image analysis to identify the protein on gels and blots is done by using PD-Quest
software. The sypro ruby stained gels are scanned and saved in TIF format using a Storm
860 Scanner (Molecular Dynamics, Sunnyvale, CA) and the Western blots developed
using a specific antibody for DNPH derivatized proteins are scanned and saved in TIF
format using Scanjet 3300C (Hewlett Packard, Palo Alto, CA). PD-Quest (Bio-Rad)
software was used for matching and analyzing visualized protein spots among multiple
gels and oxyblots. After matching all the spots, the normalized intensity of each protein
spot from individual gels (or oxyblots) is compared between groups and a protein map is
obtained using statistical analysis.
3.10.5. In-gel digestion

Individual spots that show statistically significant difference between control and
treated sample are excised from the gels and are placed in a protease buffer that favors
peptide extraction and gets absorbed in the gel surface to cleave the protein into several
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peptides in a sequence specific manner. The in-gel digestion was carried out as described
previously (Poon, Castegna et al., 2004). Briefly, the excised protein spots were washed
with ammonium bicarbonate (NH4HCO3) followed by acetonitrile at room temperature.
The gel pieces were digested with 20ng/μl modified trypsin and incubated at 37°C
overnight in a shaking incubator.
3.10.6. Mass spectrometry

Mass spectrometry is the analytical technique that provides generation, separation
and detection of ions formed by fragmentation of a molecule of interest. The ions formed
are then separated according to their mass-charge ratio (m/z) and are detected by a
detector. The m/z of each ion is collected in the form a mass spectrum that provides
structural information of an analyte. A mass spectrometer usually consist of an ion
source, an analyzer that separates ions based on m/z, a detector that quantifies the amount
of ions with same m/z and a computer processor that collects mass spectrum and process
the data generated.
3.10.7. Ion source

As described in Chapter 2, the two types of ion sources used in proteomics study
are ESI and MALDI. As a part of this dissertation study, MALDI was used as ionization
technique. MALDI produces ions by irradiation of the sample embedded in a matrix of
suitable organic compound that mixes with the sample. Sample mixture deposited on a
special metal plate is defined as “solid solution” once the solvent is evaporated from the
matrix. Upon laser irradiation, the matrix sublimes and the gaseous molecule act as
carrier of the analyte into the gas phase. In this way even labile molecules can be ionize
without decomposition. The sample preparation and matrix selection is most important
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part in MALDI. For our sample, 1 μl of α-cyano-4-hydroxy trans-cinnamic acid (10
mg/ml in 0.1% TFA: ACN, 1:1, v/v) was mixed with tryptic digests (1 μl). The mixture
(1 μl) was deposited onto the surface of a fast evaporation nitrocellulose matrix.
3.10.8. Time-of-flight (TOF) analyzer

Each single detectable ion is separated according to m/z following ionization by
MALDI method. This value is measured through a scanner device, which collects the
ions coming from ionization source and transmitted on to a time scale. There are several
kinds of analyzer based on different principles. In brief they can be divided into two
groups: analyzer with flight tube and quadrupole analyzer. MALDI is usually coupled
with a time-of-flight (TOF) analyzer. The ions separation in a TOF analyzer depends on
the fact that the ions with higher mass will reach the detector slower than the smaller
mass ions. Each ion with specific mass will have a specific “time of flight” before
reaching the detector. The relationship between mass of ion and time taken to reach the
detector can be derived as follows. An ion of mass m and charge q = ez accelerated at an
applied voltage V, flying through a distance d with a velocity v, will reach the detector
after time t
T = d/v (Eqn 1)
The kinetic energy K of ion
K = mv2/2 = zeV (Eqn 2)
Combining the two equations we get,
t = √ (m/z) [d2/2ev] (Eqn 3)
It is clear from equation 3 that time to reach detector is directly proportional to
mass of ion i.e., higher mass ions take longer time to reach the detector. As a part of this
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dissertation study, our samples were analyzed in reflectron mode with a TofSpec 2E
(Micromass, UK) matrix-assisted laser desorption ionization-time of flight (MALDITOF) mass spectrometer. The mass axis was adjusted with trypsin autohydrolysis peaks
(m/z 2239.14, 2211.10, or 842.51) as lock masses.
3.10.9. Database searching

The peptide mass fingerprints obtained from MS are characteristic of a particular
protein. The information retrieved by the mass spectrometry, i.e., a list of peptide masses,
is searched against an online database. The Swissprot database is the widest protein
sequence database (Hoogland, Sanchez et al., 1999) to which it is possible to submit a
protein identification request using special “informatics” tools that are freely accessible
through the internet. As a part of this dissertation research, the MALDI spectra used for
protein identification from tryptic fragments were searched against the Swissprot protein
databases using the MASCOT search engine. Peptide mass fingerprinting used the
assumption that peptides are oxidized at methionine residues, are monoisotopic and
cysteine residues in peptide are carbamidomethylated (Butterfield and Castegna, 2003;
Tangpong, Cole et al., 2006a). Up to 1 missed trypsin cleavage was allowed. Window of
error allowed for matching the peptide mass values was set at mass tolerance of 150 ppm.
We used the probability-based Mowse score, which indicates the probability that the
match between the database and a spectrum is a random event to assign a level of
confidence to the identification of specific proteins from the mass spectra. This
probability equals 10(−Mowse

score/10)

. Mowse scores greater than 53 were considered

significant.
The complete flow chart for proteomics is shown in Figure 3.8 below.
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Figure 3.8: Diagram showing sequence of events involved in redox proteomics.
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Chapter 4
Free radical mediated oxidative stress and toxic side effects in brain induced by the
anti cancer drug Adriamycin: Insight into chemobrain
4.1. Overview of the Study

Adriamycin (ADR) is a chemotherapeutic agent useful in treating various cancers.
Application of this drug can have serious side effects in various tissues, including brain,
apart from the known effects such as cardiotoxicity. These effects limit the successful use
of this drug in treatment of cancer. ADR is quinone-containing anthracycline
chemotherapeutic and is known to produce reactive oxygen species (ROS) in heart.
Neurons treated with ADR demonstrate significant protein oxidation and lipid
peroxidation. Patients under treatment with this drug often complain of forgetfulness,
lack of concentration, dizziness (collectively called somnolence or sometimes called
chemobrain). In this study, we tested the hypothesis that ADR induces oxidative stress in
brain. Accordingly, we examined the in vivo levels of brain protein oxidation and lipid
peroxidation induced by i.p. injection of ADR. We also measured levels of the multidrug
resistance-associated protein (MRP1) in brain isolated from ADR-injected mice. MRP1
mediates ATP-dependent export of cytotoxic organic anions, glutathione S-conjugates
and sulphates. The results showed a significant increase in levels of protein oxidation and
lipid peroxidation and increased expression of MRP1 in brain isolated from mice, 72 hrs
post i.p injection of ADR. These results are discussed with reference to potential use of
this redox cycling chemotheraputic agent in the treatment of cancer and its side effects in
brain.
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4.2. Introduction

Free radical mediated oxidative stress has been implicated in many
neurodegenerative disorders (Butterfield and Kanski, 2001). Reactive oxygen species
(ROS) lead to protein oxidation (Hensley, Hall et al., 1995; Stadtman and Berlett, 1997),
lipid peroxidation (Markesbery and Lovell, 1998; Butterfield and Lauderback, 2002),
DNA and RNA oxidation in brain (Butterfield, Drake et al., 2001) and neuronal
dysfunction and death. Oxidation of proteins leads to loss of activity of enzymes critical
for cell functioning, and recently our lab identified some of the critical proteins that are
oxidized in Alzheimer’s disease (AD), by using proteomics (Castegna, Aksenov et al.,
2002a; Castegna, Aksenov et al., 2002b; Lauderback, Drake et al., 2003). ROS
generation hence becomes imperative in understanding oxidative stress and oxidative
stress related disorders.
Adriamycin (ADR) is a cancer chemotherapeutic useful in treating various
cancers with especially good potency in the treatment of patients with solid tumors
(Weiss, Sarosy et al., 1986; Eisenhauer and Vermorken, 1998). ADR is suggested to act
as an antitumor agent by inhibiting DNA replication and DNA synthesis (Cummings,
Anderson et al., 1991) by intercalating into grooves of DNA. Another important
mechanisms of action of ADR involve its interaction with topoisomerase II, which forms
a DNA-cleavable complex (Chuang and Chuang, 1979; Cheng, Cahill et al., 1992). One
of the most accepted mechanisms of action of ADR on tumor cells is generation of free
radicals by enzymatic electron reduction of ADR by variety of oxidase, reductase and
dehydrogenase (Kappus, 1987; Gutierrez, 2000). However, ADR can have serious side
effects in various non-involved tissues, including brain, apart from its known cardiotoxic
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effects (Steinherz, Steinherz et al., 1991). These latter effects limit the successful use of
ADR in cancer treatment. A free radical-mediated mechanism has been proposed to be
responsible for ADR-induced toxicity in heart (DeAtley, Aksenov et al., 1998).
Cardiomyocytes treated with ADR lead to significant protein oxidation and lipid
peroxidation (DeAtley, Aksenov et al., 1998). Free radical scavengers are known to
reduce this effect (DeAtley, Aksenov et al., 1999). ADR also disrupts the mitochondrial
electron transport system in heart tissues (Davies, Doroshow et al., 1983; Doroshow,
1983; Yen, Oberley et al., 1999). Increased expression of manganese superoxide
dismutase (MnSOD) protects complex I against ADR-induced cardiomyopathy (Yen,
Oberley et al., 1999). ADR contains a quinone in its structure ( Chapter 2, fig 2.2), and as
is well known, quinones undergo one-electron reduction to form semiquiones, which are
free radicals (Handa and Sato, 1975; Gutteridge, 1984).
4.3. Purpose of the study

Although there are numerous reports of dizziness, confusion and dementia of
cognitive faction (somnolence) in patients treated with ADR (Schagen, Hamburger et al.,
2001), little has been reported on oxidative stress in brain due to this drug. Therefore, in
this study oxidative stress parameters were studied in brain. Protein carbonyl and 3nitrotyrosine levels (indices of protein oxidation) and 4-hydroxynonenal levels (index of
lipid peroxidation) were determined in brain from mice treated with ADR.
4.4. Experimentals
4.4.1 Animals

For the studies, male mice (2-3 months of age), approximately 30 g in size,
housed in the University of Kentucky Central Animal Facility in 12-h light/dark
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conditions and fed standard Purina rodent laboratory chow ad libitum, were used. The
animal protocols were approved by the University of Kentucky Animal Care and Use
Committee.

4.4.2 Material and Method
4.4.2.1 Chemicals

Doxorubicin HCl (ADR) was purchased from Bedford Laboratories. All other
chemicals were purchased from Sigma-Aldrich (St. Louis, MO), unless stated otherwise.
The protein oxidation detection kit was purchased from Intergen (Purchase, NY) and
primary antibody for HNE, 3NT and the multidrug resistance-associated protein (MRP1)
was purchased from Chemicon International (Temecula, CA).
4.4.2.2 Preparation of brain homogenate

Brains were isolated and dissected following sacrifice by decapitation from mice
treated i.p. with ADR (20mg/kg body weight), 72 h after injection or from saline treated
control mice, and placed in lysing buffer containing 4μg/ml leupeptin, 4μg/ml pepstatin,
5 μg/ml aprotinin, 2mM ethylenediaminetetraacetic acid (EDTA), 2mM ethylene glycolbistetraacetic acid (EGTA) and 10mM 4-(2-hydroxyethyl)-1-piperazine-ethanesulfonic
acid (HEPES), pH 7.4. The dosage and time were chosen based on prior studies (Yen,
Oberley et al., 1999). The brain was homogenized by 20 passes of a Wheaton tissue
homogenizer, and the resulting homogenate was centrifuged at 1500g for 10 minutes. The
pellet (nuclear fraction) was suspended in 1ml PBS. The supernatant was retained and
centrifuged at 20000g for 10 minutes. The pellet (membrane fraction) was suspended in
1ml phosphate buffered saline (PBS) containing 0.01% (w/v) sodium azide and 0.2%
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(v/v) Tween 20 (PBS) and the supernatant (cytosolic fraction) was retained for
fluorescence studies. All the fractions suspended in PBS were washed twice with PBS at
32000g for 10 min. The resulting fractions were assayed for protein concentration by the
Pierce BCA method (Bradford, 1976).
4.4.2.3. Protein Carbonyls

As described earlier in chapter 3, protein carbonyls are markers of protein
oxidation. The method described in section 3.5.1 was used to measure the levels of
protein carbonyl. Briefly, Samples (5μl) of brain homogenate (membrane fraction), 12%
sodium dodecyl sulfate (SDS) (5μl), and 10μl of 10 times diluted 2,4dinitrophenylhydrazine (DNPH) from 200mM stock were incubated at room temperature
for 20 min, followed by neutralization with 7.5μl neutralization solution (2M Tris in 30%
glycerol). This neutralized solution (250ng) was loaded in each well on a nitrocellulose
membrane under vacuum using a slot blot apparatus. The membrane was blocked in
blocking buffer (3% bovine serum albumin) in PBS 0.01% (w/v) sodium azide and 0.2%
(v/v) Tween 20 for 1h and incubated with a 1:100 dilution of anti-DNP polyclonal
antibody in PBS containing 0.01% (w/v) sodium azide and 0.2% (v/v) Tween 20 for 1h.
The membrane was washed in PBS following primary antibody incubation three times at
intervals of 5 min each. The membrane was incubated following washing with an antirabbit IgG alkaline phosphatase secondary antibody diluted in PBS in a 1:8000 ratio for
1h. The membrane was washed for three times in PBS for 5 min and developed in
Sigmafast tablets, [5-bromo-4-chloro-3-indolyl phosphate/Nitro blue tetrazolium
substrate (BCIP/NBT substrate)]. Blots were dried, scanned with Adobe Photoshop, and
quantified with Scion Image (PC version of Macintosh compatible NIH image).
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4.4.2.4. 3NT

As described in chapter 2, 3NT are maker of peroxynitrite-mediated tyrosine
nitration. The method described in chapter 3 section 3.5.2 was used. Briefly, Samples
(5μl) of brain homogenate (membrane fraction), 12% SDS (5μl), and 5μl of modified
Laemmli buffer containing 0.125 M Tris base pH 6.8, 4% (v/v) SDS, and 20% (v/v)
glycerol were incubated for 20 min at room temperature and were loaded (250ng) in each
well on a nitrocellulose membrane in slot blot apparatus under vacuum. The membrane
was blocked in blocking buffer (3% bovine serum albumin) in PBS containing 0.01%
(w/v) sodium azide and 0.2% (v/v) Tween 20 for 1h and incubated with a 1: 2000
dilution of anti-3-nitrotyrosine (3NT) polyclonal antibody in PBS for 1h 30min. The
membrane was washed in PBS for 5 min three times after incubation. The membrane was
incubated, following washing with an anti-rabbit IgG alkaline phosphatase secondary
antibody diluted in PBS in 1:8000 ratios for 1h. The membrane was washed for three
times in PBS for 5 min and developed in Sigmafast tablets. Blots were dried, scanned
with Adobe Photoshop, and quantified with Scion Image.
4.4.2.5. Protein-bound HNE

As described in chapter 2, HNE are lipid peroxidation products that bind to
protein by Michael addition and deactivate the protein. Method described in chapter 3
section 3.6 was used to measure the levels of protein-bound HNE. Briefly, Sample (5μl)
of brain homogenate (membrane fraction), 12% SDS (5μl), and 5μl of modified Laemmli
buffer containing 0.125 M Tris base pH 6.8, 4% (v/v) SDS, and 20% (v/v) glycerol were
incubated for 20 min at room temperature and were loaded (250ng) in each well on a
nitrocellulose membrane in a slot blot apparatus under vacuum. The membrane was

62

blocked in blocking buffer (3% bovine serum albumin) in PBS containing 0.01% (w/v)
sodium azide and 0.2% (v/v) Tween 20 for 1h and incubated with a 1: 5000 dilution of
anti-HNE polyclonal antibody in PBS for 1h 30min. The membrane was washed in PBS
for 5min, three times after incubation. The membrane was incubated, following washing
with an anti-rabbit IgG alkaline phosphatase secondary antibody diluted in PBS in 1:8000
ratios for 1h. The membrane was washed for three times in PBS for 5 min and developed
in Sigmafast tablets. Blots were dried, scanned with Adobe Photoshop, and quantified
with Scion Image.
The specificity was checked for both 3NT and HNE primary antibodies as
described elsewhere (Sultana, Newman et al., 2004). The sample were treated with
primary antibody reacted with free HNE and free 3NT. HNE blot showed very faint, nonspecific binding, which was accounted for background. 3NT blot showed no staining on
blot suggesting that there was no protein bound 3NT (data not shown) signifying the
specificity of primary antibody.
4.4.2.6. Western Blot

As described in chapter 3, section 3.9, western blot is the technique used to
separate protein based on their molecular weight and identification of expression of
protein of interest by immunochemical methods. Briefly, samples (100 μg) were
incubated with sample loading buffer, and protein samples were denatured and
electrophoresed on a 10% SDS-polyacrylamide gel. Proteins were transferred to a
nitrocellulose membrane at 90 mA/gel for 2 h. The blots were blocked for 1h in fresh
wash buffer (10 mM Tris-HCl, pH7.5), 150 mM NaCl, 0.05% Tween 20, pH 7.4,
containing 3% bovine serum albumin) and incubated with a 1:1000 dilution of anti MRP1
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monoclonal antibody in phosphate buffered saline containing 0.01% (w/v) sodium azide
and 0.2% (v/v) Tween 20 (PBS) for 1h. The membrane was washed three times in PBS
and was incubated for 1 h with an anti-rabbit IgG alkaline phosphatase secondary
antibody diluted in PBS in a 1:8000 ratio. The membrane was washed for three times in
PBS for 5 min and developed in Sigma fast tablets (BCIP/NBT substrate).
In all cases non-specific background labeling by secondary antibody was
negligible.
4.4.2.7. Statistical analysis

A two-tailed Student’s t-test was used to assess statistical significance. P values
<0.05 were considered significant for comparison between control and experimental data
sets.
4.5. Results
4.5.1. Protein carbonyls

Protein carbonyls are the most often employed index of protein oxidation
(Stadtman and Berlett, 1997). Treatment of mice with ADR (i.p.) revealed an increase in
protein carbonyls in brain. Figure 4.1 shows the protein carbonyl levels in brain
homogenate extracted from saline-injected mice (control) and brain homogenate
extracted from mice injected with ADR. There was a significant increase in protein
carbonyl levels in brain homogenates from ADR-injected mice when compared to control
(p< 0.001, n=5).
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Figure 4.1: Increased in vivo protein oxidation in brain isolated from mice

previously treated with adriamycin (20mg/kg body weight) 72 hours post i.p injection
compared to brain isolated from saline injected mice. *P< 0. 001, n=5. (434.5 arbitrary
unit was taken as 100% for control)

4.5.2. 3NT

Nitration of tyrosine residue is the marker of attack by RNS, such as
peroxynitrites that may have been formed by free radical mediated oxidative stress (van
der Vliet, Eiserich et al., 1996; Castegna, Aksenov et al., 2002a; Castegna, Aksenov et
al., 2002b). Figure 4.2 shows 3-NT levels in brain homogenate from saline-injected mice
(control) and brain homogenate extracted from mice injected with ADR. There was a

65

significant increase in 3-NT levels in brain homogenate from ADR-injected mice when
compared to control (p< 0.001, n=5).
4.5.3. HNE

Arachidonic acid from phospholipids, on attack of free radicals, produces reactive
alkenals such as HNE (Lauderback, Hackett et al., 2001). HNE binds to protein and
inactivates them by changing their conformation (Subramaniam, Roediger et al., 1997;
Markesbery and Lovell, 1998; Lauderback, Hackett et al., 2001). Figure 4.3 shows the
protein bound HNE levels in brain homogenate extracted from saline injected mice
(control) and brain homogenate extracted from mice injected with ADR. There was a
significant increase in protein bound HNE levels in brain homogenate from ADRinjected mice when compared to control (p< 0.001, n=5).
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Figure 4.2: Increased in vivo 3-Nitrotyrosine levels in brain isolated from mice

previously treated with adriamycin (20mg/kg body weight) 72 hours post i.p. injection,
compared to brain isolated from saline injected mice. *P< 0. 001, n=5. (151.67 arbitrary
unit was taken as 100% for control)

67

protein-bound HNE levles (% Control)

160
Control
ADR
140

*
120

100

80

60
Barin Homogenate

Figure 4.3: Increased in vivo protein bound HNE in brain isolated from mice

previously treated with adriamycin (20mg/kg body weight) 72 hours post i.p. injection,
compared to brain isolated from saline injected mice. * P<0.001, n=5. (526 arbitrary unit
was taken as 100% for control)
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4.5.4. MRP-1 expression

Glutathione conjugates of ADR are exported from cells via the multi drug
resistance-associated proein-1 (MRP-1) (Hipfner, Deeley et al., 1999). Oxidative
modification of MRP-1 would likely lead to accumulation of HNE (Sultana and
Butterfield, 2004), and in AD brain that is under oxidative stress (Butterfield, Drake et
al., 2001; Butterfield and Kanski, 2001; Butterfield and Lauderback, 2002), increased
expression of MRP-1 was observed. Consistent with results in AD brain (Sultana and
Butterfield, 2004), Figure 4.4 shows that MRP-1 expression is significantly elevated in
brain from ADR-injected mice (p< 0.05, n=3).
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Figure 4.4: Plot showing significant increase in MRP1 levels in brain isolated

from mice injected i.p with adriamycin compared to saline injected control mice. *P<
0.05, n=3. (272 arbitrary unit was taken as 100% for control). Also shown in the figure is
a representative western blot showing increased MRP1 expression in brain isolated from
mice injected with adriamycin. (Data Collected in collaboration with Dr. Rukhsana
Sultana)
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4.6. Discussion

ADR is a commonly used cancer chemotherapeutic agent for various solid
tumors. This agent is known to cause serious side effects in heart. However, ADR also
shows side effects in other organs including brain, which has not been studied
extensively. ADR causes cardiomyopathy or congestive heart failure. Due to the presence
of quinone in its structure, a free radical hypothesis for ADR-mediated oxidative stress
and cytotoxicity is widely accepted. In the presence of Fe2+ free radical production
increases (DeAtley, Aksenov et al., 1998). Fe2+ acts as a catalyst for oxidative stress in
neurodegenerative disorders (Stadtman and Berlett, 1997; Kienzl, Jellinger et al., 1999).
An elevated level of iron is seen in several neurodegenerative disorders, including
Alzheimer’s disease (AD). Others showed that there is accumulation of iron in ADRtreated myocardial and neoplastic cells, which leads to increase in oxidative stress (Kwok
and Richardson, 2003). In the presence of an iron chelator the ADR induced oxidative
stress is reduced in cardiomyocytes (Kalyanaraman, Morehouse et al., 1991; Dorr, 1996).
Nitric oxide synthase and cytochrome P450 reductase are some of the
flavoprotein reductases that reportedly activate ADR-dependent redox cycling (VasquezVivar, Martasek et al., 1997). Since mitochondria are target organelles for ADR-induced
cytotoxicity in cardiomyocytes (Sarvazyan, 1996; Konorev, Kennedy et al., 1999; Yen,
Oberley et al., 1999), NADH dehydrogenase, a mitochondrial enzyme, stimulates ADR to
form semiquinone radical and superoxide anion (Davies and Doroshow, 1986).
ADR was shown to induce depletion of glutathione (GSH) in heart tissue (Abd
El-Gawad and El-Sawalhi, 2004). GSH is an endogenous antioxidant that is widely
present in various tissues (Kotamraju, Konorev et al., 2000). The level of glutathione
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peroxidase was also known to be reduced by ADR, and ebselen, a glutathione peroxidase
mimetic, significantly inhibits ADR-induced oxidative stress and apoptosis (Kotamraju,
Konorev et al., 2000). All these studies provide evidence for a free radical mechanism
involved in ADR induced cytotoxicity.
Brain is particularly vulnerable to oxidative stress due to the presence of high
levels of polyunsaturated fatty acids, relatively low antioxidant capacity, the presence of
redox metal ions, and high oxygen utilization (Stadtman and Berlett, 1997). The free
radicals generated in the brain cause damage to proteins, lipids and DNA and
subsequently lead to cellular dysfunction or cell death (Yu, 1994; Butterfield, Drake et
al., 2001; Butterfield and Lauderback, 2002; Castegna, Aksenov et al., 2002a; Castegna,
Aksenov et al., 2002b). Oxidative stress induced by ADR in brain could lead to damage
to proteins critical for cell functioning and may also lead to cell death. Involvement of the
central nervous system in patients treated with ADR was previously shown (Abali and
Celik, 2002). These authors found that patients under treatment with ADR often complain
of forgetfulness, lack of concentration and dizziness (collectively called somnolence). We
demonstrated that ADR increases oxidative stress and causes cell death in neuronal cell
culture (Vide infra). The data presented in this paper shows that ADR in vivo causes
oxidative damage to brain tissue.
Previously we reported oxidized proteins in AD are critical for some vital
functions (Butterfield, Drake et al., 2001; Butterfield and Lauderback, 2002; Castegna,
Aksenov et al., 2002a; Castegna, Aksenov et al., 2002b; Lauderback, Drake et al., 2003).
The results shown in our in vivo study are consistent with our in vitro results, showing
that ADR acts as an oxidant. In the present study there was a significant increase in
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protein carbonyl formation and 3-NT levels, markers of protein oxidation and RNS attack
on tyrosine residues of protein, and in HNE, a marker of lipid peroxidation, in brain
homogenates isolated from ADR-injected mice.
ADR increases superoxide production and enhances formation of nitric oxide
(Vasquez-Vivar, Hogg et al., 1999). As a consequence, the balance between superoxide
and nitric oxide shifts and could lead to formation of peroxynitrite (van der Vliet,
Eiserich et al., 1996; Vasquez-Vivar, Hogg et al., 1999), from which 3-NT can arise
(Lauderback, Drake et al., 2003). We have seen a significant increase in 3-NT levels in
brain homogenate from ADR-treated mice when compared to those from control mice.
This could be due to reaction of peroxynitrite with tyrosine residues on polypeptide
chains. The resulting nitration changes protein conformation (Koppal, Drake et al.,
1999b) and, consequently, alters their function (Lauderback, Drake et al., 2003).
Lipid peroxidation products such as HNE and acrolein are known to be elevated
in brain under oxidative stress in various diseased conditions, including AD (Sayre,
Zelasko et al., 1997; Markesbery and Lovell, 1998; Butterfield, Drake et al., 2001;
Lauderback, Hackett et al., 2001; Butterfield and Lauderback, 2002). These alkenals react
with GSH (Lovell, Xie et al., 1998; Xie, Lovell et al., 1998), and are also known to be
involved in apoptosis, which is correlated with GSH depletion (Mark, Lovell et al.,
1997). In the current study there was a significant increase in protein bound HNE levels
in brain homogenate isolated from ADR-injected mice.
MRP1 is one of the 9-multidrug resistance proteins belonging to the ATP-binding
cassette (ABC) transporter family (Nies, Jedlitschky et al., 2004). MRP1 is an integral
plasma membrane protein, which mediates ATP-dependent export of cytotoxic organic
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anions, glutathione S-conjugates and sulphates (Jedlitschky, Leier et al., 1994;
Jedlitschky and Keppler, 2002). MRP1 is expressed in various human tumors. Oxidized
glutathione (GSSG) has been recognized as a co-substrate for MRP1 (Loe, Almquist et
al., 1996; Loe, Deeley et al., 2000). Translocation of therapeutic drugs into and out of the
CNS mediated by MRP1 has been shown (Huai-Yun, Secrest et al., 1998; Rao,
Dahlheimer et al., 1999), and others have reported expression of MRP1 in cultured
astroglial cells (Decleves, Regina et al., 2000). Involvement of MRP1 in the release of
GSSG from brain astrocytes under oxidative stress has also been reported (Hirrlinger,
Konig et al., 2001). These studies suggest that MRP1 expression is altered during
oxidative stress conditions. Consistent with this suggestion, we reported increased
expression of MRP-1 in AD brain (Sultana and Butterfield, 2004), which is under
oxidative stress (Stadtman and Berlett, 1997; Markesbery and Lovell, 1998; Butterfield,
Drake et al., 2001; Butterfield and Kanski, 2001; Butterfield and Lauderback, 2002;
Castegna, Aksenov et al., 2002a; Castegna, Aksenov et al., 2002b).
Studies have shown that MRP1 does not directly transport chemotherapeutic
agents such as ADR (Hipfner, Deeley et al., 1999). However, its not clear whether
glutathione is either co-transported as a GS-conjugate with ADR or activates MRP1 for
ADR transport (Priebe, Krawczyk et al., 1998; Hipfner, Deeley et al., 1999).
In the current study, we observed a significant increase in the levels of MRP1 in
brain isolated from ADR-injected mice compared to the level of MRP1 in brain isolated
from saline injected control mice. The increased expression could be due to increase in
GSSG because of oxidative stress caused by ADR. Since the mechanism of action of
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MRP1 is not clear yet, the increased expression could also be result of increased GSconjugate of ADR, which is transported out of brain with the help of MRP1.
Patients under prolonged treatment with ADR show symptoms of forgetfulness,
dizziness and loss of memory, a phenomenon commonly called chemobrain (Abali and
Celik, 2002). ADR leads to post-chemotherapeutics problems in children. Often, the
symptoms are noticed approximately 10 yrs after treatment. Our current in vivo studies
show that ADR acts as an oxidant in brain. Our data suggest that ADR or its metabolites
likely enter the brain and cause oxidative stress, which may contribute to chemobrain.
Further studies are necessary to find the oxidative stress mechanism induced by ADR,
which will help in designing therapeutics to reduce the side effects of such anti-cancer
drugs in tissues, including chemobrain.

Copyright © Gururaj Joshi 2006
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Chapter 5
Alteration in glutathione level and glutathione-related enzyme expression and
activity in brain induced by the anti-cancer drug Adriamycin: Implications for
oxidative stress-mediated CNS toxicity
5.1. Overview of study:

Adriamycin (ADR), a chemotherapeutic agent useful in treating solid cancers, has
side effects in various tissues, including brain, apart from its known effects in heart.
These side effects limit the successful use of this drug in treatment of cancer. This
quinone-containing anthracycline chemotherapeutic is known to produce reactive oxygen
species (ROS) in heart. One of the common observations in patients under long-term
treatment with ADR is somnolence, often termed as chemobrain by patients. Previously
our laboratory has shown significant ADR-induced protein oxidation and lipid
peroxidation in cultured neurons and brain, in vitro and in vivo, respectively. ADRinjected mice also showed an increase in MRP-1 levels, a protein that mediates export of
cytotoxic organic anions, glutathione S-conjugates and sulphates. Although, ADR doesn’t
cross blood brain barrier, we recently showed that the toxicity in the central nervous
system (CNS) induced by ADR is mediated by tumor necrosis factor α (TNF- α). Given
the oxidative stress in brain induced in vivo by ADR, in the current study we measured
the levels of brain glutathione (GSH), a major thiol antioxidant, in ADR-injected mice
brain. Accordingly, we examined the in vivo levels of GSH-related enzyme expression
and activity induced by i.p. injection of ADR. The results showed a significantly
decreased total GSH levels, increased levels of glutathione peroxidase (GPx),
glutathione-S-transferase (GST) and glutathione reductase (GR) and an increased activity
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of GPx and GST, but a significant reduction in GR activity in brain isolated from mice,
72 hrs post i.p injection of ADR (20 mg/kg). These results are consistent with brainresident oxidative stress observed in ADR treated mice and consistent with the hypothesis
that in vivo administration of ADR causes alterations in antioxidant capacity in brain.
Sequelae of ADR may be the cause of chemobrain observed in the patients treated with
this redox cycling chemotherapeutic agent. The results suggest that a potential therapeutic
intervention towards increasing the antioxidant capacity in brain might alleviate the side
effects in brain.
5.2. Introduction

Free

radical-mediated

oxidative

stress

has

been

implicated

in

many

neurodegenerative disorders (Hensley, Hall et al., 1995; Stadtman and Berlett, 1997;
Markesbery and Lovell, 1998; Butterfield, Drake et al., 2001; Butterfield and
Lauderback, 2002). Reactive oxygen species (ROS) and reactive nitrogen species (RNS)
produced as a consequence to oxidative stress leads to a significant protein oxidation
(Hensley, Hall et al., 1995; Stadtman and Berlett, 1997), lipid peroxidation (Markesbery
and Lovell, 1998; Butterfield and Lauderback, 2002) and DNA and RNA oxidation
(Butterfield, Drake et al., 2001).
Glutathione (GSH) is a major tripeptide intracellular antioxidant present
ubiquitously in the range of 1-3mM throughout the brain (Cooper, 1997), acting as a high
capacity detoxification agent. GSH maintains the cellular redox balance and is involved
in various biosynthetic processes as well (Schulz, Lindenau et al., 2000). The level of
GSH is reduced in specific regions of the central nervous system in various
neurodegenerative disorders and concomitant increase in oxidized glutathione (GSSG)
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levels contributes to the oxidative stress-mediated neuronal cell dysfunction and/or loss
in these disorders (Benzi and Moretti, 1995a; Cooper, 1997). GSH, in conjugation with
glutathione reductase (GR), glutathione peroxidase (GPx), glutathione-S-transferase
(GST) and NADPH provide protection against various toxic electrophiles and hydrogen
peroxide (Watson, Chen et al., 2003). GST-mediated glutathione-S conjugates are further
acted upon by multi drug resistant protein-1 (MRP-1), an ATP-binding cassette (ABC)
transporter family protein (Nies, Jedlitschky et al., 2004), for their export out of the cell
in an ATP-dependent manner (Sultana and Butterfield, 2004).
Adriamycin (ADR) is a quinone containing cancer chemotherapeutic agent used
to treat various solid tumors. ADR intercalates itself into the grooves of DNA and
inhibits its replication and synthesis (Cummings, Anderson et al., 1991). Although there
are various other mechanism of action of this drug described in literature, enzymatic free
radical generation by action of a variety of oxidases, reductases and dehydrogenases on
ADR is widely accepted (Kappus, 1987; Gutierrez, 2000) and could be contributing
factor towards its toxicity. The quinone in ADR undergoes one electron reduction to
produce a semiquinone, which is a free radical itself, and in the presence of oxygen it
generates superoxide radical and converts itself back to quinone, a process called redox
cycling (Handa and Sato, 1975; Gutteridge, 1984). This property of ADR may be
responsible for its serious side effects in heart. A free radical mediated protein oxidation
and lipid peroxidation has been reported in cardiomyocytes treated with ADR (DeAtley,
Aksenov et al., 1998). Apart from cardiomyopathy, patients under long term treatment
with ADR have complained of dizziness, forgetfulness and lack of concentration
(somnolence) (Meyers, 2000; Schagen, Hamburger et al., 2001; Freeman and Broshek,
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2002). Recently, we showed that systemic administration of ADR induces brain TNF
accumulation, causes neuronal mitochondrial dysfunction and may be responsible for
consequent CNS injury (Tangpong, Cole et al., 2006b). Although the biochemical basis
for ADR-mediated cognitive imbalance is not very well established, ADR is known to
cause increased protein oxidation and lipid peroxidation along with increased MRP-1
expression in brain isolated from ADR-injected mice (Joshi, Sultana et al., 2005b). ADR
cannot cross the blood brain barrier (Bigotte, Arvidson et al., 1982a; Bigotte, Arvidson et
al., 1982b; Tangpong, Cole et al., 2006b) hence, the side effects could be due to ADRmediated TNF-α production via activation of glia, which can further lead to increased
ROS and RNS.
In recent years, GSH and other cellular antioxidant enzyme systems have been
studied with reference to redox signaling mechanisms that function in cell regulation and
growth control. Among others, one such antioxidant enzyme system is superoxide
dismutase (SOD). The primary function of SOD is to convert superoxide radicals to
hydrogen peroxide, which is subsequently converted to water and oxygen by action of
GPx and/or catalase. Increased expression of certain SOD has shown to be protective
against oxidative stress in many disease models (Yen, Oberley et al., 1999). Based on
these studies we tested the hypothesis that in vivo administration of ADR modulates the
GSH antioxidant defense mechanism.
The present study was designed to look at the effect of in vivo administration of
ADR on certain antioxidant enzyme systems with prime focus on modulation of GSH and
its related enzyme expression and activities. The results shown here are discussed with
reference to chemobrain induced by free radical-mediated oxidative stress by ADR.
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5.3. Experimentals
5.3.1. Animals

For the studies, male B6C3 mice (2-3 months of age), approximately 30 g in size,
housed in the University of Kentucky Central Animal Facility in 12-h light/dark
conditions and fed standard Purina rodent laboratory chow ad libitum, were used. The
animal protocols were approved by the University of Kentucky Animal Care and Use
Committee.
5.3.2. Chemicals

Doxorubicin HCl (ADR) was purchased from Bedford Laboratories. All other
chemicals were purchased from Sigma-Aldrich (St. Louis, MO), unless stated otherwise.
The primary antibody for GST and GPx were purchased from Chemicon International
(Temecula, CA). The primary antibody for GR was purchased from Abcam, Inc
(Cambridge, MA). Sodium dodecyl sulfate (SDS) polyacrylamide gels (12.5%) and
transfer membranes were purchased from Biorad (Hercules, CA). The GSH assay kit was
purchased from Cayman chemicals (Ann Arbor, MI).
5.3.3 Preparation of brain homogenate

Brains were isolated and dissected following sacrifice by decapitation from mice
injected intraperitoneally (i.p.) with ADR (20mg/kg body weight), 72 h post i.p. injection,
or from saline treated control mice, and placed in ice cold lysing buffer containing
4μg/ml leupeptin, 4μg/ml pepstatin, 5 μg/ml aprotinin, 2mM ethylenediaminetetraacetic
acid (EDTA), 2mM ethylene glycol-bistetraacetic acid (EGTA) and 10mM 4-(2hydroxyethyl)-1-piperazine-ethanesulfonic acid (HEPES), pH 7.4. The dosage of ADR
and time used were chosen based on prior studies (Joshi, Sultana et al., 2005b). The brain
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was homogenized by 20 passes of a Wheaton tissue homogenizer, and the resulting
homogenate was centrifuged at 1500g for 10 minutes. The pellet (nuclear fraction) was
suspended in 1ml phosphate buffered saline (PBS) containing 0.01% (w/v) sodium azide
and 0.2% (v/v) Tween 20. The supernatant was retained and centrifuged at 20000g for 10
minutes. The pellet (membrane fraction) was suspended in 1ml PBS and the supernatant
(cytosolic fraction) was retained for fluorescence studies, GSH measurement and enzyme
activities. All the fractions suspended in PBS were washed twice with PBS at 32000g for
10 min. The resulting fractions were assayed for protein concentration by the Pierce BCA
method (Bradford, 1976).
5.3.4. GSH assay

The supernatant obtained from homogenate was deproteinated with 10% meta
phosphoric acid. The subsequent deproteinated supernatant was treated with 4M
triethanolmalamine (TEAM) solution. Following TEAM treatment, the GSH assay kit
was used according to the manufacturer’s direction to assay total GSH.
5.3.5. Western blots

Samples (100 μg) were incubated with sample loading buffer, and protein
samples were denatured and electrophoresed on a 12.5% SDS-polyacrylamide gel.
Proteins were transferred to a nitrocellulose membrane at 90 mA/gel for 2 h. The blots
were blocked for 1h in fresh wash buffer (10 mM Tris-HCl, pH7.5), 150 mM NaCl,
0.05% Tween 20, pH 7.4, containing 3% bovine serum albumin) and incubated with a
1:1000 dilution of the respective anti GST, GPx and GR monoclonal antibody in
phosphate buffered saline containing 0.01% (w/v) sodium azide and 0.2% (v/v) Tween 20
(PBS) for 1h. The membrane was washed three times in PBS and was incubated for 1 h
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with an anti-rabbit IgG alkaline phosphatase secondary antibody diluted in PBS in 1:8000
ratio. The membrane was washed for three times in PBS for 5 min and developed in
Sigma fast tablets (BCIP/NBT substrate).
In all cases non-specific background labeling by secondary antibody was
negligible.
5.3.6. Enzyme activity assays
5.3.6.1. Estimation of glutathione-S-transferase activity

GST (EC 2.5.1.18) activity was measured using a reaction mixture consisting of
0.1 M phosphate buffer (pH 6.5), 1.0 mM reduced glutathione, 1.0 mM CDNB and
1mg/ml of supernatant protein (Habig, Pabst et al., 1974). The changes in absorbance
were recorded at 340 nm in a 96 well microtiter plate, and the enzymatic activity was
calculated as nmol of CDNB conjugate formed min− 1 mg− 1 protein.
5.3.6.2. Estimation of glutathione peroxidase activity

GPx (EC 1.11.1.9) was measured using a reaction mixture consisting of 0.2 mM
H2O2, 1.0 mM GSH, 0.14 U of glutathione reductase (GR), 1.5 mM NADPH, 1.0 mM
sodium azide and 0.1M phosphate buffer (pH 7.4) and 1mg/ml of supernatant protein
(Wheeler, Salzman et al., 1990). The changes in absorbance were recorded at 340 nm in a
96 well microtiter plate and enzyme activity was calculated as nmol of NADPH oxidized
min− 1 mg− 1 protein.
5.3.6.3. Estimation of glutathione reductase activity

The GR (EC 1.6.4.2) activity assay reaction mixture consisted of 0.1 M phosphate
buffer (pH 7.6), 0.5 mM EDTA, 1.0 mM oxidized glutathione, 0.1 mM NADPH and
1mg/ml of supernatant protein in a total volume of 200 μl (Carlberg and Mannervik,
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1985). The enzyme activity was assayed in a 96-well plate reader by measuring the
disappearance of NADPH at 340 nm and was calculated as nmol of NADPH oxidized
min− 1 mg− 1 protein.
5.3.6.4. Estimation of total SOD activity

SOD (EC 1.15.1.1) activity assay reaction consisted of 50 mmol/l glycine buffer,
pH 10.4, and 1mg/ml supernatant protein. The reaction was initiated by the addition of 20
mg/ml solution of (–)-epinephrine and absorbance was measured at 480 nm (Stevens,
Obrosova et al., 2000). SOD activity was expressed as nmol of (–)-epinephrine protected
from oxidation min− 1 mg− 1 protein.
5.4. Statistical analysis

A two-tailed Student’s t-test was used to assess statistical significance. P values
<0.05 were considered significant for comparison between control and experimental data
sets.
5.5. Results
5.5.1. GSH assay

GSH levels in a system are an indication of its cellular redox balance. A more
reduced to oxidized ratio is indication of healthy state, whereas a reduction in total GSH
levels may be an indication of redox imbalance or oxidative stress (Watson, Chen et al.,
2003). Figure 5.1 shows a significantly reduced GSH level in brain isolated from ADRinjected mice when compared to saline-injected control (p < 0.05, n = 5).
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Figure 5.1: Brain total GSH level in saline-injected and ADR-injected mice, 72 h

post i.p. injections. A significant reduction in GSH level is seen in brain isolated from
ADR-injected mice when compared to control. * p < 0.05, n = 5. The data are presented
as mean ± SEM expressed as percentage of control.

5.5.2. Western blot analysis

Figure 5.2 shows the western blots and representative plots of GST, GPx and GR
in brain isolated from mice injected i.p. with saline or ADR. GAPDH is used as a loading
control. Plots of normalized entity of each enzyme are shown in figure 5.3. As evident
from the figures, a significant increased expression of GST, GPx and GR in brain isolated
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from ADR-injected mice when compared to saline-injected control is observed (p < 0.05,
n = 5).

GPx
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GR

GAPDH

Control

ADR

Figure 5.2: Representative Western blots of brain GPx, GST and GR 72 h post

i.p. injection of saline or ADR in mice. GAPDH is used as a loading control.
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Figure 5.3: Representative plot of GST, GPx and GR levels in saline-injected and

ADR-injected mice brain, 72 h post i.p. injections. A significant increase in GST, GPx
and GR level is seen in ADR-injected mice brain when compared to control. * p < 0.05, n
= 5. The data are presented as mean ± SEM expressed as percentage of control.
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5.5.3. Enzyme activities

Table 5.1 shows the activity of GSH related enzymes GST, GPx and GR along
with the activity of total SOD. There was a significant increase in activity of GPx,
whereas a significantly reduced activities of GST, GR and SOD in brain isolated from
ADR-injected mice when compared to saline-injected control (p < 0.05, n = 5 in each
case).

Enzyme

Brain from salineinjected Group

Brain from ADRinjected Group

GST (nmol CDNB
conjugate formed
min−1 mg−1 protein)

15.6 ± 0.3

12.1 ± 0.3 *

GPx (nmol NADPH
oxidized min−1 mg−1
protein)

83.7 ± 0.8

96.9 ± 0.7 *

GR (nmol NADPH
oxidized min−1 mg−1
protein)

34.9 ± 1.6

27.16 ± 2.0 *

SOD (nmol of (–)epinephrine protected from
oxidation min− 1 mg− 1
protein.

9.4 ± 1.6

7.1 ± 3.1 *

Table 5.1: GSH-related enzymes and SOD activity in brain homogenate obtained

from mice, 72 h post i.p. injection of saline (control) or ADR. The data are presented as
mean ± SEM (n=5), * p < 0.05.

87

5.6. Discussion

GSH is the major non-protein thiol antioxidant used in the redox balance of cells
and cellular environments. Any kind of imbalance in the ratio of reduced to oxidized
GSH may both index and cause oxidative stress that leads to significant protein oxidation
and lipid peroxidation. GSH is known to protect against cellular free radical-mediated
oxidative damage by functioning as an oxyradical scavenger thereby reducing lipid
peroxidation (Meister, 1995; Darley-Usmar and Halliwell, 1996; Sies, 1999; Schulz,
Lindenau et al., 2000; Hansen, Go et al., 2006). GSH, apart from its endogenous
antioxidant activity, also has role in wide range of metabolic processes such as activation
of transcription factors, DNA repair, enzyme activity regulation and biosynthetic
processes (Meister and Anderson, 1983).
The nervous system is particularly susceptible to oxidative insults because of high
level of polyunsaturated fatty acids, high oxygen consumption and low antioxidant
capacity. Hence, the brain is dependent on glutathione defense mechanism as a primary
endogenous neuroprotectant. GSH helps neurons in detoxification of HNE and other
reactive alkenals and damage by peroxynitrite (Mark, Lovell et al., 1997; Koppal, Drake
et al., 1999a). HNE, acrolein and other lipid peroxidation product are known to cause
damage to proteins and other biomolecules in AD brain (Sayre, Zelasko et al., 1997;
Lovell, Xie et al., 1998; Lauderback, Hackett et al., 2001). These alkenals form an
immediate substrate for GSH (Xie, Lovell et al., 1998) consequently, GSH depletion may
lead to apoptosis initiated by lipid peroxidation products (Mark, Lovell et al., 1997). In
the current study, reduced level of brain GSH was found in ADR-injected mice when
compared to saline-injected control (Fig. 5.1). We previously reported an increased
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protein carbonyls, HNE and 3NT levels in brain isolated from ADR-injected mice (Joshi,
Sultana et al., 2005b). We hypothesized that a reduced level of GSH play a role in the
observed brain protein oxidation and increased reactive alkenal in ADR-injected mice.
Oxygen is the terminal acceptor of electrons in the electron transport chain that
subsequently produces superoxide radical. Superoxide radicals are formed by action of
enzyme NADPH oxidase (NOX) on oxygen (Babior, 1999). Superoxide radicals are also
increased by ADR that enhances production of NO (Vasquez-Vivar, Hogg et al., 1999).
SOD catalyses the dismutation of superoxide free radicals to form H2O2. GPx and GR
provide protection to neurons from oxidative stress at the expense of GSH (Sies, 1999;
Hansen, Go et al., 2006). GPx converts the H2O2 to H2O and O2. The reducing electrons
are provided by GSH which is converted to its disulfide GSSG. GR converts GSSG back
to reduced GSH by utilizing NADPH as a cofactor. NADPH also reduces peroxynitrite,
thereby providing enzymatic defense against peroxynitrite (Sies, Sharov et al., 1997).
GST play a role in neuroprotection by catalyzing the conjugation of GSH to HNE, a lipid
peroxidation product, and, formation of other glutathione-S conjugates with various toxic
electrophiles. These conjugates are then cleared from neurons by the action of the MRP-1
(Sultana and Butterfield, 2004). Both GST and MRP-1 are oxidatively modified and
likely dysfunctional in AD brain (Sultana and Butterfield, 2004). We previously reported
increased expression of brain MRP-1 in ADR-injected mice (Joshi, Sultana et al., 2005b).
In the present study we found a significantly increased expression of GST, GPx and GR
(Fig 5.2 and 5.3). Although increased protein expression is not always indicative of the
activity of these enzymes, the activity of GST, GR and SOD in brain isolated from ADRinjected mice is significantly decreased whereas a significant elevated activity of GPx is

89

observed. A reduced activity in GR may result in increased GSSG levels, thereby altering
the GSG/GSSG ratio towards more oxidized form, leading to oxidative stress. A reduced
GST activity would lead to less clearance of toxic substances, which may contribute to
the observed increased protein-bound HNE levels in brain from ADR-injected mice. A
reduced SOD activity leads to an increase in superoxide radical levels. Superoxide
radical, H2O2 and NO can react directly or indirectly with each other and produce several
other toxic ROS and RNS (Halliwell and Gutteridge, 1999), which may contribute to the
oxidative stress observed.
In vivo ADR induces TNF-α production, and circulating TNF-α in brain triggers

apoptotic pathways along with production of ROS/RNS. A neutralizing antibody against
TNF eliminates these effects (Tangpong, Cole et al., 2006b). Injection of ADR causes
significant increase in protein oxidation and lipid peroxidation (Joshi, Sultana et al.,
2005b). The observed elevated oxidative stress could be either a cause or consequence of
glutathione depletion and alteration in various antioxidant enzyme defense systems and
TNF-mediated processes. Cognitive dysfunction in patients undergoing chemotherapy is
elevated (Meyers, 2000; Schagen, Hamburger et al., 2001; Freeman and Broshek, 2002).
We suggest that oxidative stress in brain could contribute to somnolence observed in
some patients undergoing ADR or other chemotherapy. The current study is the first to
show the role of GSH in ADR-mediated chemobrain. The results suggest that increment
in brain GSH levels and the activity of its dependent enzymes (GST, GPx and GR) could
be a potential therapeutic approach towards eliminating the observed cognitive
impairment in patients undergoing chemotherapy. Studies to determine if such an
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approach to prevent chemobrain may be useful, without compromising the
chemotherapeutic properties of ADR are in progress.

Copyright © Gururaj Joshi 2006
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Chapter 6
Proteomic identification of differentially expressed proteins and redox proteomic
identification of specifically oxidized proteins in brain isolated from adriamycininjected mice: Potential targets for therapeutics.
6.1. Overview of study

The central nervous system (CNS) toxicity mediated by the anti-cancer drug
adriamycin (ADR) has gained considerable importance recently. ADR is a
chemotherapeutic agent used in treatment of solid tumors. Its toxic side effects in heart
and brain limit successful use of this drug in treating cancer. Many patients report
symptoms

of

somnolence

(Chemobrain)

following

ADR

therapy.

Systemic

administration of ADR leads to significant protein oxidation, lipid peroxidation and
glutathione (GSH) depletion along with alteration in GSH dependent enzyme activities in
brain. The observed protein oxidation and lipid peroxidation was reduced by in vivo
administration of GSH precursor, γ-glutamyl cysteine ethyl ester (GCEE). Intraperitoneal (i.p.) injection of ADR induces production of tumor necrosis factor-α (TNF- α)
and causes mitochondrial dysfunction, leading to apoptosis in brain. Inducible nitric
oxide synthase is involved in ADR-mediated CNS injury, since brain mitochondria
isolated from iNOS knock-out mice previously treated with ADR are not dysfunctional
when compared to mitochondria isolated from ADR-injected wild type mice. ADR does
not cross the blood brain barrier (BBB), but ADR-induced cognitive dysfunction by
cytokine-mediated pathways appear prominent. Free radical-mediated oxidative stress
caused by ADR damages biomolecules such as proteins and membrane lipids, which
might lead to neuronal loss followed by cognitive impairment. These damaged
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biomolecules lead to antioxidant depletion, mitochondrial dysfunction and loss of
function of important metabolic protein. Although ADR-induced CNS toxicity and
chemobrain are increasingly recognized, the biochemical basis behind these effects is not
clear yet. The current study was aimed at using expression proteomics followed by
parallel redox proteomics for unbiased identification of brain proteins that are
differentially expressed or specifically oxidized. The results are discussed with reference
to ADR-mediated CNS toxicity, cognitive dysfunction and chemobrain.
6.2. Introduction

Free

radical-mediated

oxidative

stress

has

been

implicated

in

many

neurodegenerative conditions. Impaired function of central nervous system (CNS) and its
toxicity is caused, in part, by free radical-mediated protein oxidation (Stadtman and
Berlett, 1997; Butterfield and Kanski, 2001), lipid peroxidation (Markesbery and Lovell,
1998), DNA/RNA oxidation (Wang, Xiong et al., 2005) and neuronal dysfunction or
death. In most of the neurodegenerative conditions, free radicals react with brain
biomolecules such as proteins and lipids, resulting in cognitive decline (Butterfield and
Lauderback, 2002). Mitochondria, in particular, play an important role in free radical
generation. Mitochondrial dysfunction along with damaged mitochondrial enzymes lead
to increased free radical generation and increased oxidative stress (Miquel, Economos et
al., 1980). Although mitochondria are a source of free radicals, they also become
immediate targets for free radical-mediate oxidative stress thereby, causing energy
metabolism dysfunction along with triggering apoptotic signals, leading to neuronal death
(Ventura, Genova et al., 2002; Sastre, Pallardo et al., 2003).
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Adriamycin (ADR), a cancer chemotherapeutic drug used in treating various solid
tumors in breast and lung cancer, has shown various side effects in heart and brain. Apart
from its known mechanism of action of intercalating itself into the grooves of DNA and
inhibiting DNA replication (Cummings, Anderson et al., 1991), a free radical-mediated
mechanism of toxicity involving enzymatic electron reduction of ADR by variety of
oxidases, reductases and dehydrogenases, is widely accepted (Kappus, 1987; Gutierrez,
2000). The quinone-containing ADR is known to cause cardiomyopathy, a serious side
effect that limits its successful use in treating cancer (Steinherz, Steinherz et al., 1991).
Cardiomyocytes treated with ADR show significant protein oxidation and lipid
peroxidation, and antioxidants are known to prevent these effects (DeAtley, Aksenov et
al., 1998; DeAtley, Aksenov et al., 1999). Apart from its known side effects in heart,
ADR also induces cognitive decline (chemobrain) in many patients, often lasting years
following treatment with this drug (Meyers, 2000; Schagen, Hamburger et al., 2001).
ADR does not cross the blood brain barrier (BBB) (Bigotte, Arvidson et al., 1982a;
Bigotte, Arvidson et al., 1982b). In vivo ADR causes significant elevation in markers of
protein oxidation and lipid peroxidation and increased expression of multidrug resistant
protein-1 (MRP-1) in brain (Joshi, Sultana et al., 2005b). ADR also causes glutathione
(GSH) depletion and alteration in expression and activities of various GSH related
enzymes in brain (Joshi, Sultana et al., 2006). In vivo delivery of GSH precursor, γglutamyl cysteine ethyl ester (GCEE), modulated brain oxidative stress induced by ADR
(Joshi, Hardas et al., 2006).
Involvement of mitochondria and mitochondrial enzymes has been reported in
ADR mediated toxicity in heart and brain (Yen, Oberley et al., 1999; Tangpong, Cole et
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al., 2006a; Tangpong, Cole et al., 2006b). Manganese superoxide dismutase (MnSOD), a
key mitochondrial enzyme is involved in catalyzing the dismutation of superoxide
radicals to hydrogen peroxide. Increased expression of MnSOD protects mitochondrial
complex 1 against ADR-induced cardiomyopathy (Yen, Oberley et al., 1999). We
recently showed that systemic administration of ADR caused mitochondrial dysfunction
in brain by inducing tumor necrosis factor-α (TNF- α), which leads to various apoptotic
pathways (Tangpong, Cole et al., 2006b). Inducible nitric oxide synthase, leads to NO,
plays a significant role in ADR-induced CNS toxicity, since iNOS knock-out mice
treated with ADR show no brain mitochondrial dysfunction (Tangpong, Cole et al.,
2006a). An antibody against TNF prevented the mitochondrial dysfunction and apoptosis
mediated by ADR in vivo (Tangpong, Cole et al., 2006a; Tangpong, Cole et al., 2006b).
Based on these previous studies, we hypothesized that in vivo ADR cause oxidative stress
in brain and ADR-mediated CNS toxicity is involved in chemobrain and subsequent
cognitive decline in patients treated with this drug.
6.3. Purpose of the study

Recently, proteomics along with advances in bioinformatics tools has lead to the
identification, characterization and sequencing of proteins in various organisms,
including humans. Using redox proteomics (Dalle-Donne, Scaloni et al., 2006) our
laboratory has shown many key proteins that are oxidized or differentially expressed in
various neurodegenerative conditions or models thereof, such as Alzheimer’s disease
(AD) (Butterfield and Boyd-Kimball, 2004; Tangpong, Cole et al., 2006a), ageing (Poon,
Calabrese et al., 2006), amylotropic lateral sclerosis (ALS) (Poon, Hensley et al., 2005),
Parkinson’s disease (PD) (Poon, Frasier et al., 2005), mild cognitive impairment (MCI)
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(Butterfield, Poon et al., 2006) among others. Although it is clear that in vivo ADR
increases protein oxidation in brain, it is not clear which specific brain proteins show
increased oxidative damage. In the current study we used 2-dimensional gel
electrophoresis (2DE) coupled with mass spectrometric analysis (expression proteomics)
to identify proteins that are differentially expressed and 2DE followed by western blot
coupled with mass spectrometric analysis (redox proteomics) to identify proteins that are
oxidized in brain isolated from mice i.p injected with ADR.
6.4. Experimentals
6.4.1. Chemicals

All the chemicals used were purchased from Sigma-Aldrich (St. Louis, MO),
unless stated otherwise. Doxorubicin HCl (ADR) was purchased from Bedford
Laboratories. All the 2DE gels, stains, buffers and Western blot material were purchased
from Bio-Rad (Hercules, CA). The protein oxidation detection kit was purchased from
Intergen (Purchase, NY). Trypsin was purchased from Promega (Madison, WI).
6.4.2. Animals

For the studies, male mice (2-3 months of age), approximately 30 g in size,
housed in the University of Kentucky Central Animal Facility in 12-h light/dark
conditions and fed standard Purina rodent laboratory chow ad libitum, were used. The
animal protocols were approved by the University of Kentucky Animal Care and Use
Committee. The animals were divided into 2 groups. One group received saline and other
group received ADR (20mg/kg body weight). 72 h post i.p. injection the mice were
sacrificed, brains were isolated and flash frozen in liquid nitrogen till further studies. The
dosage and time were chosen based on prior studies (Joshi, Sultana et al., 2005b).
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6.4.3. Preparation of brain homogenate

Brains obtained from mice were thawed and placed in lysing buffer containing
4μg/ml leupeptin, 4μg/ml pepstatin, 5 μg/ml aprotinin, 2mM ethylenediaminetetraacetic
acid (EDTA), 2mM ethylene glycol-bistetraacetic acid (EGTA) and 10mM 4-(2hydroxyethyl)-1-piperazine-ethanesulfonic acid (HEPES), pH 7.4 and homogenized by
20 passes of a Wheaton tissue homogenizer. The resulting homogenate was centrifuged at
15,800g for 10 min to remove debris. The supernatant was retained and suspended in
PBS after washing twice with PBS at 32000g for 10 min. The resulting fractions were
assayed for protein concentration by the Pierce BCA method (Bradford, 1976).
6.4.4. 2-dimentional gel electrophoresis

Samples of the proteins from homogenate were prepared as previously described
(Poon, Castegna et al., 2004). Briefly, for isoelectric focusing, 200μg of protein were
applied to a pH 3–10 ReadyStrip™ IPG strip (Bio-Rad), and Linear Gradient (8– 16%)
Precast criterion Tris-HCl gels (Bio-Rad) were used to separate proteins according to
their molecular migration rate (MrW). Sypro ruby stain was used to stain the gel for ~ 1
h, after which the gels were placed overnight in deionized water for destaining.
6.4.5. Western blotting

Western blotting for 2DE gels was performed as previously described (Poon,
Castegna et al., 2004). Briefly, 200μg of the brain protein were incubated with 10 mM
DNPH solution in 2 N HCl at room temperature (37°C) for 20 min. The gels were
prepared in the same manner as for 2DE. The proteins from gels following the second
dimension electrophoresis were transferred onto nitrocellulose paper (Bio-Rad) using a
Transblot-Blot® SD semi-dry Transfer Cell (Bio-Rad) at 15V for 2 h. The derivatized
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carbonyl adduct of the brain proteins were detected immunochemically (Butterfield,
2004).
6.4.6. Image analysis

The gels and blots were scanned and saved in TIF format using a Storm 860
Scanner (Molecular Dynamics, Sunnyvale, CA) and Scanjet 3300C (Hewlett Packard,
Palo Alto, CA), respectively. PDQuest (Bio-Rad) software was used for matching and
analyzing visualized protein spots among different gels and oxyblots. After matching all
the spots, the normalized intensity of each protein spot from individual gels (or oxyblots)
was compared between groups using statistical analysis.
6.4.7. Trypsin digestion

Statistically significant spots were excised from the gel and were digested as
described previously (Poon, Castegna et al., 2004). Briefly, the excised protein spots
were washed with ammonium bicarbonate (NH4HCO3) followed by acetonitrile at room
temperature. The gel pieces were digested with 20ng/μl modified trypsin and incubated at
37°C overnight in a shaking incubator.
6.4.8. Mass spectrometry

1 μl of α-cyano-4-hydroxy trans-cinnamic acid (10 mg/ml in 0.1% TFA: ACN,
1:1, v/v) was mixed with tryptic digests (1 μl). The mixture (1 μl) was deposited onto the
surface of a fast evaporation nitrocellulose matrix and analyzed in reflectron mode with a
TofSpec 2E (Micromass, UK) matrix-assisted laser desorption ionization-time of flight
(MALDI-TOF) mass spectrometer. The mass axis was adjusted with trypsin
autohydrolysis peaks (m/z 2239.14, 2211.10, or 842.51) as lock masses. The MALDI
spectra used for protein identification from tryptic fragments were searched against the
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Swissprot protein databases using the MASCOT search engine. Peptide mass
fingerprinting used the assumption that peptides are oxidized at methionine residues, are
monoisotopic and cysteine residues in peptide is carbamidomethylated (Butterfield and
Castegna, 2003; Tangpong, Cole et al., 2006a). Up to 1 missed trypsin cleavage was
allowed. Window of error allowed for matching the peptide mass values was set at mass
tolerance of 150 ppm. We used the probability-based Mowse score, which indicates the
probability that the match between the database and a spectrum is a random event to
assign a level of confidence to the identification of specific proteins from the mass
spectra. This probability equals 10(−Mowse

score/10)

. Mowse scores greater than 53 were

considered significant.
6.5. Statistics

The expression level of specific proteins and carbonyl levels in specific proteins,
measured by the intensity of the carbonyl level divided by the intensity of protein level of
an individual spot, were obtained from five individual 2D gels or blot, one each from
each animal. The data were analyzed by two-tailed Student’s t tests. A value of p < 0.05
was considered statistically significant. In proteomics for identification of a smaller
member of protein, large-scale statistical analysis such as that used in DNA microarray
studies, is not appropriate.
6.6.

Results

Previously we reported (Chapter 4) an increased total protein carbonyl levels in
brain isolated from ADR-injected mice when compared to brain isolated from salineinjected controls (Joshi, Sultana et al., 2005b). Here we performed expression proteomics
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analysis and redox proteomics analysis unbaisly identify for differentially expressed brain
proteins and specifically oxidized proteins respectively, following treatment with ADR.
6.6.1. Expression proteomics

From Figure 6.1a and b, it is evident that there are proteins that are less expressed
in 2D gels of brain proteins of ADR-injected mice when compared to control. Upon
image analysis by using PDQest software we identified 6 proteins that showed
significantly decreased expression in brain from ADR-injected mice. These proteins were
dynamin 1 (DNM1), triose phosphate isomerase (TPI), NADH ubiqinone oxidoreductase,
vacoular ATP synthase (V-ATPase), visinin like protein 1 (VLP 1) and syntaxin 1B2.
These proteins are shown on representative gels in Figures 1a and b. Table 6.1 presents
the Mowse scores and p values along with molecular migration rate (MrW) and
isoelectric point (PI) of the respective proteins. The identification of the proteins was
performed by matching the obtained mass spectrum to the spectrum in the Swissprot
database. The probability of the match being a random event is indicated by the Mowse
score. A higher Mowse score indicates that the match is unlikely to be a random event.
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Dynamin
Vacuolar ATP
synthase (subunit B)
brain isoform

syntexin
TPI
Visinin like
protein-1

NADH ubiquinone
oxidoreductase

Dynamin
Vacuolar ATP
synthase (subunit
B) brain isoform

syntexi
TPI
Visinin like
protein-1

NADH ubiquinone
oxidoreductase

Figure 6.1a and b: representative 2DE gels of brain proteins from saline-injected

and ADR-injected mice, respectively. The labeled proteins on respective gels showed
significantly lower expression in brain isolated from ADR-injected mice when compared
to saline-injected control. (p < 0.05, n = 5).
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α-Enolase

Dynamin-1

β-Tubulin

Peroxiredoxin
-1
TPI

Prohibitin

α-Enolase
Dynamin-1

β-Tubulin
Peroxiredoxin-1
TPI

Prohibitin

Figure 6.2a and b: representative Western blot obtained from 2DE gels of brain

proteins from saline-injected and ADR-injected mice, respectively. The labeled proteins
on respective blots showed significantly increased oxidation in brain isolated from ADRinjected mice when compared to saline-injected control. (p < 0.05, n = 5).
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6.6.2. Redox proteomics

From Figure 6.2a and b, there are proteins that are more oxidized in 2D Western
blots of brain proteins from ADR-injected mice when compared to control. Upon image
analysis by using PDQest software we identified 6 proteins that showed significantly
increased oxidation in brain from ADR-injected mice. These proteins were α-enolase
(ENO1), DNM1, TPI, peroxiredoxin-1 (Prdx1), β-tubulin and prohibitin. These proteins
are shown on representative Western blots in figures 2a and b. Table 6.2 shows the
Mowse scores and p values along with MrW and PI of respective proteins. The
identification of the proteins was performed by matching the obtained mass spectra of
tryptic peptides to the spectra in the Swissprot database. The initial results suggest that
the accuracy of protein identification by mass spectrometry is equivalent to
immunochemical identification (Castegna, Aksenov et al., 2002a).
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Number of
% Sequence
peptides
coverage
matched

Protein

Mowse
score

p value

pI

MrW

gi accession
number

Dynamin 1

25

26%

156

0.01

7.6

98.14 gi|32172431

TPI

8

39%

77

0.04

7.0

26.90 gi|2851390

NADH
ubiquinone
oxidoreductase

7

37%

75

0.05

7.0

27.64 gi|20178012

Vacoular ATP
synthase

15

40%

145

0.07

5.5

56.8

gi|51338706

Visinin like
protein 1

9

45%

107

0.009

5.0

22.7

gi|51338697

Syntaxin 1B2

8

36%

145

0.05

5.2

33.4

gi|47117767

Table 6.1: Proteins showing decreased levels in brain isolated from ADR-injected

mice when compared to saline-injected control, as determined by PDQuest analysis on
gels obtained from 2DE. Proteins were trypsinized and analyzed by Mass spectrometry in
order to ascertain their identities. Proteins with Mowse score > 53 were considered to be
identified at statistically significant level.
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Number of
% Sequence
peptides
coverage
matched

Protein

Mowse
score

p value

pI

MrW

gi accession
number

Alpha
Enolase

6

19%

61

0.05

6.36

47.322

gi|13637776

Peroxiredoxin
1

9

45%

134

0.05

8.26

22.39

gi|547923

Dynamin 1

25

26%

156

0.01

7.61

98.14

gi|32172431

TPI

8

39%

77

0.04

7.08

26.907

gi|2851390

beta Tubulin

10

24%

95

0.07

4.78

50.095

gi|56754803

Prohibitin

9

48%

133

0.05

5.57

29.859

gi|54038837

Table 6.2: Proteins showing increased oxidation levels in brain isolated from

ADR-injected mice when compared to saline-injected control, as determined by PDQuest
analysis on the blots obtained from 2DE followed by Western blot. The normalized spots
were identified and corresponding proteins were trypsinized and analyzed by Mass
spectrometry in order to ascertain their identities. Protein with Mowse scores > 53 were
considered to be identified at a statistically significant level.
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6.7. Discussion

Previously we reported an increased protein oxidation and lipid peroxidation in
brain isolated from ADR-injected mice when compared to that of saline-injected mice
(Joshi, Sultana et al., 2005b). Increased oxidative stress markers may be cause or
consequence of a compromised antioxidant defense system. Our laboratory also reported
that ADR injection systemically causes increased TNF-α in brain that leads to increased
apoptotic bodies and mitochondrial dysfunction (Tangpong, Cole et al., 2006b). We also
recently reported that iNOS was involved in ADR-induced modulation of MnSOD and
mitochondrial dysfunction, since iNOS knock-out mice injected previously with ADR
had no brain mitochondrial dysfunction (Tangpong, Cole et al., 2006a).
The present study was carried out to identify in an unbiased manner differentially
expressed and specifically oxidized proteins in the brain isolated form saline- or ADRinjected mice. Using the proteomics approach previously utilized in our laboratories
(Castegna, Aksenov et al., 2002a; Castegna, Aksenov et al., 2002b; Poon, Castegna et al.,
2004; Poon, Calabrese et al., 2006; Tangpong, Cole et al., 2006a), we determined that
the expression levels of DNM 1, TPI, NADH ubiqinone oxidoreductase, V-ATPase,
VLP1 and syntaxin 1B2 were significantly decreased in the brains isolated from ADRinjected mice when compared to the brains isolated from saline-injected mice (Figure
6.1a & b). Further, we showed that the total level of protein oxidation increased in the
brains isolated from ADR-injected mice when compared to brain from saline-injected
mice, and that the specific carbonyl levels of ENO 1, DNM 1, TPI, Prdx1, β-tubulin and
prohibitin were significantly increased in the brains of ADR-injected mice (Figure 6.2a
& b). Upon examination of the proteomic data, we observed that the proteins that were
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differentially expressed in the brain isolated from saline- or ADR-injected mice fell into
four broadly defined functional groups, with some placed in more than one of these
groups: namely, metabolism, antioxidant defense, transport/motility, cell proliferation
and regulation. Interestingly, these processes are known to affect cognitive function.
6.7.1. Transport/mobility and cytoskeleton

Dynamins are members of a subfamily of GTP-binding proteins. DNM1 is a
GTPase that is involved in clathrin-mediated endocytosis and other vesicular trafficking
processes (Sontag, Fykse et al., 1994) and is a substrate for protein kinase C (PKC).
Phosphorylation of DNM1 by PKC enhances the GTPase activity of DNM1 (Sontag,
Fykse et al., 1994). DNM1 also functions in receptor-mediated endocytosis and vesicle
formation. DNM1 is believed to assemble around the necks of clathrin-coated pits and
assist in pinching vesicles from the plasma membrane (van der Bliek, Redelmeier et al.,
1993). It is suggested that DNM1 has a primary role in synaptic vesicle recycling in the
nerve terminal (Sontag, Fykse et al., 1994). The formation of complexes between the
actin-binding protein profilin and DNM1 at sites of synaptic vesicle recycling has been
well-characterized (Witke, Podtelejnikov et al., 1998). An observed significant decrease
in DNM1 mRNA and protein levels in AD brains was interpreted to reflect its role in
synaptic vesicle endocytosis (Yao, Zhu et al., 2003). Our laboratory recently reported that
DNM1 protein is less abundant in the olfactory bulbs of old mice (Poon, Vaishnav et al.,
2005). In the current study we showed a decreased expression of DNM1 in brain isolated
from ADR-injected mice when compared to brain isolated from saline-injected mice (Fig
6.1a & b). By redox proteomics we showed that DNM1 is significantly oxidized in brain
isolated from ADR-injected mice when compared to saline-injected control (Fig 6.2a &
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b), Consistent with the notion of altered neurotransmitter reuptake by neuronal synapses
and altered synaptic vesicle recycling with ADR injection. Since synaptic remodeling is
critical to learning and memory, these alterations could affect neuronal transport/mobility
considerably leading to decreased synaptic function, which conceivably could contribute
to chemobrain.
Tubulin is a heterodimer consisting of alpha and beta-tubulin subunits present
ubiquitously among eukaryotic cells (Chakraborty, Sarkar et al., 1999). Like DNM1, beta
tubulin is a GTPase and forms the structural subunit of microtubules (Tian, Bhamidipati
et al., 1999). α- and β-tubulin polymerize to form microtubules that help in cellular
trafficking (Pennisi, 1998). Hence, β-tubulin inactivation may not only alter cytoskeleton
and intracellular transport but also alter cell proliferation. The level of α-tubulin is
significantly decreased as a function of age (Nishibayashi, Ogawa et al., 1994; Poon,
Calabrese et al., 2006). Recently our laboratory showed oxidation of β-tubulin in a
model of AD by using redox proteomics (Boyd-Kimball, Sultana et al., 2005b). In the
present study we showed significant oxidation of β-tubulin in brain isolated from ADRinjected mice when compared to brain isolated from saline-injected mice. Oxidation of βtubulin may implicate altered intracellular trafficking and disruption of the cytoskeleton
that may contribute to chemobrain.
6.7.2. Energy Metabolism

NADH ubiquinone oxidoreductase, a component of mitochondrial complex 1, is
involved in catalyzing the oxidation of NADH, the reduction of ubiquinone, and the
transfer of 4H+/NADH across the coupling membrane. This protein provides the input to
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the oxidative phophorylation for ATP production from the NAD-linked dehydrogenases
of the citric acid cycle (Weiss, Friedrich et al., 1991). Mutation and dysregulation in this
complex is associated with many neurodegenerative disorders including AD (Robinson,
Luo et al., 1998; Karry, Klein et al., 2004). Dysfunctional NADH ubiquinone
oxidoreductase is linked to altered energy metabolism. Consistent with this notion we
showed a lower expression of this enzyme in brain isolated from ADR-injected mice
when compared to brain isolated from saline-injected mice. An altered energy
metabolism may lead to mitochondrial dysfunction, which was observed in the brain
isolated from ADR-injected mice when compared to control (Tangpong, Cole et al.,
2006a; Tangpong, Cole et al., 2006b) and may be related to cognitive dysfunction
following ADR chemotherapy.
V-ATPase, found in the endomembrane of eukaryotic cells and the plasma
membrane of some specialized eukaryotic cells, is primarily involved in ATP hydrolysis
to drive a proton pump. Apart from its ATPase activity V-ATPase also is involved in
active transport of metabolites, protein trafficking, receptor mediated endocytosis and
neurotransmitter release (Finbow and Harrison, 1997; Stevens and Forgac, 1997; Nelson
and Harvey, 1999; Futai, Oka et al., 2000; Nishi and Forgac, 2002; Wilkens, Inoue et al.,
2004). In all cases, V-ATPase carries proton transport from the cytoplasmic compartment
to the opposite side of the membrane in an ATP dependent manner (Nishi and Forgac,
2002). The proton gradient generated by V-ATPase is also used to accumulate
neurotransmitters in synaptic vesicles by specific vesicular transporters in neurons
(Verdier, Huszar et al., 2005). Any alteration in V-ATPase may have consequences in
energy production and/or neurotransmitter accumulation in presynaptic vesicles. In the
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present study we reported a decreased expression of V-ATPase in brain isolated from
ADR-injected mice when compared to brain isolated from saline injected mice. A
decreased expression may hence implicate altered functions of V-ATPase that have roles
in the various cellular processes described above, which conceivably could be involved in
cognitive dysfunction associated with cancer chemotherapy.
ENO1 is a key glycolytic enzyme present in the cytosol. The prime function of
ENO1 is to catalyze the formation of phophoenolpyruvate from 2-phospho-D-glycerate.
In the subsequent reaction in glycolysis, phophoenolpyruvate is converted to pyruvate
and ATP by an enzyme, pyruvate kinase. ENO1, also known as α-enolase [brain-specific
subunit of enolase, (Keller, Berod et al., 1994)], hence becomes a key enzyme in the
process of ATP synthesis. Previously our lab reported possible post-transcriptional
regulation of ENO1 in aging by transcriptional analysis (Poon, Vaishnav et al., 2005),
which may indicate reduced proteasomal degradation of this protein possibly being
oxidized/nitrated or as a result of decreased proteasomal activity during aging (Keller,
Dimayuga et al., 2004). ENO1 is also up-regulated at the protein level in AD brains
(Schonberger, Edgar et al., 2001). ENO1 is a specific target of oxidation and is both
oxidized and nitrated in brain that is under oxidative stress in AD patients (Castegna,
Aksenov et al., 2002a; Castegna, Aksenov et al., 2002b; Castegna, Thongboonkerd et al.,
2003; Reverter-Branchat, Cabiscol et al., 2004). In the present study we showed that
ENO1 is specifically oxidized in brain isolated from ADR-injected mice when compared
to brain isolated from saline-injected mice. Since oxidatively modified protein are
generally dysfunctional (Butterfield, Poon et al., 2006; Sultana, Perluigi et al., 2006) the
possible implications of oxidative modification of ENO1 may relate to altered energy
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metabolism and directly or indirectly might affect mitochondrial dysfunction. Lower
ATP production could affect deleteriously the maintenance of ion gradients, the activities
of pumps and channels, among others processes related to normal cognition. Hence,
altered ENO1 may contribute to the symptoms of cognitive dysfunction or chemobrain.
TPI catalyzes the reversible interconversion of dihydroxyacetone phosphate and
glyceraldehyde 3-phosphate during glycolysis. TPI is ubiquitously expressed in
cytoplasm. TPI deficiency has been reported in chronic nonspherocytic hemolytic anemia
that eventually developed into cerebellar dysfunction and spasticity with hyperreflexia
(Chang, Artymiuk et al., 1993). In another study, decreased neuronal ATP production
followed by progressive neuronal death was observed upon inhibition of TPI (Sheline and
Choi, 1998). Previous studies from our laboratory have reported oxidation/nitration of
TPI in AD (Castegna, Thongboonkerd et al., 2003), however, the activity of TPI is not
altered in either AD or demented patients (Iwangoff, Armbruster et al., 1980; MeierRuge, Iwangoff et al., 1984). In the current study, we observed an increased oxidation
and decreased expression of TPI in brain isolated from ADR-injected mice when
compared to brain isolated from saline-injected control. A lower expression and increased
oxidation may implicate altered energy metabolism, lower ATP production leading to
chemobrain as described above.
6.7.3. Antioxidant proteins

Prdx1 is an antioxidant protein that contain essential catalytic cysteine residues
and use thioredoxin as an electron donor (Yim, Chae et al., 1994; Neumann, Krause et
al., 2003). The primary function of Prdx 1 is to scavenge peroxides and Prdx1 and prdx2
are thought to be involved in the cellular response to ROS. Prdx1 is ubiquitously
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expressed predominanlty in cytosol and alternatively in nucleus. In brain Prdx1 is
localised in astrocytes, whereas Prdx2 is expressed in neurons (Sarafian, Verity et al.,
1999) . Prdx1 expression can be induced by oxidative stress (Ishii, Yamada et al., 1993;
Prosperi, Ferbus et al., 1998). Transfection studies show that Prdx1 can regulate ROS
induced by growth factor signalling and can eliminate peroxide in vivo (Kang, Chae et
al., 1998). Altered expression of various Prdx have been observed in oxidative stressmediated neurodegenerative disorders including AD (Krapfenbauer, Engidawork et al.,
2003). A decreased expression of Prdx1 may lead to increased peroxidative stress. In the
current study we observed an increased oxidative modification of Prdx1 in brain isolated
from ADR-injected mice when compared to brain isolated from saline-injected control.
Increased oxidative modification of the antioxidant protein Prdx1 may decrease the
clearance of various peroxides and increase ROS. This alteration may be related to ADRmediated elevated oxidative stress in brain and to cognitive dysfunction in ADR-treated
pateints.
6.7.4. Regulation/Homeostasis

Syntaxin 1B2 is an integral membrane protein belonging to the membrane
transport proteins. In neurons it forms an integral part of synaptic vesicles. The primary
function of syntaxin 1B2 is docking/priming of synaptic vesicles at presynaptic active
zones (Morciano, Burre et al., 2005). It is sometimes also described as a vesicular
trafficking protein. Although not much research has been done on this protein, its
expression is known to be decreased in neurons of transgenic mice with altered glial
fribrillary acidic protein (GFAP), a model of Alexander’s disease, a fatal
neurodegenerative disorder resulting from missense mutations of the intermediate
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filament protein, GFAP (Hagemann, Gaeta et al., 2005). In the present study we observed
a decreased protein expression of this protein in brain isolated from ADR-injected mice
when compared to brain isolated from saline-injected mice. Lower expression may
implicate defective vesicle docking to the presynaptic membrane, leading to
dysfunctional neurotransmitter release, which could be related to cognitive dysfunction or
chemobrain.
Prohibitin is ubiquitously expressed predominantly in mitochondria, associated
with the inner mitochondrial membrane (McClung, Jupe et al., 1995). Prohibitin is a
multi-functional protein, ranging from cell proliferation, inhibiting DNA synthesis,
serving as a chaperone protein in the mitochondria, tumor suppression or progression in
breast cancer cells and their ability to target to lipid rafts (McClung, Jupe et al., 1995;
Mishra, Murphy et al., 2006). Prohibitin is also localized in the nucleus and can modulate
transcriptional activity by interacting with various transcription factors, including steroid
hormone receptors (Mishra, Murphy et al., 2006). Prohibitin may play role in regulating
mitochondrial respiration activity and in aging. All these function suggests that altered
prohibitin may lead to mitochondrial dysfunction and might also have implication in
various neurodegenerative conditions. In the present study we see an increased
carbonylation of prohibitin in brain isolated from ADR-injected mice when compared to
brain isolated from saline-injected mice. Oxidative modification of this protein may alter
its function, which suggests an altered regulation of mitochondrial respiration activity.
We previously showed decreased mitochondrial respiration activity in brain upon
systemic administration of ADR in mice (Tangpong, Cole et al., 2006a; Tangpong, Cole
et al., 2006b).
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VLP1 is primarily localized in the plasma membrane, predominantly expressed in
brain (Bernstein, Baumann et al., 1999). VLP1 belongs to a family of neuronal Ca2+
sensor/binding proteins (Braunewell and Gundelfinger, 1999; An, Bowlby et al., 2000).
VLP1, upon binding to calcium undergoes a conformational change, a mechanism termed
as Ca2+-myristoyl switch that facilitates its association with lipid bilayers (Ames, Ishima
et al., 1997). VLP1 is also shown to modulate cGMP signaling pathways in transfected
neurons, in vitro (Braunewell, Brackmann et al., 2001). Possible involvement of VLP1 in
pathology and possibly pathophysiology of changed calcium homeostasis in AD has been
previously studied (Schnurra, Bernstein et al., 2001). VLP1 showed reduced
immunoreactivity in neurons from temporal cortex of AD patients (Schnurra, Bernstein et
al., 2001). In the current study we have observed a decreased expression of VLP1 in brain
isolated from ADR-injected mice when compared to brain isolated from saline-injected
mice. Lower expression may cause Ca2+ dyshomeostasis that may lead to neuronal
apoptosis with subsequent effect on cognition.
The present proteomics identification of differentially expressed brain proteins
and specifically oxidized proteins are consistent with our previous in vivo (Joshi, Sultana
et al., 2005b; Tangpong, Cole et al., 2006a; Tangpong, Cole et al., 2006b). The
previously observed ADR-induced increased oxidative stress, altered glutathione and its
dependent enzyme expression and activity, TNF-α production, and circulating TNF
causing mitochondrial dysfunction and appearance of apoptotic bodies in brain may be
related to the observed differential expression or specific oxidation of key protein in
brain.
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The proteins involved in our study are fall under four major categories that have
implication in neurodegeneration: transport/mobility and cytoskeleton, antioxidant,
energy metabolism, and regulation/homeostasis. Impairment and alteration in these
proteins lead to mitochondrial and cellular dysfunction, increased oxidative stress and
apoptotic cascade, ultimately leading to neuronal death as observed in our previous in
vivo studies. All the previous studies and the present study show that mice injected with

ADR are under oxidative stress. The results presented in this study suggest that a
therapeutic strategy aimed towards preventing the observed differential expression and
oxidative modification of specific proteins may modulate the observed cognitive
impairment in patients undergoing chemotherapy. Studies to test this notion are in
progress.

Copyright © Gururaj Joshi 2006
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Chapter 7
Glutathione elevation by γ-glutamyl cysteine ethyl ester as a potential therapeutic
strategy towards preventing oxidative stress in brain mediated by in vivo
administration of adriamycin: Implication for chemobrain.
7.1. Overview of the study

Oxidative stress in heart and brain by the cancer chemotherapeutic drug
adriamycin (ADR), used for treating solid tumors, is well established. Long-term
treatment of ADR in breast cancer patients has shown symptoms of cardiomyopathy.
Less well recognized, but increasingly documented, is cognitive dysfunction. Following
chemotherapy, free radical-mediated oxidative stress has been reported in both heart and
brain. We recently showed a significant increase in protein oxidation and lipid
peroxidation in brain isolated from mice injected intraperitonially (i.p) with ADR.
Systemic administration of ADR also induces tumor necrosis factor-α (TNF-α), that leads
to production of reactive oxygen species (ROS) and reactive nitrogen species (RNS) in
brain. Circulating TNF also causes mitochondrial dysfunction leading to apoptotic
pathways in brain. Inducible nitric oxide synthase also plays a role in ADR-induced TNFmediated neurotoxicity. We also previously showed a significant decrease in glutathione
(GSH) levels in brain isolated from ADR injected mice, along with increased expression
of multidrug resistant protein-1 (MRP-1), glutathione-S-transferase (GST), glutathione
peroxidase (GPx), and glutathione reductase (GR). There was a significant decrease in
activity of brain GST. The present study was designed to test the hypothesis that by
elevating brain levels of GSH, the brain would be protected against oxidative stress in
ADR-injected mice. γ-Glutamyl cysteine ethyl ester (GCEE), a precursor of glutathione,
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injected i.p (150mg/kg body weight) 4 h prior ADR injection (20mg/kg body weight) led
to significantly decreased protein oxidation and lipid peroxidation in subsequently
isolated mice brain when compared to brain isolated from ADR-injected mice without
GCEE. The GSH levels were restored to that of brain isolated from saline-injected mice.
Further, the enzyme activity of GST was increased in brain isolated from ADR-injected
mice previously injected with GCEE when compared to the brain isolated from ADRinjected mice previously injected with saline. These results are discussed with relevance
to potential pharmacological prevention of brain cognitive dysfunction in patients
receiving ADR chemotherapy.

7.2. Introduction

Oxidative stress has been implicated in many neurodegenerative disorder
conditions including Alzheimer’s disease (AD) (Butterfield, Drake et al., 2001;
Lauderback, Kanski et al., 2002). In brain, free radical-mediated oxidative stress leads to
significantly increased protein oxidation (Hensley, Hall et al., 1995; Stadtman and
Berlett, 1997; Butterfield and Kanski, 2001), lipid peroxidation (Markesbery and Lovell,
1998; Butterfield and Lauderback, 2002), DNA and RNA oxidation (Wang, Xiong et al.,
2005), neuronal dysfunction and death. Brain is particularly vulnerable to oxidative stress
because of the relatively large amount of polyunsaturated fatty acids (PUFA), higher
oxygen consumption and relatively low antioxidant capacity. By using redox proteomics,
our laboratory has previously identified many key enzymes and proteins that are
oxidatively modified in AD subjects and models of AD (Tangpong, Cole et al., 2006a),
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aging (Poon, Calabrese et al., 2006) and in the patients with mild cognitive impairment
(MCI) (Butterfield, Poon et al., 2006).
Adriamycin (ADR), a cancer chemotherapeutic drug used to treat solid tumors, is
known to cause side effects in heart and brain (Steinherz, Steinherz et al., 1991; Joshi,
Sultana et al., 2005b; Tangpong, Cole et al., 2006a; Tangpong, Cole et al., 2006b).
Cardiomyocytes treated with ADR have elevated levels of protein oxidation and lipid
peroxidation (DeAtley, Aksenov et al., 1998). Free radical scavengers are known to
protect cardiomyocytes from this effect (DeAtley, Aksenov et al., 1999). Brain isolated
from mice treated peripherally with ADR shows evidence of oxidative damage and
mitochondrial dysfunction (Joshi, Sultana et al., 2005b; Tangpong, Cole et al., 2006a;
Tangpong, Cole et al., 2006b). Patients under long-term treatment with ADR for breast
and lung cancer have shown symptoms of cognitive dysfunction such as lack of
concentration, forgetfulness and dizziness (Meyers, 2000; Schagen, Hamburger et al.,
2001; Freeman and Broshek, 2002). The side effects in heart limit the use of ADR in
chemotherapy, while the side effects in brain limit the quality of life of patients
undergoing chemotherapy.
ADR intercalates into the major groove of DNA and prevents its replication
(Cummings, Anderson et al., 1991). ADR is also known to inhibit topoisomerase II to
form a cleavable complex with DNA thereby preventing tumor growth (Chuang and
Chuang, 1979; Cheng, Cahill et al., 1992). Apart from these mechanisms of action, the
quinone containing ADR is also known to generate superoxide radical (O2-.) (Deres,
Halmosi et al., 2005). A free radical-mediated mechanism of toxicity of ADR is widely
accepted. The quinone in ADR undergoes one electron reduction to generate
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semiquinone, which is a free radical, and in the presence of oxygen converts back to
quinone producing O2-., a process known as redox cycling. ADR dependent redox cycling
is likely activated by nitric oxide synthase and cytochrome P 450 (Gutierrez, 2000;
Deres, Halmosi et al., 2005). Cardiotoxicity mediated by ADR is known to target
mitochondria and NADH dehydrogenase, a mitochondrial enzyme, stimulates ADR to
form semiquinone radical and O2-. (Doroshow and Davies, 1986).

O2-. radicals are

converted to hydrogen peroxide (H2O2) enzymatically by superoxide dismutase.
Overexpression of MnSOD is known to protect complex I of mitochondrial electron
transport chain in ADR-mediated cardiomyopathy (Yen, Oberley et al., 1999).
Superoxide radical can react with H2O2 and other reactive species to generate various
other reactive oxygen species/reactive nitrogen species (ROS/RNS) (Halliwell and
Gutteridge, 1999).
Apart from SOD, another major antioxidant defense system includes glutathione
(GSH) and its dependent enzymes such as glutathione peroxidase (GPx), glutathione
reductase (GR) and glutathione-S-transferase (GST). GSH is a non-protein thiol present
in millimolar concentrations in brain (Cooper, 1997). GSH provides protection against
H2O2-mediated toxicity by providing reduced electrons and is oxidized to glutathione
disulfide (GSSG). This reaction is catalyzed by GPx. GSSG is converted to GSH by
action of glutathione reductase (GR) with the help of the cofactor NADPH (Cooper,
1997). GPx is also known to reduce peroxynitrite thereby providing protection against
peroxynitrite-induced toxicity (Sies, Sharov et al., 1997).
GSH also forms glutathione-S conjugates with xenobiotics and reactive alkenals
such as 4-hydroxynonenal (HNE) and acrolein, products of lipid peroxidation, with the
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help of GST, and these conjugates are removed from cells by the multidrug resistant
protein-1 (MRP-1), an ATP binding cassette (ABC) family protein (Sultana and
Butterfield, 2004) MRP-1 is an integral plasma membrane protein that exports
glutathione-S conjugates out of the cell in an ATP-dependent manner (Nies, Jedlitschky
et al., 2004; Conseil, Deeley et al., 2005). GSH, apart from its endogenous antioxidant
properties, is also involved in biosynthetic processes, DNA repair, enzyme activity
regulation and activation of transcription factors (Meister and Anderson, 1983). GSH
levels are decreased in certain regions of central nervous system (CNS) in various
neurodegenerative disorders (Benzi and Moretti, 1995a). An imbalance in the ratio of
reduced to oxidized GSH level indexes oxidative stress. Studies also have shown reduced
GST activity in brain and ventricular fluids in AD (Lovell, Xie et al., 1998). Increased
expression of GST increased resistance towards oxidative stress in neuroblastoma cells
and provides protection against HNE mediated toxicity in neuronal cell culture (Lovell,
Xie et al., 1998).
7.3. Purpose of the study

Involvement of oxidative stress-mediated toxicity in neurodegenerative events
and neuronal cell death has been extensively studied (Good, Werner et al., 1996; Moreira,
Smith et al., 2005). Hence, various experimental approaches for effective protection by
antioxidants have emerged. In different models of oxidative stress-induced cell death, a
number of potential free-radical scavengers and antioxidant have been tested, such as
Vitamin E (Behl, Davis et al., 1992), Vitamin C, melatonin (Pappolla, Sos et al., 1997),
ginko biloba (Smith and Luo, 2003), steroid hormones (Goodman, Bruce et al., 1996;
Behl, Skutella et al., 1997), N-acetylcysteine (Adair, Knoefel et al., 2001), etc. Due to
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poor blood brain barrier (BBB) permeability of many of these antioxidants, clinical trials
largely have been unsuccessful.
Studies have shown that an increase in endogenous GSH levels by dietary or
pharmacological intake of GSH precursors or GSH mimetic or substrates for GSH
synthesis protects brain against oxidative stress (Anderson and Luo, 1998; Halliwell,
2001; Pocernich, Cardin et al., 2001; Butterfield, Castegna et al., 2002a; Joshi, Sultana et
al., 2005a; Pocernich, Sultana et al., 2005). Considering the importance of developing
new antioxidant compounds and their relevance in the treatment of neurodegenerative
conditions, we examined γ-glutamyl cysteine ethyl ester (GCEE), a GSH precursor.
Cysteine is the limiting substrate in the synthesis of GSH (Anderson and Luo, 1998).
Additionally, γ -glutamylcysteine ligase (GCL) is the rate-limiting enzyme for GSH
synthesis, the enzyme that catalyzes the ligation of the substrate glutamate to cysteine.
GCL is feedback inhibited by the excess production of GSH. Based on this concept, we
hypothesized that GCEE administered to the cell would avoid feedback inhibition and the
limiting substrate for GSH synthesis would be provided to the process (Drake, Kanski et
al., 2002). The ethyl ester moiety on γ - glutamylcysteine would further increase the
efficacy of γ - glutamylcysteine to cross the plasma membrane and upregulate GSH
biosynthesis.
Previous studies from our laboratory have shown protection against peroxynitriteinduced oxidative stress in brain following in vivo administration of GCEE (Drake,
Kanski et al., 2002). GSH up-regulation by GCEE also protects mitochondria against
peroxinitrite, in vivo (Drake, Sultana et al., 2003). Furthermore, elevation of GSH by
GCEE protects neurons against Aβ(1-42)-mediated oxidative stress and neurotoxicity
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(Boyd-Kimball, Sultana et al., 2005a). The present study was carried out to test the
hypothesis that in vivo GCEE elevates GSH levels in brain and thereby prevents
oxidative stress mediated by in vivo ADR.
7.4. Experimentals
7.4.1. Animals

For this study, male B6C3 mice (2-3 months of age), approximately 30 g in size,
housed in the University of Kentucky Central Animal Facility in 12-h light/dark
conditions and fed standard Purina rodent laboratory chow ad libitum, were used. The
animal protocols were approved by the University of Kentucky Animal Care and Use
Committee.
7.4.2. Chemicals

All the chemicals were purchased from Sigma-Aldrich (St. Louis, MO), unless
stated otherwise. Doxorubicin HCl (ADR) was purchased from Bedford Laboratories.
GCEE was purchased from Bachem (Torrance, CA). The OxyBlot kit used for protein
carbonyl determination was purchased from Intergen (Purchase, NY). The GSH assay kit
was purchased from Cayman Chemicals (Ann Arbor, MI). The primary antibody for 4hydroxynonenal was purchased from Alpha Diagnostics (San Antonio, TX).
7.4.3. Treatments

Mice were divided into 4 groups. Two groups received saline and another two
groups were given 150 mg/kg bodyweight of GCEE. One of the saline-injected and
GCEE-injected group received 20 mg/kg bodyweight ADR, i.p., 4 h after saline or GCEE
injection. The dose and time for GCEE and ADR used were chosen based on prior studies
(Drake, Kanski et al., 2002; Joshi, Sultana et al., 2005b). Following 72 h post-i.p.
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injections of ADR, mice were sacrificed and brain was isolated and flash frozen in liquid
nitrogen.
7.4.4. Preparation of brain homogenate

Brains were isolated, thawed and dissected from all the treatment groups and
placed in ice cold lysing buffer containing 4μg/ml leupeptin, 4μg/ml pepstatin, 5 μg/ml
aprotinin, 2mM ethylenediaminetetraacetic acid (EDTA), 2mM ethylene glycolbistetraacetic acid (EGTA) and 10mM 4-(2-hydroxyethyl)-1-piperazine-ethanesulfonic
acid (HEPES), pH 7.4. The brain was homogenized by 20 passes of a Wheaton tissue
homogenizer, and the resulting homogenate was centrifuged at 20000g for 10 minutes.
The pellet was suspended in 1ml phosphate buffered saline (PBS) containing 0.01%
(w/v) sodium azide and 0.2% (v/v) Tween 20. The supernatant (cytosolic fraction) was
retained for fluorescence studies, GSH measurement and enzyme activities. All the
fractions suspended in PBS were washed twice with PBS at 32000g for 10 min. The
resulting fractions were assayed for protein concentration by the Pierce BCA method
(Bradford, 1976).

7.4.5. GSH assay

A known volume of supernatant obtained from homogenate was deproteinated
with 10% meta phosphoric acid. The subsequent deproteinated supernatant was treated
with 4M triethanolamine (TEAM) solution. Following TEAM treatment, the GSH assay
kit was used according to the manufacturer’s direction to determine GSH levels as
described in chapter 3.
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7.4.6. Protein Carbonyls

Samples (5μl) of brain homogenate, 12% sodium dodecyl sulfate (SDS) (5μl), and
10μl of 10 times diluted 2,4-dinitrophenylhydrazine (DNPH) from 200mM stock were
incubated at room temperature for 20 min, followed by neutralization with 7.5μl
neutralization solution (2M Tris in 30% glycerol). Protein (250ng) was loaded in each
well on a nitrocellulose membrane under vacuum using a slot blot apparatus. The
membrane was blocked in blocking buffer (3% bovine serum albumin) in PBS 0.01%
(w/v) sodium azide and 0.2% (v/v) Tween 20 for 1h and incubated with a 1:100 dilution
of anti-DNP polyclonal antibody in PBS containing 0.01% (w/v) sodium azide and 0.2%
(v/v) Tween 20 for 1h. The membrane was washed in PBS following primary antibody
incubation three times at intervals of 5 min each. The membrane was incubated following
washing with an anti-rabbit IgG alkaline phosphatase secondary antibody diluted in PBS
in a 1:8000 ratio for 1h. The membrane was washed three times in PBS for 5 min and
developed in Sigma fast tablets, [5-bromo-4-chloro-3-indolyl phosphate/Nitro blue
tetrazolium substrate (BCIP/NBT substrate)]. Blots were dried, scanned with Adobe
Photoshop, and quantified with Scion Image (PC version of Macintosh compatible NIH
image). No non-specific binding of antibody to the membrane was observed.
7.4.7. 4-Hydroxynonenal (HNE)

Sample (5μl) of brain homogenate, 12% SDS (5μl), and 5μl of modified Laemmli
buffer containing 0.125 M Tris base pH 6.8, 4% (v/v) SDS, and 20% (v/v) glycerol were
incubated for 20 min at room temperature and were loaded (250ng) in each well on a
nitrocellulose membrane in a slot blot apparatus under vacuum. The membrane was
treated as above and incubated with a 1: 5000 dilution of anti-HNE polyclonal antibody

124

in PBS for 1h 30min. The membranes were further developed and quantified as above. A
faint background staining due to the antibody alone was observed, but since each sample
had a control, this minor effect was controlled.
7.4.8. 3-Nitrotyrosine (3-NT)

Samples (5μl) of brain homogenate, 12% SDS (5μl), and 5μl of modified
Laemmli buffer containing 0.125 M Tris base pH 6.8, 4% (v/v) SDS, and 20% (v/v)
glycerol were incubated for 20 min at room temperature and were loaded (250ng) in each
well on a nitrocellulose membrane in slot blot apparatus under vacuum. The membrane
was treated as above and incubated with a 1: 2000 dilution of anti-3-nitrotyrosine (3NT)
polyclonal antibody in PBS for 1h 30min. The membranes were developed further and
quantified as described above. No non-specific binding of antibody to the membrane was
observed.
7.4.9. Enzyme activity assays
Estimation of glutathione-S-transferase activity

GST (EC 2.5.1.18) activity was measured using a reaction mixture consisting of
0.1 M phosphate buffer (pH 6.5), 1.0 mM reduced glutathione, 1.0 mM CDNB and
1mg/ml of supernatant protein (Habig, Pabst et al., 1974). The changes in absorbance
were recorded at 340 nm in a 96 well microtiter plate, and the enzymatic activity was
calculated as nmol of CDNB conjugate formed min− 1 mg− 1 protein.
7.5. Statistical analysis

Two-way ANOVA followed by a multiple comparisons test (Turkey HSD) was
used to assess statistical significance. P values <0.05 were considered significant for
comparison between control and experimental data sets.

125

7.6. Results
7.6.1. GSH assay

As shown in Figure 7.1, there were significant reductions in GSH levels in brain
isolated from ADR-injected mice when compared to the levels in brain isolated from
saline or GCEE-injected mice. Administration of GCEE elevated the levels of GSH
significantly (p < 0.05, n = 5) in brain isolated from mice injected with GCEE followed
by saline or ADR, although the GSH level in the latter case did not reach the level of the
saline control.
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Figure 7.1: Levels of GSH in all the treatment groups. There is a significant

decrease in GSH level in brain isolated from ADR-injected mice when compared to
control (* p < 0.05, n = 5). I.p injection of GCEE increases GSH level significantly in
brain. The brain isolated from GCEE-injected mice followed by ADR injection shows a
significant increase in GSH levels when compared to the levels in brain isolated from
ADR injected mice that were previously injected with saline ( * p < 0.05, n = 5). The data
are presented as mean ± SEM expressed as percentage of control.
7.6.2. Protein carbonyl, 3 nitrotyrosine and 4-hydroxynonenal

Figures 7.2, 7.3 and 7.4 show the levels of protein carbonyls, 3-NT (markers of
protein oxidation) and protein bound HNE (a lipid peroxidation product) levels,
respectively, in all the treatment groups. There was significant elevation in protein
carbonyl, 3-NT and protein bound HNE levels in brain isolated from ADR-injected mice
when compared to the levels in brain isolated from saline or GCEE-injected mice (p <
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0.05, n = 5), confirming our previous findings (Joshi, Sultana et al., 2005b).
Administration of GCEE reduced the levels of protein carbonyls, 3-NT and proteinbound HNE significantly (p < 0.05, n = 5) in brain isolated from mice injected with
GCEE followed by saline or ADR.
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Figure 7.2: Levels of protein carbonyl in all the treatment groups. There is a

significant increase in protein carbonyl level in brain isolated from ADR-injected mice
when compared to control (* p < 0.05, n = 5). I.p injection of GCEE decreases protein
carbonyl level significantly in brain. The brain isolated from GCEE-injected mice
followed by ADR injection shows a significant decrease in protein carbonyl levels when
compared to the levels in brain isolated from ADR injected mice that were previously
injected with saline (* p < 0.05, n = 5). The data are presented as mean ± SEM expressed
as percentage of control.
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Figure 7.3: Levels of 3NT in all the treatment groups. There is a significant

increase in 3NT level in brain isolated from ADR-injected mice when compared to
control (* p < 0.05, n = 5). I.p injection of GCEE decreases 3NT level significantly in
brain. The brain isolated from GCEE-injected mice followed by ADR injection shows a
significant decrease in 3NT levels when compared to the levels in brain isolated from
ADR injected mice that were previously injected with saline (* p < 0.05, n = 5). The data
are presented as mean ± SEM expressed as percentage of control.
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Figure 7.4: Levels of HNE in all the treatment groups. There is a significant

increase in HNE level in brain isolated from ADR-injected mice when compared to
control (* p < 0.05, n = 5). I.p injection of GCEE decreases HNE level significantly in
brain. The brain isolated from GCEE-injected mice followed by ADR injection shows a
significant decrease in HNE levels when compared to the levels in brain isolated from
ADR injected mice that were previously injected with saline (* p < 0.05, n = 5). The data
are presented as mean ± SEM expressed as percentage of control.
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7.6.3. GST activity

Figure 7.5 shows the activity of GST in all the treatment groups. There was
significant reduction in GST activity in brain isolated from ADR-injected mice when
compared to the activities in brain isolated from saline or GCEE-injected mice (p < 0.05,
n = 5). Administration of GCEE elevated the GST activity significantly (p < 0.05, n = 5)
in brain isolated from mice injected with GCEE followed by ADR. Injection of GCEE
alone significantly increased GST activity when compared to saline-injected control.
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Figure 7.5: Plot of activity of GST in all the treatment groups. There is a

significant decrease in GST activity in brain isolated from ADR-injected mice when
compared to control (* p < 0.05, n = 5). I.p injection of GCEE increases GST activity
significantly in brain. The brain isolated from GCEE-injected mice followed by ADR
injection shows a significant increase in GST activity when compared to the activity in
brain isolated from ADR injected mice that were previously injected with saline (** p <
0.01, n = 5). The data are presented as mean ± SEM expressed as percentage of control.
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7.7. Discussion

ADR-mediated oxidative stress in brain has gained increasing importance recently
(Joshi, Sultana et al., 2005b; Joshi, Sultana et al., 2006; Tangpong, Cole et al., 2006a;
Tangpong, Cole et al., 2006b). Free radical-mediated protein oxidation and lipid
peroxidation in cardiomyocytes and involvement of ADR in cardiomyopathy has been
extensively studied by various groups (Doroshow and Davies, 1986; Sarvazyan, 1996;
Vasquez-Vivar, Martasek et al., 1997; Yen, Oberley et al., 1999). We previously showed
increased protein oxidation and lipid peroxidation in brain isolated from ADR-injected
mice that conceivably could be involved in the symptoms of chemobrain observed in
patients treated with ADR (Joshi, Sultana et al., 2005b). ADR does not cross the BBB
(Bigotte, Arvidson et al., 1982a; Bigotte, Arvidson et al., 1982b; Tangpong, Cole et al.,
2006b). The first investigation of potential biochemical pathways for ADR-mediated
CNS toxicity was recently reported by our group (Tangpong, Cole et al., 2006b).
Systemic administration of ADR significantly elevated the level of circulating TNF-α,
which crossed the blood brain barrier to reside in neurons. Neuronal-resident TNF-α
caused brain mitochondrial dysfunction leading to activation of apoptotic pathways. Proapoptotic p53 migrates to brain mitochondria to interact with anti-apoptotic Bcl-xL. The
evidence of apoptosis in brain following ADR suggest p53 interacts with Bcl-xL
inhibited the function of the latter protein. A neutralizing antibody against TNF abrogated
these effects in brain (Tangpong, Cole et al., 2006b). More recently, we showed a role of
iNOS in these effects. ADR given to mice lacking iNOS did not demonstrate a brain
mitochondrial dysfunction (Tangpong, Cole et al., 2006a). ADR was shown to lead to
nitrated and dysfunctional MnSOD, a mitochondrial-resident protective enzyme.
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We recently showed a role for GSH, a major endogenous cellular thiol
antioxidant, and its related enzyme expression and activity, in ADR-mediated oxidative
stress in brain (Joshi, Sultana et al., 2006). There was a significant depletion in GSH
levels in brain isolated from ADR-injected mice (Joshi, Sultana et al., 2006). GCEE, a
precursor of GSH, is known to elevate GSH levels in brain by providing the rate limiting
substrate, γ –glutamylcysteine (Drake, Kanski et al., 2002). In vivo administration of
GCEE elevated the GSH level significantly in brain isolated from saline- or ADRinjected mice (Fig 1). The increase in GSH levels in GCEE followed by ADR injection in
mice was almost that of control mice. GCEE alone showed a significantly increased GSH
levels when compared to all the treatment groups. Moreover, the protection of brain
against peroxynitrite by prior GCEE administration (Drake, Sultana et al., 2003) is
concomitant with GSH scavenging of NO to form nitrosothiol functionality on GSH.
Increasing GSH levels by pharmacological or dietary intervention has been shown
to reduce oxidative stress in models of various neurodegenerative conditions (Pocernich,
Cardin et al., 2001; Boyd-Kimball, Sultana et al., 2005a). In vivo GCEE administration
followed by ADR injection to mice reduced the protein oxidation (Figs. 7.2 and 7.3) and
lipid peroxidation (Fig 4) in brain when compared to brain isolated from ADR-injected
mice previously injected i.p. with saline. Increasing GSH by GCEE suggests increased
antioxidant capacity of brain, hence improved protection against free radical-mediated
oxidative stress caused by ADR.
GST is a major detoxification enzyme that works with MRP-1 to remove
toxicants from the cell (Sultana and Butterfield, 2004). We showed ADR caused
elevation of expression of MRP-1 (Joshi, Sultana et al., 2005b), an ATP binding cassette
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(ABC) family protein in brain. MRP-1 in conjugation with GST is known to transport
glutathione-S conjugates of electrophiles, anions and other xenobiotics out of the cell. We
previously showed a significant elevation in expression of GST in brain isolated from
ADR-injected mice (Joshi, Sultana et al., 2006). Although the expression of GST was
increased, there was a significant decrease in its activity of brain GST in ADR-injected
mice (Joshi, Sultana et al., 2006). In vivo GCEE elevated the activity of GST in brain
isolated from ADR-injected mice previously injected with GCEE when compared to
brain isolated from saline- or ADR-injected mice (Fig 5). Increased activity of GST may
result in improved formation of glutathione-S- conjugates and these conjugates including
GS-HNE conjugate are cleared from cell by action of MRP1 from the cell, putatively
leading to less toxicity and reduced oxidative stress. As noted above, elevated GSH could
serve as a substrate for NO, produced in response to oxidative stress to form nitrosothiol
adduct. This would have the effect of decreasing peroxynitrite and therefore 3-NT
formation as observed in Fig 3. These results are consistent with the notion that brain
accessible GCEE may protects brain from oxidative stress induced by ADR via TNF- or
iNOS-mediated processes.
In conclusion, the protection of brain against the oxidative damage caused by in
vivo ADR by GCEE is consistent with previous other studies in which GCEE protected

neurons against AD-related amyloid beta-peptide (Boyd-Kimball, Sultana et al., 2005c).
Further studies on an animal model could form the basis for eventual treatment strategy
for preventing oxidative stress mediated by ADR. The current results suggest that GCEEmediated increment in brain GSH levels and the activity of GST could be a potential
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therapeutic approach towards modulating cognitive impairment in patients undergoing
chemotherapy.

Copyright © Gururaj Joshi 2006
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Chapter 8
In Vivo Protection of Synaptosomes from Oxidative Stress Mediated by
Fe2+/H2O2 or 2,2-Azobis (2-amidino-propane) dihydrochloride (AAPH) by the
Glutathione Mimetic Tricyclodecan-9-yl-xanthogenate (D609)
8.1. Overview of the study

D609 (tricyclodecan-9-yl-xanthogenate) is a phosphatidylcholine- specific
phospholipase C inhibitor that also has been reported to protect rodents against oxidative
damage caused by lethal doses of ionizing radiation. We previously showed that D609
mimics glutathione. D609 has a free thiol group, which upon oxidation forms a disulfide.
The resulting dixanthate is a substrate for glutathione reductase, regenerating D609.
Recent studies from our laboratory have also shown that D609 reduces the Alzheimer’s
amyloid β peptide [Aβ (1-42)]-induced oxidative stress and cytotoxicity in neuronal cell
culture. The present study was undertaken to test the hypothesis that D609 would provide
neuroprotection against free radical oxidative stress in vivo. Synaptosomes isolated from
gerbils, previously injected intraperitoneally (i.p.) with D609, were treated with the
oxidants, Fe2+/H2O2 or 2,2- Azobis (2-amidino-propane) dihydrochloride (AAPH), which
produce free radicals. Synaptosomes isolated from the gerbils i.p. injected with D609 and
treated with Fe2+/H2O2 and AAPH showed significant reduction in reactive oxygen
species (ROS), levels of protein carbonyl, protein bound hydroxynonenal (HNE, a lipid
peroxidation product) and 3-nitrotyrosine (3NT, another marker of protein oxidation
formed by reaction of tyrosine residues with peroxynitrite) when compared to oxidative
stress in synaptosomes isolated from gerbils that were injected with saline, but treated
with Fe2+/H2O2 and AAPH. These results are discussed with reference to potential use of
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this brain accessible glutathione mimetic in the treatment of oxidative stress related
neurodegenerative disorders.
8.2. Introduction

Alzheimer’s disease (AD) is an age-associated dementing disorder characterized
by loss of synapses and the presence of senile plaques and neurofibrillary tangles,
affecting more than four million Americans (Katzman and Saitoh, 1991). Oxidative stress
has been implicated in many neurodegenerative disorders including AD (Hensley, Hall et
al., 1995; Stadtman and Berlett, 1997; Markesbery and Lovell, 1998; Butterfield, Drake
et al., 2001; Butterfield and Lauderback, 2002). Reactive oxygen species (ROS) leads to
protein oxidation (Hensley, Hall et al., 1995; Stadtman and Berlett, 1997), lipid
peroxidation (Markesbery and Lovell, 1998; Butterfield and Lauderback, 2002), DNA
and RNA oxidation (Butterfield, Drake et al., 2001) and neuronal dysfunction or death.
ROS generation hence becomes important in understanding oxidative stress and oxidative
stress related disorders. Many antioxidant therapies for neurological disorder are under
investigation.
Glutathione (GSH) is an intracellular antioxidant that maintains redox balance in
cell. GSH is the major thiol participating in various cellular redox functions and
biosynthesis (Schulz, Lindenau et al., 2000). Reduced levels of GSH have been observed
in oxidative stress related disorders (Bains and Shaw, 1997). Reduced levels of GSH in
specific regions of the central nervous system of AD patients contribute to the oxidative
stress mediated neuronal cell dysfunction and/or loss (Benzi and Moretti, 1995a). In AD,
increased levels of oxidized glutathione (GSSG) have been observed (Cooper, 1997).
Studies have shown that an increase in endogenous GSH levels by dietary or
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pharmacological intake of GSH precursors or GSH mimetics or substrates for GSH
synthesis protects brain against oxidative stress (Anderson and Luo, 1998; Halliwell,
2001; Butterfield, Castegna et al., 2002a). Previously, our lab showed that endogenous
elevation of GSH by i.p. injection of N-acetyl cysteine (NAC) or gamma- glutamylcysteine ethyl ester (GCEE) reduced oxidative stress markers in synaptosomes treated
with various oxidants (Pocernich, Cardin et al., 2001; Drake, Kanski et al., 2002; Drake,
Sultana et al., 2003). Recently, we showed that tricyclodecan-9-yl-xanthogenate (D609),
a glutathione mimetic, protects primary neuronal culture against amyloid β-peptide (1-42)
[Aβ (1-42)]-induced oxidative stress and neurotoxicity (Sultana, Shelley et al., 2004).
D609 (Figure 8.1) is a phosphatidylcholine-specific phospholipase C inhibitor
(Monick, Carter et al., 1999) that has been shown to trap hydroxyl free radical and to
reduce oxidative stress induced by ionizing radiation (Zhou, Lauderback et al., 2001).
D609 has antiviral and antitumor activity (Amtmann, 1996). Previously we showed that
D609 mimics glutathione (GSH) function in that it has a free thiol group, which upon
oxidation forms a disulfide. The resulting dixanthate is a substrate for glutathione
reductase, regenerating D609 (Lauderback, Drake et al., 2003). D609 has the ability to
scavenge hydrogen peroxide and hydroxyl free radicals. In addition, D609 can bind to
reactive alkenals formed due to peroxidation of lipids and detoxifies their effect, thereby
preventing these alkenals from damaging synaptosomes (Lauderback, Drake et al., 2003).
Based on these studies we tested the hypothesis that D609 delivered in vivo, modulates
oxidative stress in brain induced by various oxidants.
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8.3. Purpose of the study

Our study was aimed at determining the effects of intraperitoially (i.p). injected
D609 in gerbils against oxidative stress in subsequently isolated synaptosomes induced
by Fe2+/H2O2 (hydroxyl radical formation) and AAPH (alkoxyl and peroxyl radical
formation).
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Figure 8.1: Tricyclodecan-9-yl-xanthogenate (D609)

8.4. Experimentals
8.4.1. Animals

For all the studies male Mongolian gerbils (2-3 months of age), approximately
100 g in size, housed in the University of Kentucky Central Animal Facility in 12-h
light/dark conditions and fed standard Purina rodent laboratory chow ad libitum, were
used. The animal protocols were approved by the University of Kentucky Animal Care
and Use Committee.
8.4.2. Chemicals

D609 was purchased from Biomol (Plymouth Meeting, PA) and all other
chemicals were purchased from Sigma-Aldrich (St. Louis, MO), unless stated otherwise.
Fresh 10 mM stock solution of 2,7-dichlorofluoroscin diacetate (DCFH-DA) was
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prepared in ethanol for DCF fluorescence assay. Fresh D609 (50mg/kg bodyweight) was
prepared in phosphate-buffered saline (PBS). The protein oxidation detection kit was
purchased from Intergen (Purchase, NY) and primary antibody for HNE and 3NT were
purchased from Chemicon International.
8.4.3. Preparation of Synaptosomes

Synaptosomes were isolated from gerbils injected i.p. with saline (control) or with
D609 (50mg/kg body weight), 60min after injection. This level was chosen based on
previous experiments conducted at various concentrations (Figure 2). The synaptosomal
isolation procedure has been described elsewhere (Whittaker, 1993). Briefly, the gerbils
were sacrificed by decapitation and the brain was isolated on a cold plate and placed in
0.32M sucrose isolation buffer containing 4μg/ml leupeptin, 4μg/ml pepstatin, 5 μg/ml
aprotinin, 2mM ethylenediaminetetraacetic acid (EDTA), 2mM ethylene glycolbistetraacetic acid (EGTA) and 20mM 4-(2-hydroxyethyl)-1-piperazine-ethanesulfonic
acid (HEPES), 20μg/ml trypsin inhibitor and 0.2mM phenylmethanesulfonyl fluoride
(PMSF), pH 7.4. The whole brain was homogenized by 20 passes with a Wheaton tissue
homogenizer. The homogenate was centrifuged at 1500 g for 10 min. The pellet was
discarded and the supernatant was retained and centrifuged at 20000 g for 10 min. The
resulting pellet was resuspended in approximately 1ml of 0.32M sucrose isolation buffer
and layered over discontinuous sucrose gradient (0.85M pH 8.0, 1.0M pH8.0, 1.18M
pH8.5 sucrose solutions each containing 2mM EDTA, 2mM EGTA and 10mM HEPES)
and spun at 82500g for 1h at 4o C. The purified synaptosomes were collected from the
sucrose gradient interface at the 1.0/1.18M interface and washed with phosphate buffered
saline containing 0.01% (w/v) sodium azide and 0.2% (v/v) Tween 20 (PBS), twice and
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centrifuged at 32000 g. The resulting synaptosomal membranes were assayed for protein
concentration by Pierce BCA method (Bradford, 1976). The synaptosomes obtained were
divided in two aliquots. One part was incubated with 30 mM FeSO4 and 10 mM H2O2,
and the other aliquot was incubated with 1mM AAPH for 1h at 37o C. The synaptosomal
samples were washed following incubation and suspended in PBS.
8.4.4. DCF fluorescence

10 μM DCFH-DA was incubated with synaptosomes (1mg/ml) for 30 minutes at
37o C. Intracellular esterases convert DCFH-DA into anionic DCFH, which because of its
negative charge is trapped in the synaptosomes. Upon oxidation with ROS, DCFH is
converted to 2,7- dichlorofluoroscein (DCF), a fluorescent compound. Synaptosomes
were spun at 3000 g in a tabletop Eppendorf centrifuge for 5 minutes at 4o C.
Synaptosomes were resuspended in 500 μl of PBS and loaded in triplicate (100 μl per
well) in a black microtiter plate and fluorescence was measured in a Spectramax
microtiter plate reader (λex = 495nm, λem = 530nm) and quantified using softPro max
software. To verify that ester cleavage and efflux of the dye were not contributing to
changes in fluorescence, similar studies were done with an oxidation-insensitive dye
CDCF-DA (C369).
8.4.5. Protein carbonyls

Protein carbonyls are the markers of protein oxidation and were assed by
following the standard protocol described elsewhere (Stadtman and Berlett, 1997).
Sample (5 μl) (normalized to 4mg/ml), 5μl of 12% sodium dodecyl sulfate (SDS) and
10μl of 10 times diluted 2,4-dinitrophenylhydrazine (DNPH) from 200mM stock were
incubated at room temperature for 20 min. Samples were neutralized with 7.5μl
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neutralization solution (2M Tris in 30% glycerol). The resulting solution was solution
was loaded in each well on nitrocellulose membrane under vacuum using a slot blot
apparatus. The membrane was blocked in blocking buffer (3% bovine serum albumin) in
phosphate buffered saline containing 0.01% (w/v) sodium azide and 0.2% (v/v) Tween 20
(PBS) for 1 h and incubated with a 1:100 dilution of anti DNP polyclonal antibody in
phosphate buffered saline containing 0.01% (w/v) sodium azide and 0.2% (v/v) Tween 20
(PBS) for 1h. The membrane was washed three times in PBS and was incubated for 1 h
with an anti-rabbit IgG alkaline phosphatase secondary antibody diluted in PBS in a
1:8000 ratio. The membrane was washed for three times in PBS for 5 min and developed
in Sigma fast tablets (BCIP/NBT substrate). Blots were dried, scanned with Adobe
Photoshop, and quantified with Scion Image (PC version of Macintosh compatible NIH
image).
8.4.6. 4-Hydroxynonenal (HNE)

Sample (5 μl) (normalized to 4mg/ml), 5μl of 12% sodium dodecyl sulfate (SDS)
and 5μl of modified Laemmli buffer containing 0.125 M tris base pH 6.8, 4% (v/v) SDS,
and 20% (v/v) glycerol were incubated for 20 minutes at room temperature. Sample (250
ng) was loaded in each well on nitrocellulose membrane in slot blot apparatus under
vacuum. The membrane was blocked in blocking buffer (3% bovine serum albumin) in
phosphate buffered saline containing 0.01% (w/v) sodium azide and 0.2% (v/v) Tween 20
(PBS) for 1 hr and incubated with a 1: 5000 dilution of anti-HNE polyclonal antibody in
PBS for 1 h 30 min. The membrane was washed in PBS for 5 min three times after
incubation. The membrane was incubated for 1 h, following washing, with an anti-rabbit
IgG alkaline phosphatase secondary antibody diluted in PBS in 1:8000 ratio. The
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membrane was washed three times in PBS for 5 min and developed in Sigma fast tablets
(BCIP/NBT substrate). Blots were dried, scanned with Adobe Photoshop, and quantified
with Scion Image as above.
8.4.7. 3-Nitrotyrosine (3NT)

Sample (5 μl) (normalized to 4mg/ml), 5μl of 12% sodium dodecyl sulfate (SDS)
and 5μl of modified Laemmli buffer containing 0.125 M tris base pH 6.8, 4% (v/v) SDS,
and 20% (v/v) glycerol were incubated for 20 minutes at room temperature. Sample (250
ng) was loaded in each well on nitrocellulose membrane in slot blot apparatus under
vacuum. The membrane was blocked in blocking buffer (3% bovine serum albumin) in
phosphate buffered saline containing 0.01% (w/v) sodium azide and 0.2% (v/v) Tween 20
(PBS) for 1 hr and incubated with a 1: 2000 dilution of anti-3-nitrotyrosine (3NT)
polyclonal antibody in PBS for 1 h 30 min. The membrane was washed in PBS for 5 min
three times after incubation. The membrane was incubated for 1 h, following washing,
with an anti-rabbit IgG alkaline phosphatase secondary antibody diluted in PBS in 1:8000
ratio. The membrane was washed for three times in PBS for 5 minutes and developed in
Sigma fast tablets. Blots were dried, scanned with Adobe Photoshop, and quantified with
Scion Image as above.
8.4.8. Western blot for Protein oxidation

Samples (100 μg) were incubated with DNPH at room temperature for 30 min and
then precipitated with tricholro acetic acid (TCA) following incubation. The pellet was
washed with 1:1 Ethanol: Ethyl acetate for three times. After addition of sample loading
buffer, protein sample were denatured and electrophoresed on a 10% SDSpolyacrylamide gel. Proteins were transferred to nitrocellulose at 90 mA/gel for 2 h. The
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blots were blocked for 1h in fresh wash buffer (10 mM tris-HCl 9pH7.5), 150 mM NaCl,
0.05% Tween 20, pH 7.4, containing 3% bovine serum albumin) and incubated with a
1:100 dilution of anti DNP polyclonal antibody in phosphate buffered saline containing
0.01% (w/v) sodium azide and 0.2% (v/v) Tween 20 (PBS) for 1h. The membrane was
washed three times in PBS and was incubated for 1 h with an anti-rabbit IgG alkaline
phosphatase secondary antibody diluted in PBS in a 1:8000 ratio. The membrane was
washed for three times in PBS for 5 min and developed in Sigma fast tablets (BCIP/NBT
substrate). The blot was stripped and reprobed for GAPDH to show equal loading of
protein.
8.5. Statistical analysis

Analysis of variance (ANOVA) was used for comparison among the groups and
statistical evaluation. Results are presented as means ± SEM. P values < 0.05 were
considered significant.
8.6. Results
8.6.1. DCF fluorescence

The DCF assay is useful to monitor ROS generation. DCF is sensitive to many
oxidative stress-inducing compounds including hydroxyl radical, ONOO-, AAPH and Aβ
(Wang and Joseph, 1999; Keller, Lauderback et al., 2000; Lauderback, Kanski et al.,
2002). Figure 8.2 shows the ROS levels in synaptosomes isolated from saline-injected
gerbils (control), synaptosomes isolated from saline-injected gerbils treated with
Fe2+/H2O2 or AAPH and Fe2+/H2O2 or AAPH treated synaptosomes isolated from gerbils
previously injected i.p. with D609, respectively. There was a significant increase in ROS

145

generation in synaptosomes isolated from control gerbils treated with Fe2+/H2O2 or
AAPH (p < 0.0001) when compared to control. Synaptosomes isolated form D609
injected gerbils and subsequently treated with Fe2+/H2O2 or AAPH showed significant
decrease in ROS levels when compared to synaptosomes treated with Fe2+/H2O2 or
AAPH, isolated from gerbils injected i.p. with saline (p < 0.005).
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Figure 8.2: Significant increase in ROS in synaptosomes isolated from saline injected

gerbils and subsequently treated with Fe2+/H2O2 or AAPH compared to ROS in
synaptosomes isolated from saline-injected gerbils, * p < 0.005. Decreased ROS in
synaptosomes isolated from gerbils injected i.p. with D609 subsequently treated with
Fe2+/H2O2 or AAPH relative to ROS in synaptosomes isolated from gerbils injected with
saline and subsequently treated with Fe2+/H2O2 or AAPH, ** p < 0. 005; the data are the
mean ± SEM expressed as percentage of control values, (n = 6).
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To ensure that ester cleavage or efflux of the DCFH, prior to the reaction with
ROS, was not contributing to changes in fluorescence, the oxidation-insensitive dye
(C369) was used in similar studies and was used as control. No difference in fluorescence
was found in all the studies, confirming that a change in fluorescence shown in Figure 8.3
was due to oxidation of the dye and not because of some other parameter.
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Figure 8.3: Measurement of ROS generation using the oxidation-insensitive

probe C369. The oxidation-insensitive fluorescence probe C369 was used as control to
show esterase activity and drug efflux changes of DCFH-DA.
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8.6.2. Protein carbonyl

Figure 8.4 shows the protein carbonyl levels in synaptosomes isolated from saline
injected gerbils (control), synaptosomes isolated from control gerbils subsequently
treated with Fe2+/H2O2 or AAPH and Fe2+/H2O2 - or AAPH-treated synaptosomes
isolated from gerbils previously injected i.p. with D609. There was a significant increase
in protein carbonyl levels in synaptosomes isolated from control gerbils treated with
Fe2+/H2O2 or AAPH (p < 0.000001) when compared to control. Synaptosomes isolated
from D609 injected gerbils subsequently treated with Fe2+/H2O2 and AAPH showed
significantly decreased protein carbonyl levels when compared to synaptosomes isolated
from saline-injected gerbils and subsequently treated with Fe2+/H2O2 or AAPH (p <
0.00005).
Figure 8.5 show representative western blots for total protein oxidation. It is clear
that decreased protein oxidation is found in Fe2+/H2O2 or AAPH treated synaptosomes
isolated from gerbils previously injected with D609.
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Figure 8.4: Significant increase in protein carbonyl levels in synaptosomes

isolated from saline injected gerbils and subsequently treated with Fe2+/H2O2 or AAPH
compared to protein carbonyls in synaptosomes isolated from saline injected gerbils, * p
< 0.005. Decreased protein carbonyl level in synaptosomes isolated from gerbils injected
i.p. with D609 subsequently treated with Fe2+/H2O2 or AAPH relative to protein carbonyl
level in synaptosomes isolated from gerbils injected with saline and subsequently treated
with Fe2+/H2O2 or AAPH, ** p < 0. 005; the data are the mean ± SEM expressed as
percentage of control values, (n = 6).
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Figure 8.5: Representative western blot showing protein carbonyl levels from

various treatments.
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8.6.3. HNE

Arachidonic acid from phospholipids, on attack by free radicals, produces reactive
alkenals, such as HNE. HNE binds to proteins by Michael addition (Butterfield and
Stadtman, 1997) and inactivates them by changing their conformation (Subramaniam,
Roediger et al., 1997; Zhou, Lauderback et al., 2001) Figure 8.6 shows the protein-bound
HNE levels in synaptosomes isolated from saline-injected gerbils (control), synaptosomes
isolated from control gerbils treated with Fe2+/H2O2 or AAPH and Fe2+/H2O2- or AAPHtreated synaptosomes isolated from gerbils previously injected i.p. with D609. There was
a significant increase in protein-bound HNE levels in synaptosomes isolated from control
gerbils treated with Fe2+/H2O2 or AAPH (p < 0.0001) when compared to control.
Synaptosomes isolated from D609 injected gerbils subsequently treated with Fe2+/H2O2
or AAPH showed significant decrease in protein bound HNE levels when compared to
synaptosomes isolated from saline-injected gerbils treated with Fe2+/H2O2 or AAPH (p <
0.001).
8.6.4. 3NT

Figure 8.7 shows levels of 3-NT in synaptosomes isolated from saline injected
gerbils (control), synaptosomes isolated from control gerbils treated with Fe2+/H2O2 or
AAPH and Fe2+/H2O2- and AAPH-treated synaptosomes isolated from gerbils previously
injected i.p. with D609 . There was a significant increase in 3-NT levels in synaptosomes
isolated from saline-injected gerbils treated with Fe2+/H2O2 or AAPH (p < 0.001) when
compared to control. Synaptosomes isolated from D609 injected gerbils subsequently
treated with Fe2+/H2O2 and AAPH showed a significant decrease in 3-NT levels when
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compared to synaptosomes isolated from saline injected gerbils treated with Fe2+/H2O2 or
AAPH (p < 0.001).
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Figure 8.6: Significant increase in protein bound HNE levels in synaptosomes

isolated from saline injected gerbils and subsequently treated with Fe2+/H2O2 or AAPH
compared to protein carbonyls in synaptosomes isolated from saline injected gerbils, * p
< 0.005. Decreased protein bound HNE level in synaptosomes isolated from gerbils
injected i.p. with D609 subsequently treated with Fe2+/H2O2 or AAPH relative to protein
carbonyl level in synaptosomes isolated from gerbils injected with saline and
subsequently treated with Fe2+/H2O2 or AAPH, ** p < 0. 005; the data are the mean ±
SEM expressed as percentage of control values, (n = 6).
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Figure 8.7: Significant increase in 3NT levels in synaptosomes isolated from

saline-injected gerbils and subsequently treated with Fe2+/H2O2 or AAPH compared to 3NT levels in synaptosomes isolated from saline-injected gerbils, * p < 0.005. Decreased
3NT levels in synaptosomes isolated from gerbils injected i.p. with D609 subsequently
treated with Fe2+/H2O2 or AAPH relative to protein carbonyl level in synaptosomes
isolated from gerbils injected with saline and subsequently treated with Fe2+/H2O2 or
AAPH, ** p < 0. 005; the data are the mean ± SEM expressed as percentage of control
values, (n = 6).
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8.7. Discussion

Oxidative stress has been implicated in many neurodegenerative disorders
including AD (Butterfield, Drake et al., 2001). Oxidative stress arises due to an
imbalance in the antioxidant system and generation of oxidants such as free radicals (Yu,
1994). In AD, synaptic membranes are known to show increased oxidative stress
(Hensley, Carney et al., 1994; Hensley, Hall et al., 1995). Synaptosomes were selected
for our studies for the following reasons. Synaptic membranes have receptors for
glutamate which mediate increase in intracellular Ca2+ and exitotoxicity and cause
production of ROS and RNS including peroxynitrite and lead to subsequent protein
oxidation (Hensley, Carney et al., 1994; Mattson, 1996). Elevation in Ca2+ level also
causes change in mitochondrial potential and lead to production of superoxide ion
radicals. Due to more energy usage in the synaptic region of neuron, mitochondria are
concentrated in these areas of cell. Hence, the synaptic region of neurons becomes more
vulnerable to oxidative stress.
There are increasing evidence to demonstrate that AD brain is under oxidative
stress (Butterfield, Drake et al., 2001). Oxidative damage to protein, lipids and DNA lead
to cellular dysfunction and also cell death (Yu, 1994; Butterfield, 2002; Butterfield and
Lauderback, 2002; Castegna, Aksenov et al., 2002a; Castegna, Aksenov et al., 2002b;
Castegna, Thongboonkerd et al., 2003).

Due to relatively poor antioxidant defense

available in brain, the high content of polyunsaturated fatty acids and the high oxygen
utilization in brain, vulnerability of neurons towards oxidative stress is increased. Among
the antioxidants present in brain, glutathione (GSH) is the most abundant and is present
ubiquitously (Cooper, 1997).
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A well known antioxidant and is a free radical scavenger, GSH is also involved in
maintenance of cellular redox status, DNA synthesis and repair, protein synthesis, amino
acid transport, binding of heavy metals and other functions (Cooper, 1997). Normally, in
most cells the GSH/GSSG ratio is vastly shifted to the reduced form of GSH except
under oxidative stress conditions. These two forms are interconvertible by the action of
glutathione peroxidase and glutathione reductase (Hayes and McLellan, 1999).
Many studies have shown that GSH protects the brain against various oxidants
found in AD (Bains and Shaw, 1997). GSH is known to detoxify HNE, a lipid
peroxidation product found to be elevated in AD brain (Sayre, Zelasko et al., 1997;
Lovell, Xie et al., 1998; Xie, Lovell et al., 1998). It has also been shown that GSH
protects cultured neurons against oxidative damage resulting from amyloid β-peptide,
iron and HNE (Mark, Lovell et al., 1997; Mark, Pang et al., 1997). In addition, GSH can
also protect brain from damage by peroxinitrite, hydroxyl free radicals or reactive
alkenals (Koppal, Drake et al., 1999a; Koppal, Drake et al., 1999b; Pocernich, La
Fontaine et al., 2000; Pocernich, Cardin et al., 2001; Drake, Kanski et al., 2002; Drake,
Sultana et al., 2003). Low levels of GSH are associated with aging and many diseased
conditions including AIDS, amyotrophic lateral sclerosis, AD (Bains and Shaw, 1997).
The diminution of GSH levels in these conditions could be due to malfunctioning of
enzymes required for GSH synthesis or due to insufficient supply of substrate involved in
GSH metabolism.
Tricyclodecan-9-yl-xanthogenate (D609) is a derivative of xanthic acid (Rao,
1971) that has been reported as a phosphatidylcholine-specific phospholipase C inhibitor
(Sauer, Amtmann et al., 1984; Monick, Carter et al., 1999). In performing this function,
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D609 protects brain from ceramide-induced apoptosis and transcription of inflammatory
molecules mediated by NF-κB (Schutze, Potthoff et al., 1992; Cifone, Roncaioli et al.,
1995; Li, Maher et al., 1998; Sortino, Condorelli et al., 1999). Since oxidative stress is
involved in these processes, the antioxidant property of D609 was studied. Our lab
demonstrated that D609 scavenges H2O2 (Lauderback, Drake et al., 2003). These studies
suggested that D609 mimics glutathione (GSH) function in that it has a free thiol group,
which upon oxidation forms a disulfide. The resulting dixanthate formed acts as a
substrate for glutathione reductase, regenerating D609 (Lauderback, Drake et al., 2003).
In addition, D609 binds to reactive alkenals formed due to peroxidation of lipids and
detoxifies their effect, there-by preventing these alkenals from damaging synaptosomes
(Lauderback, Drake et al., 2003).
Intracellular elevation of glutathione has been used as therapeutics in many
diseases (Anderson and Luo, 1998). Previously, our lab showed that i.p. injection of Nacetyl cysteine (NAC) and gamma- glutamyl-cysteine ethyl ester (GCEE) reduced the
oxidative stress markers in synaptosomes (Pocernich, Cardin et al., 2001; Drake, Kanski
et al., 2002) by elevating the endogenous GSH levels. The i.p. injection of NAC protects
synaptosomes against hydroxyl radical and acrolein and is also shown to protect in vitro
oxidative stress caused by peroxynitrite (Koppal, Drake et al., 1999a; Pocernich, Cardin
et al., 2001). Similar results have been shown with GCEE (Drake, Kanski et al., 2002).
D609 reduces oxidative stress markers in vitro (Lauderback, Drake et al., 2003). Recent
studies have also shown that D609 reduces the Aβ (1-42) induced oxidative stress and
cytotoxicity in neuronal cell culture (Sultana, Shelley et al., 2004).
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Protein oxidation is elevated in AD brain (Butterfield and Lauderback, 2002).
Oxidation of protein leads to deactivation of enzymes critical for cell functioning, and
recently our lab showed some of the critical proteins that are oxidized in AD by
proteomics studies (Castegna, Aksenov et al., 2002a; Castegna, Aksenov et al., 2002b;
Castegna, Thongboonkerd et al., 2003). Fe2+/H2O2 (hydroxyl radical formation) and
AAPH (alkoxyl and peroxyl radical formation) are known to induce protein oxidation
(Pocernich, La Fontaine et al., 2000; Kanski, Lauderback et al., 2001). We previously
demonstrated by using Fenton chemistry (Fe2+/H2O2), D609 inhibits the formation of a
PBN spin adduct, which shows hydroxyl radical scavenging property (Lauderback, Drake
et al., 2003). Decreased protein oxidation was observed in neuronal cell culture pretreated
with D609 on incubation with Aβ (1-42) (Sultana, Shelley et al., 2004). The results
shown in this in vivo study are in consistent with the in vitro data, showing that D609 acts
as an antioxidant. There was a significant reduction in protein carbonyl formation and
3NT levels, both markers of protein oxidation, in synaptosomes isolated from D609
injected gerbils subsequently treated with Fe2+/H2O2 or AAPH in comparison with
synaptosomes isolated from saline injected gerbils and subsequently treated with
Fe2+/H2O2 or AAPH.
Lipid peroxidation products such as HNE and acrolein are known to be elevated
in AD brain (Sayre, Zelasko et al., 1997; Lauderback, Hackett et al., 2001). These
alkenals form the immediate substrate for GSH (Lovell, Xie et al., 1998; Xie, Lovell et
al., 1998) and these lipid peroxidation products are known to be involved in apoptosis,
which is seen as a consequence of GSH depletion (Mark, Lovell et al., 1997). Lipid
peroxidation induced by Fenton chemistry was reduced by D609 in synaptosomes
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(Lauderback, Drake et al., 2003). Decreased lipid peroxidation was observed in neuronal
cell culture pretreated with D609 on incubation with Aβ (1-42) (Sultana, Shelley et al.,
2004) . We demonstrated previously that treatment of neuronal cultures with D609
prevents apoptosis induced by Aβ (1-42) mediated oxidative stress (Sultana, Shelley et
al., 2004). In the present study, there was a significant reduction in protein bound HNE
levels in synaptosomes isolated from D609 injected gerbils subsequently treated with
Fe2+/H2O2 and AAPH in comparison with synaptosomes isolated from saline injected
gerbils and subsequently treated with Fe2+/H2O2 and AAPH.
All the in vitro studies and studies on cultures show that D609 acts as an
antioxidant. Our in vivo data are consistent with previously observed results. There was a
reduction in ROS levels in synaptosomes isolated from gerbils injected i.p with D609 and
subsequently treated with Fe2+/H2O2 or AAPH when compared to synaptosomes isolated
from saline-injected gerbils and subsequently treated with Fe2+/H2O2 or AAPH. These
results are consistent with the notion that D609 or its key metabolites may cross the blood
brain barrier (BBB) and protect synaptosomes from oxidative stress induced by
Fe2+/H2O2 or AAPH. In some of the data presented, the level of oxidative stress markers
are below the control level in synaptosomes isolated from D609-treated rodent. This
could be due to the presence of D609 in the system that could prevent oxidation of
synaptosomes due to environmental oxidants, the kind of protection that is lacking in
controls.
In conclusion, the protection of synaptosomes, in vivo, by D609 is consistent with
previous in vitro and cell culture studies. The presence of the thiol group in D609 is the
basis for its antioxidant property, since the methylated derivative of D609 is inactive
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(Sultana, Shelley et al., 2004). Xanthates in general are known to be the strong reducing
agents (Rao, 1971). The thiol group in D609 could react with lipid peroxidation products
and form Michael adducts and prevent these reactive lipid peroxidation products from
causing neurotoxicity. These studies on an animal model could form the basis for
eventual treatment strategies for oxidative stress related disorders, although additional
studies are required to determine if this notion has merit. Studies on the effect of D609 on
animal models of oxidative stress-related disorders are on progress.

Copyright © Gururaj Joshi 2006
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Chapter 9
In vivo protection by the xanthate D609 against amyloid β-peptide (1-42)-induced
oxidative stress: Implications for Alzheimer’s disease
9.1. Overview of the study

Considerable evidence supports the role of oxidative stress in the pathogenesis of
Alzheimer’s disease (AD). One hallmark of AD is the accumulation of amyloid β-peptide
(Aβ), which invokes a cascade of oxidative damage to neurons that can eventually result
in neuronal death. Aβ is the main component of senile plaques and generates free radicals
ultimately leading to neuronal damage of membrane lipids, proteins and nucleic acids.
Therefore, interest in the protective role of different antioxidant compounds has been
growing for treatment of AD and other oxidative stress-related disorders. Among
different antioxidant drugs, much interest has been devoted to “thiol-delivering”
compounds.

Tricyclodecan-9-yl-xanthogenate

(D609)

is

an

inhibitor

of

phosphatidylcholine specific phospholipase (PC-PLC), and recent studies reported its
ability to act as a glutathione–mimetic compound. In the present study, we investigate the
in vivo ability of D609 to protect synaptosomes against Aβ-induced oxidative stress.

Gerbils were injected intraperitoneally (i.p.) with D609 or with saline solution, and
synaptosomes were isolated from the brain. Synaptosomal preparations isolated from
D609 injected gerbils and treated ex vivo with Aβ(1-42) showed a significant decrease of
oxidative stress parameters: reactive oxygen species (ROS) levels, protein oxidation
(protein carbonyl and 3-nitrotyrosine levels) and lipid peroxidation (4-hydroxy-2-nonenal
levels). Our results are consistent with the hypothesis that modulation of free radicals
generated by amyloid β-peptide might represent an efficient therapeutic strategy for
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treatment of AD and other oxidative-stress related disorders. Based on the above data, we
suggest that D609 is a potent antioxidant and could be of importance for the treatment of
AD and other oxidative stress-related disorders.
9.2. Introduction

Alzheimer’s disease (AD) is a progressive neurological disorder characterized by
loss of memory cognition. Major pathological hallmarks of AD include loss of synapses
and the presence of senile plaques and neurofibrillary tangles. The major protein
component of the core of senile plaques is amyloid β-peptide (Aβ). Aβ is formed upon
proteolytic processing, by β- and γ-secretases (Haass and De Strooper, 1999), of the
larger amyloid precursor protein (APP), a ubiquitously expressed transmembrane
glycoprotein (Glenner and Wong, 1984; Glenner, Eanes et al., 1988). The amyloid βcascade hypothesis, suitably updated, postulates that Aβ is likely central to the
pathogenesis of AD (Hardy and Allsop, 1991; Smith, Chen et al., 1999; Selkoe, 2001).
The mechanisms involved in the Aβ-mediated neurotoxicity are unknown, but there is
evidence suggesting that oxidative stress plays a key role (Butterfield, Drake et al., 2001;
Butterfield and Lauderback, 2002; Canevari, Abramov et al., 2004). Growing attention
has been focused to investigate the oxidative mechanism of Aβ toxicity and as well in the
search for novel neuroprotective agents. Previous studies from our laboratory and others
reported that Aβ peptide induces in vitro reactive oxygen species production, protein
oxidation, DNA and RNA oxidation and lipid peroxidation (Butterfield, 2002).
Because

of the

involvement

of

oxidative

stress-mediated

toxicity

in

neurodegenerative events and neuronal cell death (Good, Werner et al., 1996; Moreira,
Smith et al., 2005), various experimental approaches for effective protection by
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antioxidants have emerged. In addition, antioxidant therapy is being discussed for
Parkinson’s disease (Ebadi, Srinivasan et al., 1996; Prasad, Cole et al., 1999), ischemia
(Marczin, El-Habashi et al., 2003) as well as for AD (Grundman and Delaney, 2002;
Gilgun-Sherki, Melamed et al., 2003) and other age-related disorders (Ames, 2004).
Numerous potential free-radical scavengers have been tested in different experimental
paradigms of oxidative stress-induced cell death, such as Vitamin E (Behl, Davis et al.,
1992), Vitamin C, melatonin (Pappolla, Sos et al., 1997), ginko biloba (Smith and Luo,
2003), steroid hormones (Goodman, Bruce et al., 1996; Behl, Skutella et al., 1997), Nacetylcysteine (Adair, Knoefel et al., 2001), etc. However, many clinical trials are still
unsuccessful because all the antioxidants tested are poorly active in crossing the blood
brain barrier (BBB).
Glutathione is one of the major intracellular defense systems, and depletion of
GSH is known to be involved in several neurodegenerative disorders (Benzi and Moretti,
1995b; Markesbery, 1997; Butterfield, Castegna et al., 2002a). Many attempts have been
made to develop antioxidant compounds able to “mimic” GSH as scavenger of reactive
oxygen species (ROS) and to maintain the intracellular redox state. Increase in
endogenous GSH levels by dietary or pharmacological intake of GSH precursor or GSH
mimetic protects brain against oxidative stress (Anderson and Luo, 1998; Butterfield,
Drake et al., 2001; Halliwell, 2001). Considering the importance of developing new
antioxidant compounds and the relevance of their application in the treatment of
neurodegenerative diseases, we focused our attention on tricyclodecan-9-yl-xanthogenate
(D609). D609 is an inhibitor of phosphatidylcholine-specific phospholipase C (PC-PLC)
(Schutze, Potthoff et al., 1992; Wiegmann, Schutze et al., 1994) and sphingomyelinase
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(Yu, Nikolova-Karakashian et al., 2000; Meng, Luberto et al., 2004). D609 exhibits a
variety of potent biological properties, including antitumor (Amtmann and Sauer, 1987),
antiviral (Amtmann, Muller-Decker et al., 1987; Villanueva, Navarro et al., 1991) and
anti-inflammatory activities (Machleidt, Kramer et al., 1996). The xanthate D609 is a
reducing agent and it has been reported to protect rodents against UV-induced oxidative
damage (Zhou, Lauderback et al., 2001). Previous studies from our laboratory have
shown that D609 exerts its antioxidant properties acting as a glutathione (GSH)-mimetic
compound (Lauderback, Drake et al., 2003). The free thiol group of the xanthate is
oxidized to the corresponding disulfide (dixanthate) that is a substrate for GSH-reductase,
regenerating D609 active form (xanthate). D609 can scavenge hydrogen peroxide and
hydroxyl free radicals. In addition, D609 can bind directly to reactive alkenals, providing
detoxification of these lipid peroxidation end-products thereby preventing oxidative
damage of synaptic membranes (Lauderback, Drake et al., 2003). Recently, Sultana et al.
demonstrated that D609 is protective against Aβ-induced toxicity in primary neuronal
cultures (Sultana, Newman et al., 2004).
9.3. Purpose of the study

Based upon the mechanisms by which D609 scavenges free radicals, the aim of
the present study was to investigate the ability of D609 to provide in vivo neuroprotection
against Aβ-induced oxidative stress. The results are consistent with the hypothesis that
D609 is a potent antioxidant and could be beneficial in the treatment of AD and other
oxidative stress-related disorders.
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9.4. Experimentals
9.4.1. Chemicals

D09 was purchased from Biomol Inc (Plymouth Meeting, PA) and most other
chemicals were purchased from Sigma-Aldrich (St.Loius, MO, USA). The fluorescent
indicator for ROS measurement, 2,7-dichlorofluorescein diacetate (DCFH-DA), was
obtained from Molecular Probes (Eugene, OR, U.S.A.), and a fresh 10 mM stock solution
was prepared in ethanol. Fresh D609 was dissolved in phosphate-buffered saline (PBS).
The OxyBlot oxidized protein kit was obtained from Intergen, Inc. (Purchase, NY).
Amyloid-β peptide (1-42) (HPLC and MS certified quality) was purchased from
Anaspec, Inc. (San Jose, CA). For all experiments, Aβ was incubated for 24 hr in PBS at
37 °C before application to synaptosomes. Primary antibodies for 4-hydroxynonenal
(HNE) and 3-nitrotyrosine were obtained from Chemicon.
9.4.2. Animals

For the present study, three month-old male Mongolian gerbils, approximately
100 g in size, were used to isolate synaptosomes. All the following protocols were
approved by the University of Kentucky Animal Care and Use Committee. All the
animals were kept under twelve hours light/dark condition at University of Kentucky
Animal Facility, and fed with standard Purina rodent laboratory chow ad libidum. The
gerbils (n=12, 12 separate sets of experiments) were injected i.p. with freshly prepared
D609 (50 mg/Kg body weight) 1 hr before sacrifice. The dose and the time were chosen
according to previous experiments performed in our laboratory (Joshi, Sultana et al.,
2005a). Control animals were injected with saline solution for the same time (n=12). The
animals were euthanized with sodium pentobarbital before sacrifice.
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9.4.3. Synaptosomal preparation

Synaptosomes were prepared according to the procedure described by Keller et al.
(Keller, Lauderback et al., 2000). The brain was isolated immediately after decapitation
and placed in a 0.32M sucrose isolation buffer containing 4 μg/mL leupeptin, 4 μg/mL
pepstatin, 5 μg/mL aprotinin, 20 μg/mL trypsin inhibitor, 0.2 mM PMSF, 2 mM EDTA,
2mM EGTA, 20 mM HEPES pH 7.4. Samples were homogenized with a Wheaton tissue
homogenizer and centrifuged at 1,500 x g for 10 minutes. The supernatant was collected
and centrifuged at 20,000 x g for 10 min. The pellet was resuspended in 1mL of 0.32
sucrose isolation buffer and layered onto discontinuous sucrose density gradients of 10
mL each of 0.85M, pH 8.0; 1.0M, pH 8.0; 1.18M, pH 8.5 sucrose solution each
containing 10mM Hepes, 2mM EDTA and 2mM EGTA. The gradients were spun in a
Beckman L7-55 ultracentrifuge at 82,550 x g for 1 hr at 4 C. The synaptosomal layer was
collected at the 1/1.18M sucrose interface, washed twice with PBS for 10 min at 32000g,
yielding synaptosomes. Protein concentrations of the purified synaptosomes were
determined by the BCA assay (Pierce, Rockford, IL). Synaptosomal preparations
(1mg/mL) were incubated with 10 μM Aβ(1-42) for 6 hr at 37°C.
9.4.4. Reactive oxygen species (ROS) measurements

ROS levels were measured by dichlorofluorescein (DCF) assay. After incubation
with Aβ(1-42), synaptosomes (1mg/mL) were washed with PBS and incubated with 10
μM of non-fluorescent dichlorofluorescin diacetate (DCFH-DA) for 30 min. Cytosolic

esterases cleaved DCFH-DA, forming the anion DCFH that is trapped within the
synaptosomes. The reaction of intracellular ROS with DCFH yields the fluorescent dye
DCF. Synaptosomes were spun at 3,000 x g in a tabletop Eppendorf centrifuge for 5 min
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at 4°C. Synaptosomes were resuspended in 500 μL of PBS and run in triplicate (100 μL
per well) in a black microtiter plate. The measurements were performed on a Molecular
Devices SpectraMax microtiter plate reader with λex = 495 nm and λem = 530 nm. Data
are given as percentage of corresponding controls and are the mean of at least six
independent experiments.
9.4.5. Protein carbonyl measurement

Protein carbonyls are an index of protein oxidation and were determined as
described previously (Berlett and Stadtman, 1997). Briefly, 5 μL of synaptosome
preparations (4 mg/mL) were incubated at room temperature with 10 mM 2,4dinitrophenylhydrazine in the presence of 5 μL of 12% SDS for 20 min at room
temperature. The samples were neutralized with 7.5 μL of the neutralization solution (2
M Tris in 30% glycerol). 250 ng of protein sample was loaded into the wells of the slot
blot apparatus. Proteins were transferred directly to nitrocellulose paper under vacuum
pressure and standard immunochemical techniques were performed. Membranes were
blocked in the presence of 3% bovine serum albumin (BSA) in TBS-T (10 mM Tris-HCl,
pH 7.5, 150 mM NaCl, 0.05% Tween 20) for 1 h, followed by incubation with rabbit
polyclonal antibody anti-DNP (1:100) for 1 h. The membrane were washed three times
with TBS-T and incubated with alkaline-phosphatase (AP)-conjugated secondary
antibody for 1 h. The specificity of primary antibodies has been previously demonstrated
by experiments performed in our laboratory (Aksenov, Aksenova et al., 2001). Samples
were developed using SigmaFast Tablets (BCIP/NBT) substrate), and blots were scanned
into Adobe Photoshop (Adobe System, Inc., Mountain View, CA) and quantitated with
Scion Image (PC version of Macintosh compatible NIH Image).
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9.4.6. 3NT

Nitrotyrosine contents were determined by incubating 5 μL of synaptosomes
preparations with Laemmli buffer (0.125 M Trizma base, pH 6.8, 4% SDS, 20% glycerol)
for 20 min. 250 ng of protein were blotted onto nitrocellulose membranes and
immunochemical methods were performed. The rabbit anti–3-NT primary antibody was
incubated 1:200 in blocking buffer (BSA 3% in TBS-T) for 2 h. The membranes were
washed three times with TBS-T and incubated with alkaline phosphatase-conjugated goat
anti-rabbit secondary antibody (1: 10,000). Densitometric analysis of bands in images of
the blots was used to calculate levels of 3-NT.
9.4.7. HNE

Protein-bound HNE levels were measured as markers of lipid peroxidation. The
samples (5 μL) were incubated with 10 μL Laemmli buffer for 20 min at room
temperature. 250 ng of protein samples were loaded in each well on nitrocellulose
membrane in a slot blot apparatus under vacuum. The membranes were incubated with
anti–HNE rabbit polyclonal antibody (1: 5000) for 2 h, washed three times with TBS-T
and then incubated with an anti-rabbit IgG alkaline phosphatase-conjugated secondary
antibody (1:10,000). Controls in which the primary antibody was reacted with free HNE
resulted in faint and non-specific binding of the antibody (data not shown). In addition,
the specificity of primary and secondary antibodies was demonstrated by experiments
previously performed in our laboratory (Sultana, Newman et al., 2004; Perluigi, Fai Poon
et al., 2005). Samples were developed using SigmaFast Tablets (BCIP/NBT substrate),
and blots were scanned into Adobe Photoshop (Adobe System, Inc., Mountain View, CA)
and quantitated with Scion Image (PC version of Macintosh compatible NIH Image).
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9.4.8. GSH assay

GSH levels were measured by a GSH Assay Kit (Cayman Chemical Company,
Ann Harbor, MI). Briefly, the cytosolic fraction isolated from brain homogenates was
precipitated with 10% (w/v) metaphosphoric acid and then centrifuged for 5 min at 5,000
X g. The supernatants were neutralized with 4M triethanolamine and then analyzed

according to manufacturer instructions. GSH concentration in the samples was calculated
using the kinetic method by measuring the absorbance at 405 nm with a Bio-Tek
Powerwave X Microtiter Plate Reader (Bio, Inc.). A plot of the corrected absorbance vs
the concentration of GSH standards (μM) was utilized to calculate the average
concentration of GSH present in the samples.
9.4.9. iNOS expression levels

Synaptosome samples (50 μg) were mixed with sample loading buffer, denatured
for 5 min at 100 °C and then loaded on 10% SDS-polyacrylamide gels. Proteins were
transferred to nitrocellulose membrane in 25 mM Tris, 192 mM glycine containing 20%
(v/v) at 80 mA/gel for 2 h. For iNOS detection, membranes were probed first with 10 ml
of blocking buffer (3% BSA in TBS-T) containing rabbit anti-iNOS polyclonal antibody
(Santa Cruz Biotechnology Inc., CA 1:1000) for 2 h at 27 °C, followed by 10 ml of
blocking buffer containing alkaline phosphatase (AP)-conjugated goat anti-rabbit IgG
from Sigma Chemical Co. (St. Louis, MO, 1:5000) for 1 h at 27 °C. Membranes were
washed three times with T-TBS (0.5% tween in TBS) and the bands were visualized
using SigmaFast Tablets (BCIP/NBT) substrate). iNOS protein levels were normalized
relative to the β-actin level in each sample.
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9.5. Statistical analysis

ANOVA was used for statistical evaluation of data followed by Student’s t-test. P
values < 0.05 were considered significant for comparison between control and
experimental data.
9.6. Results
9.6.1. D609 prevents in vivo ROS accumulation

The DCFH-DA method was used to monitor the ROS levels generated by Aβ(142) in our experimental model. Figure 9.1 shows the levels of ROS in synaptosomes
isolated from saline/D609 injected gerbils (CTR), in synaptosomes isolated from saline
injected gerbils and treated in vitro with Aβ(1-42) and in synaptosomes isolated from
D609 injected gerbils and treated in vitro with Aβ(1-42). In the absence of10 μM Aβ(142), levels of ROS in synaptosomes from saline injected gerbils did not show any
significant difference compared with the levels measured in synaptosomes from D609
injected gerbils. Hence, both these groups can be referred as CTR. Thus, D609 itself does
not reduce basal oxidation levels. Synaptosomes isolated from saline injected gerbils and
treated with 10 μM Aβ(1-42) for 6 hrs displayed an increased fluorescence, about 20%
compared to control synaptosomes (untreated) (p < 0.005). Synaptosomes isolated from
D609 injected gerbils were not affected by Aβ(1-42)-induced ROS accumulation (p <
0.002). Thus, D609 is able to prevent ROS accumulation in synaptosomes.
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Figure 9.1: D609 prevents Aβ(1-42)-induced ROS production. ROS levels were

determined by the DCF fluorescence assay. Ctr = synaptosomes isolated from saline
injected gerbils with no further treatment (n=6, six separate sets of experiments); D609 =
synaptosomes isolated from D609 injected gerbils with no further treatment (n=6); Aβ(142) = synaptosomes isolated from saline injected gerbils and treated with 10 μM Aβ(142) for 6 hrs (n=6); Aβ(1-42) + D609 = synaptosomes isolated from D609 injected
gerbils and treated with 10 μM Aβ(1-42) for 6hrs (n=6). The data are the mean ± S.E.M
of six independent experiments, expressed as percentage of control values. Statistical
comparison was made using ANOVA test (n=6 for each group). (*) p < 0.005, Aβ(1-42)
vs Control; (**) p < 0.002, Aβ(1-42) vs Aβ(1-42) + D609.
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9.6.2. D609 in vivo protects against Aβ(1-42)-induced protein oxidation and
lipid peroxidation

Protein carbonyls and 3-NT levels were measured as markers of protein oxidation
(Stadtman and Berlett, 1997). Collectively, ROS can lead to the oxidation of amino acid
residue side chains, formation of protein-protein cross-linkages and oxidation of the
protein backbones resulting in protein fragmentation. The presence of carbonyl groups in
proteins has therefore been used as a marker of ROS-mediated protein oxidation. Fig.
9.2a shows the carbonyl levels in synaptosomes isolated from saline injected gerbils and
from D609 injected gerbils, and then treated in vitro with Aβ(1-42). The level of
carbonyls was found to be significantly higher (p < 0.001) in synaptosomes obtained
from saline injected gerbils and treated with Aβ(1-42). D609 treatment protects
synaptosomes against Aβ(1-42)-induced oxidative protein damage (p < 0.004).
In order to demonstrate the specificity of D609, two other Aβ peptides, Aβ(1-40)
and control reverse of Aβ peptide (Aβ (42-1)) were used. Figure 9.2b shows the carbonyl
levels in Various Aβ peptide treated synaptosomes and in synaptosomes isolated from
D609 injected gerbils subsequently treated with Aβ(1-42), Aβ(1-40) and Aβ(42-1)
respectively. As shown in figure, D609 treatment protects synaptosomes against Aβ(142) and Aβ(1-40)-induced oxidative protein damage (p < 0.05). There was no significant
increase in protein carbonyl levels in synaptosomes isolated from saline injected and
D609 injected gerbils subsequently treated with Aβ(42-1).
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Figure 9.2a: Protective effects of D609 on Aβ-induced protein oxidation.

Synaptosomes isolated from saline injected gerbils and treated with 10μM Aβ(1-42)
demonstrate a higher level of protein carbonyls than that of untreated controls (Ctr and
D609). (*) p < 0.001, Aβ(1-42) vs Control. Synaptosomes isolated from D609 injected
gerbils were completely protected from Aβ-induced oxidative modifications [Aβ(1-42) +
D609]. (**) p < 0.004, Aβ(1-42) vs Aβ(1-42) + D609. (Data collected in collaboration
with Dr. Marzia Perluigi)
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Figure 9.2b: Protective effects of D609 on Aβ-induced protein oxidation.

Synaptosomes isolated from saline injected gerbils and treated with 10μM Aβ(1-42) and
10μM Aβ(1-40) demonstrate a higher level of protein carbonyls than that of untreated
controls, whereas 10μM Aβ(42-1) did not show any significant increase in protein
carbonyls. Synaptosomes isolated from D609 injected gerbils were completely protected
from Aβ(1-42) andAβ (1-40) induced oxidative modifications. (*) p < 0.05, n = 5.
The antioxidant properties of D609 were further confirmed by measuring 3NT
levels, formed by reaction of reactive nitrogen species (RNS) with proteins (Castegna,
Thongboonkerd et al., 2003). Figure 9.3 shows the protective effects of D609 on Aβ(142)-induced formation of 3NT. Synaptosomes isolated from saline injected gerbils
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showed increased levels of 3NT (p < 0.005) when treated in vitro with Aβ(1-42), while
synaptosomes isolated from D609 injected gerbils were completely protected (p < 0.05).
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Figure 9.3: Protective effect of D609 on Aβ-induced 3-NT formation. 3-NT

levels were determined as described in the “Material and Methods” section. Ctr =
synaptosomes isolated from saline or D609 injected gerbils with no further treatment;
D609 = synaptosomes isolated from D609 injected gerbils with no further treatment;
Aβ(1-42) = synaptosomes isolated from saline injected gerbils and treated with 10 μM
Aβ(1-42) for 6 hrs; Aβ(1-42) + D609 = synaptosomes isolated from D609 injected
gerbils and treated with 10 μM Aβ(1-42) for 6 hrs. The data are the mean ± S.E.M
expressed as percentage of control values (n=6). (*) p < 0.005, Aβ(1-42) vs Control; (**)
p < 0.05, Aβ(1-42) vs Aβ (1-42) + D609. (Data collected in collaboration with Dr.
Marzia Perluigi)
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Free radical attack on phospholipids PUFA leads to the formation of reactive
aldehydes, among which one of the most neurotoxic is HNE (Esterbauer, Schaur et al.,
1991). This alkenal reacts with proteins forming stable covalent adducts to histidine,
lysine and cysteine residues via Michael addition. The extent of this reaction can be
measured immunochemically by quantifying the levels of HNE-bound proteins. Figure
9.4 shows the HNE-bound protein levels in synaptosomes isolated from gerbils
previously injected with D609 or with saline solution and incubated in vitro with 10 μM
Aβ(1-42) for 6 hrs. Consistent with the protein oxidation results showed above, we
observed in vivo protection by D609 against 10 μM Aβ-induced lipid peroxidation. HNE
levels were found to be higher in Aβ(1-42)-treated synaptosomes isolated from saline
injected gerbils, while Aβ(1-42)-treated synaptosomes isolated from D609 injected
gerbils showed reduced levels of HNE-bound proteins. These results are consistent with
recent in vitro data obtained on primary neuronal cultures (Sultana, Newman et al.,
2004), indicating that D609 acts as a potent antioxidant thus preventing protein oxidation
and lipid peroxidation.
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Figure 9.4: Protective effect of D609 on Aβ-induced lipid peroxidation (HNE

levels). HNE levels were determined as described in the “Material and Methods” section.
Ctr = synaptosomes isolated from saline/D609 injected gerbils; D609 = synaptosomes
isolated from D609 injected gerbils with no further treatment; Aβ(1-42) = synaptosomes
isolated from saline injected gerbils and treated with 10 μM Aβ(1-42) for 6 hrs; Aβ(1-42)
+ D609 = synaptosomes isolated from D609 injected gerbils and treated with 10 μM
Aβ(1-42) for 6 hrs. The data are the mean ± SEM expressed as percentage of control
values (n=6). (*) p < 0.005, Aβ(1-42) vs Control; (**) p < 0.05, Aβ(1-42) vs Aβ (1-42) +
D609. (Data collected in collaboration with Dr. Marzia Perluigi)
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9.6.3. D609 modulates Aβ(1-42)-induced iNOS expression levels

As shown in Fig. 9.5, iNOS levels were significantly increased (40%) in
synaptosomes isolated from DMSO-injected gerbils treated with Aβ(1-42) when
compared with controls (p < 0.01). In contrast, we observed a decrease in expression of
iNOS in synaptosomes isolated from D609-injected gerbils (p < 0.05) and subsequently
treated with Aβ(1-42), a result that is consistent with our findings of decreased levels of
3-NT. Several lines of evidence show that iNOS expression is induced by oxidative stress
and that antioxidant compounds suppress its expression either at gene level or at protein
level (Ayasolla, Khan et al., 2004; Calabrese, Stella et al., 2004). In the present study, we
observed that both iNOS and 3NT levels were increased in Aβ(1-42)-treated
synaptosomes and that D609 treatment showed protection against the Aβ(1-42)-induced
increase of iNOS and 3-NT levels.
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Figure 9.5: Western blot analysis of synaptosomes for iNOS protein expression

levels. Samples containing 50 μg of protein were loaded onto 10% SDS-PAGE gels, and
the blots were probed with the polyclonal anti-iNOS antibody (1:1000) for 2 h.
Immunoblots were scanned by densitometry and all values were normalized to β-actin. A
representative immunoblot (A) and densitometric values (B) are shown. Densitometric
values represent the mean ± S.E.M. obtained from three independent experiments.
Significant differences were assessed by ANOVA. * p < 0.01, control vs Aβ(1-42); ** p
< 0.05, Aβ(1-42) + D609. (Data collected in collaboration with Dr. Marzia Perluigi)
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9.7. Discussion

Oxidative damage is present in the brains of patients with AD, and is observed
within every class of biomolecules, including nucleic acids, proteins, lipids and
carbohydrates (Butterfield, Drake et al., 2001; Butterfield and Lauderback, 2002;
Castegna, Thongboonkerd et al., 2003). Our laboratory has suggested a comprehensive
model for neurodegeneration in AD combining two established notions: i) elevated
oxidative stress in AD brain; ii) centrality of Aβ in the cause and consequences of this
dementing disorder (Butterfield and Lauderback, 2002; Castegna, Thongboonkerd et al.,
2003). Many additional studies from different labs have supported the view that oxidative
stress may be central to the Aβ-driven neurodegeneration. Based on these notions,
treatment with brain accessible antioxidants may be a promising approach for slowing
disease progression to the extent that oxidative damage may be responsible for the
cognitive and functional decline observed in AD.
Previous studies from our laboratory and others have shown that Aβ(1-42) is
associated with free radical generation leading to oxidative damage of proteins, lipids,
DNA and RNA (Varadarajan, Yatin et al., 2000; Butterfield, Drake et al., 2001;
Butterfield and Lauderback, 2002). The oxidation of proteins by free radicals or free
radical oxidation products may be responsible for damaging enzymes critical in neuronal
function (Varadarajan, Yatin et al., 2000; Butterfield, Boyd-Kimball et al., 2003).
In the present study, we showed the ability of in vivo-injected D609 to provide
neuroprotection against oxidative stress induced by Aβ(1-42) on subsequently isolated
synaptosomes. A variety of well established and new potential antioxidant compounds
are under investigation to prevent Aβ-induced toxic effects (Behl, 2002; Grundman and
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Delaney, 2002). Among different classes of antioxidant drugs, much interest has been
devoted to “thiol-delivering” compounds. Because decreased levels of GSH are
associated with aging and neurodegeneration (Liu and Choi, 2000; Butterfield, Castegna
et al., 2002a), therapeutic strategies based on elevation of GSH levels have been shown to
be protective against oxidative stress conditions of the brain (Butterfield, Castegna et al.,
2002a). The age-related decrease of GSH may represent a key factor in the aging process
and may underlie a number of changes occurring in normal aging and the onset of various
diseases.
We have previously shown that the antioxidant properties of D609 are associated
with the free thiol group of the xanthate (Lauderback, Drake et al., 2003). For example,
methylated D609 is unable to protect cultured neurons from damage by Aβ(1-42)
(Sultana et al., 2004).

D609 in its reduced form is oxidized to the corresponding

disulfide (dixanthate) that is converted back to the xanthate by GSH reductase
(Lauderback et al., 2003). D609 has been reported to protect against glutamate toxicity
and ionizing radiation-induced oxidative stress in lymphocytes by maintaining
intracellular GSH homeostasis (Zhou, Lauderback et al., 2001). The results presented in
this paper demonstrated that in vivo injection of D609 was effective in reducing protein
oxidation, lipid peroxidation and ROS production induced by Aβ(1-42) treatment.
The concept that Aβ induces lipid peroxidation is a key component of the Aβ(142)-associated free radical model for neurodegeneration in AD (Butterfield, 1997;
Varadarajan, Yatin et al., 2000; Lauderback, Hackett et al., 2001). HNE alters the
conformation of transmembrane and cytoskeletal synaptosomal proteins (Esterbauer,
Schaur et al., 1991; Subramaniam, Roediger et al., 1997). GSH blocks the damaging
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effects of this unsaturated aldehyde on synaptosomal proteins (Pocernich, La Fontaine et
al., 2000; Pocernich, Cardin et al., 2001). As noted above, D609 binds to α,β-unsaturated
aldehydes to prevent their toxicity (Lauderback, Drake et al., 2003). Taken together,
these data support the notion that the ability of D609 to exert its protective effects against
Aβ-associated lipid peroxidation involves its direct binding to HNE thus providing an
efficient tool for detoxication. Consistent with the Aβ-associated free radical process,
Aβ(1-42) induces protein oxidation, indexed by the increase of carbonyl levels and of
nitrotyrosine residues. Oxidative modification of crucial proteins results in alteration of
their structural and functional properties, eventually leading to synapse loss and
neurodegeneration.
There is compelling evidence supporting that enhanced pro-inflammatory
activities induced by Aβ are associated with the pathogenesis and/or progression of AD,
and that some anti-inflammatory agents protect neurons against Aβ-induced neurotoxicity
(Breitner, 1996). One of the principal enzymes that play a pivotal role in mediating an
inflammatory response is inducible nitric oxide synthase (iNOS). iNOS is mainly
localized in astrocytes and microglia, and catalyzes the oxidative deamination of Larginine to produce nitric oxide (NO), a potent pro-inflammatory mediator. In
Alzheimer’s tissue, pro-inflammatory iNOS is notably up-regulated and colocalized in
Aβ plaques. Several studies have demonstrated that Aβ stimulates microglial and
astrocytic iNOS induction and subsequent NO production (Akama and Van Eldik, 2000).
We observed an increase in 3NT levels in synaptosomes isolated from DMSO-injected
gerbils and treated with Aβ(1-42) that coincides with a parallel increase in iNOS levels.
Pre-treatment with D609 reduced significantly the levels of iNOS and of nitrated
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proteins. iNOS induction may reflect the degree of inflammation associated to Aβ(1-42),
and the ability of D609 to block this effect may represent a further additional protective
mechanism in addition to the antioxidant potential of this xanthate.
The levels of oxidized glutathione are consistently elevated in Alzheimer’s
patients as compared to their age-matched controls and correlate with cognitive
dysfunction (Vina, Lloret et al., 2004). Recent findings suggested that Aβ could initiate a
cascade of events resulting in a severe depletion of glutathione (Abramov, Canevari et al.,
2003). Alteration of glutathione homeostasis impairs neuronal viability because GSH
depletion leaves the neurons vulnerable to damage by oxidative stress. Here, we
demonstrated that D609 is able to provide neuroprotection against Aβ-induced
neurotoxicity acting as a glutathione-mimetic compound, thus modulating the effects of
GSH depletion. Previous studies from our laboratory have shown that i.p. administration
of N-acetylcysteine and of gamma-glutamyl-cysteine ethyl ester (GCEE) protected
synaptosomes against oxidative stress (Pocernich, Cardin et al., 2001; Butterfield,
Castegna et al., 2002a; Boyd-Kimball, Sultana et al., 2005a). These compounds led to an
increase of brain glutathione by serving as precursor for GSH biosynthesis. Because
glutathione itself penetrates the blood-brain barrier only poorly and cannot be taken up by
neurons directly, other treatment options to increase brain concentration of glutathione
including glutathione analogs, mimetic or precursors have been used in patients or animal
models. Based on the results presented in the current paper and on our previous studies
(Sultana, Newman et al., 2004), we hypothesized that D609 is a potential brain-accessible
GSH-mimetic compound. This hypothesis that D609 is a GSH mimetic that is itself not
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GSH is further supported by the finding that D609 treatment does not lead to an increase
of brain GSH levels (Table 9.1).
Injection

GSH (mM) ± S.E.M

Control

4.27 ± 0.87

D609

3.98 ± 0.54

Table 9.1: D609 does not influence total brain GSH levels. Results presented are

the mean ± S.E.M, n=6. Total GSH levels, following i.p D609 injection, were measured
by a GSH assay kit as described in the Chapter 3.
The ability of in vivo D609 to prevent Aβ-induced oxidative stress could also be
related to its property as an inhibitor of PC-PLC and sphingomyelinase. Most of D609
biological activities (antitumor, antiviral, anti-inflammatory) have been largely attributed
to the inhibition of PC-PLC and sphingomyelinase. However, the identification of D609
as a potent antioxidant implies that D609 may exert some of the reported activities by its
antioxidant properties. The biological activity of PC-PLC and sphingomyelinase involves
regulation of Ca+2 homeostasis through the production of ceramide. Since Aβ may lead to
altered Ca+2 homeostasis in neurons (Mattson, Barger et al., 1993), it is reasonable to
argue that the protective effects of D609 could rely also on its inhibitory activity on PCPLC or sphingomyelinase. Thus, we suggest that multiple biological functions of D609
could potentially contribute to counteract Aβ-driven neurotoxicity in the brain. The
presence of the free thiol group in the molecule confers to the xanthate a strong reducing
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property (Rao, 1971; Lauderback, Drake et al., 2003; Sultana, Newman et al., 2004) that
is undoubtedly responsible for the antioxidant activity of D609.
Considering that Aβ(1-42) is a potent inducer of oxidative stress and that the
deposition of this peptide can induce the cascade of pathological changes occurring in
AD, many attempts to test effective protection by antioxidants are currently under
investigation.

However, many clinical trials are unsuccessful due to a low brain-

accessible capability of the antioxidant compounds tested. Based on these notions,
searches for new potential antioxidant compounds could be of relevance for future
directions of AD treatments.
In conclusion, the present study demonstrated the ability of D609 to act as a
potent antioxidant in vivo, thereby providing neuroprotection against Aβ-induced
oxidative stress. Further studies are required to gain insight into the potential use of D609
in the treatment of AD and other oxidative stress-related disorders. Investigations of the
use of D609 on animal models of AD are in progress.
Note: A part of this study was carried out by Dr. Marzia Perluigi in Prof. Butterfield`s

laboratory that has been supported by a post-doc grant of the University of Rome “La
Sapienza”.

Copyright © Gururaj Joshi 2006
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Chapter 10
In vivo administration of D609 leads to protection of subsequently isolated gerbil
brain mitochondria subjected to in vitro oxidative stress inducers: Relevance to
Alzheimer’s disease and other oxidative stress related neurodegenerative disorders
10.1. Overview of the study

Tricyclodecan-9-yl-xanthogenate (D609) has in vivo and in vitro antioxidant
properties. D609 mimics glutathione (GSH), has a free thiol group, which upon oxidation
forms a disulfide. The resulting dixanthate is a substrate for glutathione reductase,
regenerating D609. Recent studies have also shown that D609 protects brain in vivo and
neuronal cultures in vitro against the potential Alzheimer’s disease (AD) causative
factor, Aβ (1-42)-induced oxidative stress and cytotoxicity. Mitochondria are important
organelles with both pro- and anti-apoptotic factor proteins. The present study was
undertaken to test the hypothesis that i.p. injection of D609 would provide
neuroprotection against free radical-induced, mitochondria-mediated apoptosis, in vitro.
Brain mitochondria were isolated from gerbils 1 h post injection intraperitonially (i.p.)
with D609 and subsequently treated in vitro with the oxidants Fe2+/H2O2 (hydroxyl free
radicals), 2,2-azobis-(2-amidinopropane) dihydrochloride (AAPH, alkoxyl and peroxyl
free radicals) and AD-relevant amyloid β-peptide 1-42 [Aβ (1-42)]. Brain mitochondria
isolated from the gerbils previously injected i.p. with D609 and subjected to these
oxidative stress inducers, in vitro, showed significant reduction in levels of protein
carbonyls, protein-bound hydroxynonenal (HNE) [a lipid peroxidation product], 3nitrotyrosine (3-NT), and cytochrome-c release compared to oxidant-treated brain
mitochondria isolated from saline-injected gerbils. D609 treatment significantly
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maintains the GSH/GSSG ratio in oxidant-treated mitochondria. Increased activity of
glutathione-S-transferase (GST), glutathione peroxidase (GPx) and glutathione reductase
(GR) in brain isolated from D609-injected gerbils is consistent with the notion that D609
acts like GSH. These anti-apoptotic findings are discussed with reference to the potential
use of this brain-accessible glutathione mimetic in the treatment of oxidative stressrelated neurodegenerative disorders, including AD.
10.2. Introduction

Oxidative stress has been implicated in many neurodegenerative disorders,
including Alzheimer's disease (AD) (Hensley, Hall et al., 1995; Markesbery and Lovell,
1998; Butterfield, Drake et al., 2001; Butterfield and Lauderback, 2002), AD is
characterized clinically by progressive dementia and pathologically by extracellular
amyloid protein deposits, intracellular neurofibrilary tangles (NFTs) (composed mostly of
hyperphosphorylated tau protein), loss of synapses, mitochondrial dysfunction and
programmed cell death (PCD) (Katzman and Saitoh, 1991; Bosetti, Brizzi et al., 2002).
The reduced energy metabolism in AD may be due to oxidative dysfunction of some of
the key metabolic or mitochondrial enzymes (Castegna, Aksenov et al., 2002a; Castegna,
Thongboonkerd et al., 2003; Butterfield, 2004; Castegna, Thongboonkerd et al., 2004;
Sultana, Boyd-Kimball et al., 2006b; Sultana, Poon et al., 2006b), which may lead to
increased reactive oxygen species (ROS) production.
It is well known that mitochondria are the major cellular site of energy
production, and these organelles also play a key role in the ROS generation, resulting in
oxidative damage to neurons. Amyloid deposition, oxidative stress, mitochondria DNA
deletion and mitochondrial structural and functional abnormalities are prominent in AD
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(Bosetti, Brizzi et al., 2002; Huang, Zhang et al., 2004; Aliyev, Chen et al., 2005). Many
pro-apoptotic signals and anti-apoptotic defenses converge in the mitochondria
(Antonsson, 2004). Protein factors (cytochrome-C, Apaf1, AIF and SMAC/DIBLO) and
Ca2+ released from mitochondria during oxidative stress activate caspase dependent
and/or caspase independent mechanisms that lead to apoptotic cell death (Antonsson,
2004). The role of mitochondria is not only as ATP producers but also as regulators of
intracellular Ca2+ homeostasis and endogenous producers of ROS. Increased
mitochondrial Ca2+ overload has been associated with the generation of superoxide and
the release of pro-apoptotic mitochondrial proteins leading to cell death (Zamzami,
Marchetti et al., 1995; Sheehan, Swerdlow et al., 1997).

The alterations in Ca2+

homeostasis and ROS generation lead to increased susceptibility to cell death under
circumstances that are otherwise not ordinarily toxic (Sheehan, Swerdlow et al., 1997).
In AD brain ROS lead to protein oxidation (Hensley, Hall et al., 1995; Castegna,
Aksenov et al., 2002a; Castegna, Thongboonkerd et al., 2003; Butterfield, 2004;
Castegna, Thongboonkerd et al., 2004; Sultana, Boyd-Kimball et al., 2006b; Sultana,
Poon et al., 2006b), lipid peroxidation (Markesbery and Lovell, 1998; Butterfield and
Lauderback, 2002), DNA and RNA oxidation (Mecocci, MacGarvey et al., 1993; Lovell,
Gabbita et al., 1999; Nunomura, Perry et al., 1999), and neuronal dysfunction or death.
Recent studies indicate that protein oxidation and lipid peroxidation in brain from mild
cognitive impairment subjects (Butterfield, Poon et al., 2006; Butterfield, Reed et al.,
2006), suggesting oxidative stress is an early event in the pathogenesis of AD. ROS
generation from mitochondria and its impact on neuronal systems hence becomes
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important in understanding oxidative stress and oxidative stress-related disorders,
including AD.
Mitochondrial electron transport is a potential source of ROS production (Ide,
Tsutsui et al., 1999). It is now well known that ROS such as superoxide anion (O2-),
hydroxyl radical (OH), hydrogen peroxide (H2O2), and peroxynitrite (ONOO-) contribute
to neurodegeneration (Zhang, Dawson et al., 1994; Rego and Oliveira, 2003; Ansari,
Ahmad et al., 2004; Butterfield, Reed et al., 2006; Tangpong, Cole et al., 2006a).
Mitochondrial membrane potential depolarization induces cytochrome-c release into the
cytoplasm and elevates the activity of caspase-3, suggesting a role for mtDNA-derived
mitochondrial dysfunction in AD degeneration (Bosetti, Brizzi et al., 2002).
Glutathione is widely recognized as an endogenous nonenzymatic antioxidant, an
oxyradical scavenger, thereby useful in protecting against oxidative damage by free
radicals and inhibiting lipid peroxidation and DNA damage (Meister, 1995; DarleyUsmar and Halliwell, 1996; Sies, 1999; Schulz, Lindenau et al., 2000; Hansen, Go et al.,
2006). Glutathione has been implicated in a wide range of metabolic processes, including
cell division, DNA repair, regulation of enzyme activity, activation of transcription
factors, modulation of anion and cation homeostasis and protection against oxidative
damage (Meister and Anderson, 1983). The nervous system is particularly susceptible to
oxidative insults, and dependent on its glutathione defense.
Tricyclodecan-9-yl-xanthogenate (D609) exhibits a variety of potent biological
functions, including antiviral (Amtmann, 1996) and anti-inflammatory (Amtmann and
Sauer, 1987; Sauer, Amtmann et al., 1990; Tschaikowsky, Schmidt et al., 1998)
activities. Most of these activities have been linked to the inhibitory effect of D609 on
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phosphatidylcholine-specific phospholipase C (PC-PLC) (Schutze, Potthoff et al., 1992;
Amtmann, 1996). Such inhibition decreases production of the secondary messenger
diacylglycerol (DAG) that activates protein kinase C (PKC) and acidic sphingomyelinase
(aSMase) (Cifone, Roncaioli et al., 1995). However, with a free thiol group, D609 may
also possess strong antioxidant activity (Rao, 1971) with in vitro and in vivo radical
scavenging properties and inhibition of free radial-induced oxidative stress (Zhou,
Lauderback et al., 2001; Lauderback, Drake et al., 2003; Sultana, Newman et al., 2004;
Joshi, Sultana et al., 2005a; Perluigi, Joshi et al., 2006).
10.3. Purpose of the study

The particular species of ROS that D609 can effectively scavenge is not clear, but
this xanthate has ability to scavenge hydroxyl radicals (Zhou, Lauderback et al., 2001;
Lauderback, Drake et al., 2003; Sultana, Newman et al., 2004; Joshi, Sultana et al.,
2005a; Perluigi, Joshi et al., 2006). The reaction with other ROS is also possible since
xanthates generally have high reductive potential (Rao, 1971). D609 may protect
intracellular GSH, which is important intracellular defense molecule against oxidative
stress in neurons and has been shown to play an important role in radiation protection
(Anderson and Luo, 1998; Halliwell, 2001; Zhou, Lauderback et al., 2001). Recently, we
showed that D609, a glutathione mimetic (Lauderback, Drake et al., 2003), protects
primary neuronal culture against amyloid β-peptide (1-42) [Aβ (1-42)]-induced oxidative
stress and neurotoxicity in vitro (Sims, 1990) and in synaptosomes in vivo (Perluigi, Joshi
et al., 2006).
We performed the current study to test the hypothesis that the D609-mediated in
vivo protection of brain mitochondria against subsequent in vitro treatment of various
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oxidants, including Aβ (1-42), is associated with D609-mediated modulation of GSH and
GSH related enzyme activities.
10.4. Experimentals
10.4.1. Animals

For all studies male Mongolian gerbils (2–3 months of age), approximately 100 g
in size, housed in the University of Kentucky Central Animal Facility under 12-h
light/dark conditions and fed standard Purina rodent laboratory chow ad libitum, were
used. The animal protocols were approved by the University of Kentucky Animal Care
and Use Committee.
10.4.2. Chemicals

D609 was purchased from Biomol (Plymouth Meeting, PA, USA) and all other
chemicals were purchased from Sigma–Aldrich (St. Louis, MO, USA). Fresh D609 (50
mg/ kg body wt) was prepared in phosphate-buffered saline (PBS). The primary anti body
for 4-hydroxy-nonenal (HNE) and 3-nitrotyrosine (3-NT) were purchased from
Chemicon International.
10.4.3. Preparation of mitochondria

Brain mitochondria were isolated from gerbils previously injected i.p. with saline
(control) or with D609 (50 mg/ kg body wt), 60 min after injection. This time and level of
D609 were chosen based on previous (Joshi, Sultana et al., 2005a) dose-response
experiments. The brain mitochondria were isolated according to the procedure of Sims et
al. (Sims, 1990) with minor modifications. Gerbils were decapitated and the whole brain
was isolated on ice. Whole brain was homogenized in ice-cold isolation buffer (250 mM
sucrose, 10 mM HEPES, and 1 mM potassium EDTA, pH 7.2, 4 μg/ml leupeptin, 4
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μg/ml pepstatin, 5 μg/ml aprotinin 20 μg/ml trypsin inhibitor) with 6 passes of a Wheaton

tissue homogenizer. The homogenate was centrifuged for 3 min at 1,330× g at 4°C, and
the resulting pellet was resuspended in isolation buffer and centrifuged at 1,330× g for 3
min. The supernatants from both spins were combined and spun at 21,200x g for 10 min
at 4°C. The pellet was resuspended in 15% Percoll solution (v/v in isolation buffer) and
layered onto discontinuous Percoll gradients of 23 and 40% Percoll (v/v in isolation
buffer). Gradients were centrifuged at 30,700× g for 5 min at 4°C. At the 23-40% Percoll
interface, mitochondria were isolated and resuspended in respiration buffer (250 mM
sucrose, 2 mM magnesium chloride, 20 mM HEPES, and 2.5 mM phosphate buffer, pH
7.2) and centrifuged at 16,700× g for 10 min at 4°C. The pellet was resuspended in
respiration buffer, centrifuged at 6,900× g for 10 min at 4°C, and the resulting pellet was
washed in PBS at 6,900× g for 10 min at 4°C.
10.4.4. Protein estimation and treatment

The pellet was resuspended in 250 μl PBS and protein concentration determined
by the Pierce BCA method (Bradford, 1976), using bovine serum albumin (BSA) as a
standard. The mitochondrial samples were divided into six aliquots and incubated at 37
0

C. The first sample set was incubated without treatment of any oxidant for 1 h; the

second set of mitochondria was incubated with 30 μM Fe SO4 and 2.0 mM H2O2, a
process that induces hydroxyl radical formation (Halliwell and Gutteridge, 1999), the
third and fourth set of samples were also incubated in same manner with/or without the
oxidant AAPH (1 mM) for 1 h at 37 0C. The fifth sample set was incubated without
treatment of any oxidant for 6 h and the sixth sample set was incubated with Aβ(1-42) for
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6 h. The mitochondrial samples were washed after incubation and resuspended in
PBS/Tween.
10.4.5. Protein carbonyls

Protein carbonyls are markers of protein oxidation and were assessed by
following the standard protocol described previously (Joshi, Sultana et al., 2005a).
Samples (5 μl) (normalized to 4 mg/ml), 5 μl of 12% sodium dodecyl sulfate (SDS), and
10 μl of 10 times diluted 2,4-dinitrophenyl hydrazine (DNPH) from 200 mM stock were
incubated at room temperature for 20 min. Samples were neutralized with 7.5 μl
neutralization solution (2 M Tris in 30% glycerol). The resulting solution was loaded into
each well on nitrocellulose membrane under vacuum using a slot-blot apparatus. The
membrane was blocked in blocking buffer (3% bovine serum albumin) in PBS/Tween for
1 h and incubated with a 1:100 dilution of anti-DNP polyclonal antibody in PBS/Tween
for 1 h. The membrane was washed three times in PBS/Tween and was incubated for 1 h
with an anti-rabbit IgG alkaline phosphatase secondary antibody diluted in PBS/ Tween
in a 1:8000 ratio. The membrane was washed three times in PBS/ Tween for 5 min and
developed in Sigma Fast tablets (BCIP/ NBT substrate). Blots were dried, scanned with
Adobe PhotoShop, and quantified with Scion Image (PC version of Macintoshcompatible NIH Image). No non-specific binding of antibody to the membrane was
observed.
10.4.6. 3NT

Samples (5 μl) (normalized to 4 mg/ml), 5 μl of 12% SDS, and 5 μl of modified
Laemmli buffer containing 0.125 M Tris base, pH 6.8, 4% (v/v) SDS, and 20% (v/v)
glycerol were incubated for 20 min at room temperature. Sample (250 ng) was loaded
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into each well on a nitrocellulose membrane in a slot blot apparatus under vacuum. The
membrane was blocked in blocking buffer (3% bovine serum albumin) in PBS/Tween for
1 h and incubated with a 1:2000 dilution of anti-3-N T polyclonal antibody in
PBS/Tween for 1 h 30 min. The membrane was washed in PBS/Tween for 5 min three
times after incubation. The membrane was incubated for 1 h, after washing, with an antirabbit IgG alkaline phosphatase secondary anti body diluted in PBS/Tween in a 1:8000
ratio. The membrane was washed three times in PBS/Tween for 5 min and developed in
Sigma Fast tablets. Blots were dried, scanned with Adobe PhotoShop, and quantified
with Scion Image as above. No non-specific binding of antibody to the membrane was
observed.
10.4.7. HNE

Sample (5 μl) (normalized to 4 mg/ml), 5 μl of 12% SDS, and 5 μl of modified
Laemmli buffer containing 0.125 M Tris base, pH 6.8, 4% (v/v) SDS, and 20% (v/v)
glycerol were incubated for 20 min at room temperature. Sample (250 ng) was loaded
into each well on a nitrocellulose membrane in a slot blot apparatus under vacuum. The
membrane was blocked in blocking buffer (3% bovine serum albumin) in PBS/Tween for
1 h and incubated with a 1:5000 dilution of anti-HNE polyclonal antibody in PBS/Tween
for 1 h 30 min. The membrane was washed in PBS/Tween for 5 min three times after
incubation. The membrane was incubated for 1 h, after washing, with an anti-rabbit IgG
alkaline phosphatase secondary antibody diluted in PBS/Tween in a 1:8000 ratio. The
membrane was washed three times in PBS/Tween for 5 min and developed in Sigma Fast
tablets. Blots were dried, scanned with Adobe PhotoShop, and quantified with Scion
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Image as above. A faint background staining due to the antibody alone was observed, but
since each sample had a control, this minor effect was well controlled.
10.4.8. Estimation of cytochrome-c release

Cytochrome c release was detected by the method of Yang et al., (1997) (Yang,
Liu et al., 1997)with slight modification. After incubation and spun of mitochondrial
samples, supernatant was used for Western blot analysis to cytochrome c release. The
membrane was blocked in blocking buffer (3% bovine serum albumin) in PBS/Tween for
1 h and incubated with a 1:2000 dilution of anti-cytochrome-c polyclonal antibody (C5723; anti-sheep; Sigma) in PBS/Tween for 1 h 30 min. The membrane was washed in
PBS/Tween for 5 min three times after incubation. The membrane was incubated for 1 h,
after washing, with an anti-sheep IgG alkaline phosphatase secondary anti body diluted in
PBS/Tween in a 1:8000 ratio. The membrane was washed three times in PBS/Tween for
5 min and developed in Sigma Fast tablets. Blots were dried, scanned with Adobe
PhotoShop, and quantified with Scion Image as above.
10.4.9. Estimation of reduced glutathione (GSH)

Determination of GSH was performed by the method of Hissin and Hilf (Hissin
and Hilf, 1976). The reaction mixture containing 0.1 M sodium phosphate buffer (pH8.0), 5.0 mM EDTA, 10 μl O-phthaldehyde (1.0 mg/ml) and 10 μl of sample. After
incubation for 15 min at room temperature, fluorescence at emission 420 nm was
recorded by excitation at 350nm.
10.4.11. Estimation of oxidized glutathione (GSSG)

The estimation of GSSG was performed by the method of Hissin and Hilf (Hissin
and Hilf, 1976). The samples were incubated first with 0.04 M N-ethyleimide (NEM) for
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30 min to interact with GSH present in sample. The reaction mixture containing 0.1 N
NaOH, 5.0 mM EDTA, 10 μl O-phthaldehyde (1.0 mg/ml) and 10 μl of sample. After
incubation for 15 min at room temperature, fluorescence at emission 420 nm was
recorded by excitation at 350nm.
10.4.12. Enzyme activities
10.4.12.1. Estimation of glutathione-S-transferase activity

GST (EC 2.5.1.18) activity was measured in a 96-well plate reader, with the
reaction mixture consisting of 0.1 M phosphate buffer (pH 6.5), 1.0 mM reduced
glutathione, 1.0 mM CDNB and 0.1 μl of PMS in a total volume of 200 μl(Habig, Pabst
et al., 1974). The changes in absorbance were recorded at 340 nm, and the enzymatic
activity was calculated as nmol CDNB conjugate formed min− 1 mg− 1 protein.
10.4.12.2. Estimation of glutathione peroxidase activity

GPx (EC 1.11.1.9) activity was measured in a 96-well plate reader at 37 °C by a
coupled assay system (Wheeler, Salzman et al., 1990). The reaction mixture consisted of
0.2 mM H2O2, 1.0 mM GSH, 0.14 U of GR, 1.5 mM NADPH, 1.0 mM sodium azide and
0.1M phosphate buffer (pH 7.4) and 10 μl PMS in a total volume of 200 μl. The enzyme
activity was calculated as nmol NADPH oxidized min− 1 mg− 1 protein.
10.4.12.3. Estimation of glutathione reductase activity

The assay system to estimate GR (EC 1.6.4.2) activity consisted of 0.1 M
phosphate buffer (pH 7.6), 0.5 mM EDTA, 1.0 mM oxidized glutathione, 0.1 mM
NADPH and 10 μl PMS in a total volume of 200 μl (Carlberg and Mannervik, 1985). The
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enzyme activity was assayed in a 96-well plate reader by measuring the disappearance of
NADPH at 340 nm and was calculated as nmol NADPH oxidized min− 1 mg− 1 protein.
10.5. Statistical analysis

ANOVA was used for statistical evaluation of data followed by Student's t-test.
Results are presented as mean ± SEM. P-values less than 0.05 were considered
significant.
10.6. Results
10.6.1. Protein Oxidation and Lipid Peroxidation

Fig. 10.1, 10.2 and 10.3 show the levels of protein carbonyl, 3NT and HNE
respectively in mitochondria isolated from brain of gerbils that had been previously
injected i.p. with saline or D609. These isolated brain mitochondrial samples were
subsequently treated with Fe2+/H2O2, AAPH or Aβ (1-42), in vitro. The concentrations of
these oxidants were chosen based on prior dose-response studies of the agents in in vivo
investigations (Joshi, Sultana et al., 2005a; Perluigi, Joshi et al., 2006). The levels of
protein carbonyl, 3NT and HNE were found significantly increased in mitochondria
isolated from saline-injected gerbils brain and subsequently treated with oxidants, in
vitro, compared to control (without treatment of oxidants). Brain mitochondria isolated
from gerbils previously injected i.p. with D609 and subsequent in vitro treatment with
Fe2+/H2O2, AAPH and Aβ (1-42) showed significantly decreased protein carbonyl, 3NT
and HNE levels as compared to brain mitochondria isolated from gerbils previously
injected i.p. with saline and subsequently treated with Fe2+/H2O2, AAPH and Aβ (1-42),
in vitro. The D609-alone sample had no significant effect on the levels of protein
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carbonyls, 3NT or HNE in brain mitochondria. It is clear that less protein oxidation and
lipid peroxidation product, HNE was found in Fe2+/H2O2, AAPH and Aβ (1-42) treated
mitochondria isolated from gerbils previously injected with D609.
Protein carbonlyl
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Figure 10.1: Shows the increment in protein carbonyl formation in brain

mitochondria isolated from saline-injected gerbils and treated with various oxidants
compared to control. The protective effects of D609 against protein carbonyl formation in
brain mitochondria isolated from gerbils injected i.p. 1h before sacrifice with D609 and
treated with AAPH, Fe2+/H2O2 and Aβ (1-42) also are shown. *p<0.01 and **p<0.001
compared to control and # p<0.01 compared to oxidant treatment. The data are presented
as mean ± SEM expressed as percentage of control (n=6). (Data collected in collbration
with Dr Mubeen Ansari)
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Figure 10.2: Shows the increment in 3-NT levels in brain mitochondria isolated

from saline-injected gerbils and subsequently treated with AAPH, Fe2+/H2O2 or Aβ (142) compared to 3NT levels in brain mitochondria isolated from saline-injected gerbil
that received no treatment of any oxidant, *p<0.01 and **p<0.001. This figure also
shows decreased 3NT levels shows in brain mitochondria isolated from gerbils
previously injected i.p. with D609 1 h before sacrifice and treated with AAPH, Fe2+/H2O2
or Aβ (1-42) compared to the oxidant treatment but no prior injection of D609, # p<0.01.
The data are presented as mean ± SEM expressed as percentage of control (n=6). (Data
collected in collaboration with Dr Mubeen Ansari)
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Figure 10.3: Shows the significantly elevated protein-bound HNE content in

brain mitochondria isolated from saline-injected gerbils and treated with different
oxidants [AAPH, Fe2+/H2O2 or Aβ (1-42)]. The protective effects of D609 against HNE
formation of protein-bound HNE in brain mitochondria isolated from gerbil injected i.p.
with D609 1 h before sacrifice and treated with AAPH, Fe2+/H2O2 or Aβ (1-42) also are
shown. *p<0.01 and **p<0.001 compared to control, # p<0.01 and ## p<0.001 compared
to oxidant treatment. The data are presented as mean ± SEM expressed as percentage of
control (n=6). (Data collected in collaboration with Dr Mubeen Ansari)
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10.6.2. Reduced glutathione (GSH)

Fig. 10.4a shows the levels of GSH in mitochondria isolated from gerbil brain
from saline- as well as D609-injected rodents. These brain mitochondrial samples were
subsequently treated with Fe2+/H2O2, AAPH or Aβ (1-42), in vitro. The levels of GSH
were found significantly decreased in mitochondria isolated from saline-injected gerbils
brain and treated in vitro with oxidants compared to control. In contrast, brain
mitochondria isolated from D609-injected gerbils and subsequently treated in vitro with
Fe2+/H2O2, AAPH or Aβ (1-42) showed increased levels of GSH.
10.6.3. Oxidized Glutathione (GSSG)

Fig. 10.4b shows significantly increased GSSG levels in brain mitochondria
treated with different oxidants [Fe2+/H2O2, AAPH or Aβ (1-42)] that were isolated from
saline-injected gerbils (control). In contrast, there were significantly decreased GSSG
levels in mitochondria isolated from gerbils previously injected i.p. with D609 and
treated with Fe2+/H2O2, AAPH or Aβ (1-42), in vitro.
10.6.4. The Ratio of Reduced and Oxidized Glutathione (GSH/GSSG)

Fig.10.4c shows the significantly decreased GSH/GSSG ratio in brain
mitochondria isolated from saline-injected gerbils (control) and treated with different
oxidants, in vitro.

This GSH/GSSG ratio was significantly increased in brain

mitochondria isolated from gerbils previously injected i.p. with D609 and treated with
Fe2+/H2O2, AAPH or Aβ (1-42), in vitro.
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Figure 10.4a: Shows a significant decrement in GSH levels in brain mitochondria

isolated from saline-injected gerbils and subsequently treated with AAPH, Fe2+/H2O2 or
Aβ (1-42) compared to GSH levels in brain mitochondria isolated from saline-injected
gerbils not subjected to treatment of any oxidant. Also shown is the protection of GSH
levels in brain mitochondria isolated from gerbils previously injected i.p. with D609 1 h
before sacrifice and treated with AAPH, Fe2+/H2O2 or Aβ (1-42) compared to GSH
levels in brain mitochondria isolated from saline-treated gerbils and then treated with
oxidants. *p<0.01 and **p<0.001 compared to control, # p<0.01 and ## p<0.01
compared to oxidant treatment. The data are presented as mean ± SEM expressed as
percentage of control (n=6).
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Figure 10.4b: Shows the increased level of GSSG in brain mitochondria isolated

from saline-injected gerbils and subsequently treated with AAPH, Fe2+/H2O2 or Aβ (142) as compared to GSSG levels in brain mitochondria isolated from saline-injected
gerbils but not subjected to treatment of any oxidant. The reduction in GSSG level shows
in brain mitochondria isolated from gerbils previously injected i.p. with D609 1 h before
sacrifice and treated with AAPH, Fe2+/H2O2 or Aβ (1-42) compared to GSSG levels in
brain mitochondria isolated from saline-treated gerbil and then treated with oxidants.
*p<0.01 and **p<0.001 compared to control, # p<0.01 and ## p<0.01 compared to
oxidant treatment. The data are presented as mean ± SEM expressed as percentage of
control (n=6).
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Figure 10.4c: Shows the ratio of GSH/GSSG, decreased in brain mitochondria

isolated from saline-injected gerbils and subsequently treated with AAPH, Fe2+/H2O2 or
Aβ (1-42), compared to the GSH/GSSG ratio in brain mitochondria isolated from salineinjected gerbils but not subjected to treatment of any oxidant. The increment in the ratio
of GSH/GSSG in brain mitochondria isolated from gerbils previously injected i.p. with
D609 1 h before sacrifice and then treated with AAPH, Fe2+/H2O2 or Aβ (1-42) compared
to this ratio determined in brain from mice treated with oxidant but no pre-injection of
gerbils with D609 is also shown. *p<0.01 and **p<0.001 compared to control, # p<0.01
and ## p<0.01 compared to oxidant treatment. The data are presented as mean ± SEM
expressed as percentage of control (n=6).
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10.6.5. Cytochrome-c Release

Reactive oxygen species are produced by mitochondria that can cause the release
of cytochrome-c from the mitochondrial membrane. Figure 11.5 shows the level of
cytochrome-c released from brain mitochondria isolated from saline- as well as D609injected gerbils and subsequently treated with different oxidants, in vitro. There was a
significant reduction in cytochrome-c release from brain mitochondria by prior i.p. D609
treatment compared to that in brain mitochondria isolated from saline-injected gerbils.
Increased cytochrome-c release from brain mitochondria isolated from control gerbils
with subsequent in vitro treatment of Fe2+/H2O2, AAPH or Aβ (1-42) compared to control
was discussed. Brain mitochondria isolated from D609-injected gerbils and subsequently
treated with Fe2+/H2O2, AAPH or Aβ (1-42), in vitro, showed a significant decrease in
cytochrome-c release compared to mitochondria isolated from saline-injected gerbils
treated with oxidants (Figure 11.5).
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Figure 10.5: Shows the increased level of cytochrome-c released from brain

mitochondria isolated from saline-injected gerbils and treated with various oxidants
(AAPH, Fe2+/H2O2 or Aβ (1-42) as compared to cytochrome-c released from brain
mitochondria isolated from saline-injected gerbils but not subjected to treatment of any
oxidant. Also shown is the decrement of cytochrome-c release from brain mitochondria
isolated from gerbils previously injected i.p. with D609 1 h before sacrifice and treated
with AAPH, Fe2+/H2O2 or Aβ (1-42) compared to that released from brain mitochondria
isolated from gerbils subjected to oxidant treatment. The D609 only treatment shows
significantly less cytochrome-c release compared control. *p<0.01 as compared to
control, # p<0.01 compared to oxidant treatment. The data are presented as mean ± SEM
expressed as percentage of control (n=5). (Data collected in collaboration with Dr
Mubeen Ansari)
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10.6.6. The Activity of GSH-relevant Enzymes

Table 10.1 shows the activity of some GSH-relevant enzymes in gerbil brain from
which mitochondria were isolated. The activities of glutathione-S-transferase (GST) and
glutathione peroxidase (GPx) were increased significantly in post mitochondrial
supernatant from D609-injected gerbils. The activity of glutathione reductase (GR) also
was increased, but non-significantly. Thus, these results suggest that D609 has a role in
the redox cycle of GSH (oxidation and reduction of GSH) and in the neuroprotection
against free radicals.

Enzyme

Brain from Control
Group

Brain from D609
Treated Group

GST (nmol CDNB
conjugate formed
min−1 mg−1 protein)

38.4±3.44

61.5±4.74*

GPx (nmol NADPH
oxidized min−1 mg−1
protein)

34.5±2.87

43.1±3.41#

GR (nmol NADPH
oxidized min−1 mg−1
protein)

23.4±2.89

26.6±3.10

Table 10.1:

Activities of some GSH-related enzymes in post mitochondrial

supernatant obtained from gerbil brain mitochondria that were previously injected i.p.
with saline (control) or D609. The data are presented as mean ± SEM expressed as
percentage of control (n=6). *p<0.01 and #p<0.05 compared to control. (Data collected
in collaboration with Dr Mubeen Ansari).
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10.7. Discussion

Oxidative stress reflects a marked imbalance between ROS and their removal by
anti-oxidant systems. This imbalance may originate from an overproduction of ROS or
from a reduction in antioxidant defenses or both (Butterfield and Stadtman, 1997). An
inverse relationship between lipid peroxidation and GSH and its dependent enzymes,
along with the activities of catalase and superoxide dismutase is well known (Sies, 1999;
Hansen, Go et al., 2006). A reduction in GSH may impair H2O2 clearance and promote
hydroxyl radical formation, thus increasing the free radical load, which triggers oxidative
stress. Conversely, GSH is converted to GSSG, a process that in conjunction with the
cofactor NADPH can reduce lipid peroxides, free radicals and H2O2. NADPH also acts as
a peroxynitrite reductant, thereby providing enzymatic defense against peroxynitrite
(Sies, Sharov et al., 1997). Glutathione peroxidase (GPx) and glutathione reductase (GR)
protect the neurons from oxidative stress by catalyzing the reduction of H2O2 at the
expense of glutathione (Sies, 1999; Hansen, Go et al., 2006). Glutathione-S-transferase
(GST) play a role in neuroprotection by catalyzing the formation of the GSH-HNE
conjugate, which is then removed from neurons by the action of the multidrug resistant
protein-1 (Sultana and Butterfield, 2004). In AD brain, both GST and MRP-1 are
oxidatively modified and likely dysfunctional (Sultana and Butterfield, 2004). In our
results GST (Table I) and GPx have higher activities following in vitro oxidant treatment
of brain homogenate isolated from previously D609-injected gerbils. GR activity in brain
(Table I) of D609-injected animals was not significantly elevated following subsequent in
vitro oxidant treatment to isolated mitochondria relative to control.

Reduced levels of GSH (Fig. 4A) have been observed in oxidative stress-related
disorders (Bains and Shaw, 1997) in specific regions of the central nervous system of AD
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patients, and thus reduced GSH may contribute to the neuronal cell dysfunction and/or
loss. In AD, increased levels of GSSG (Cooper, 1997) have been observed. Studies have
shown that an increase in endogenous GSH levels by dietary or pharmacological intake
of GSH precursors or GSH mimetics or substrates for GSH synthesis protects the brain
against oxidative stress (Anderson and Luo, 1998; Fontaine, Geddes et al., 2000;
Pocernich, La Fontaine et al., 2000; Halliwell, 2001; Pocernich, Cardin et al., 2001;
Drake, Kanski et al., 2002; Drake, Sultana et al., 2003). The increase in the content of
GSH and decrease in the extent of GSSG in mitochondria isolated from gerbil brain
previously injected with D609 in our study is in agreement with earlier reports (Perluigi,
Joshi et al., 2006).
We earlier showed that D609 could effectively scavenge hydroxyl radicals (Zhou,
Lauderback et al., 2001). The identification of D609 as a potent antioxidant implies that
D609 may exert some of the reported activities that have been largely attributed to the
inhibition of phosphatidyl choline-specific phospholipase C (PC-PLC) by its antioxidant
properties. Among these activities are inhibition of LPS-and TNF-induced NF-kB
activation and inflammatory cytokine production (Schutze, Potthoff et al., 1992;
Amtmann, 1996). ROS activated NF-kB causes a differential change in gene expression
between neurons and astrocytes in the AD brain (Tanaka, Takehashi et al., 2002;
Onyango, Bennett et al., 2005). We earlier reported the anticarcinogenic activity of D609
might be due to its antioxidant property (Zhou, Lauderback et al., 2001). In vitro, D609
kills a variety of tumor cells but has limited toxic effects on normal cells (Sauer,
Amtmann et al., 1990). Although D609 might be involved in alternate biochemical
pathways, its glutathione mimetic property cannot be ignored. The free thiol group in
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D609 may act as substrate for hydroxyl radicals, or may act as electron acceptor from
hydrogen peroxide to form a dixanthate, which forms the substrate for glutathione
reductase to convert it back to xanthate. This property of D609 is yet to be explored.
Protein carbonyls, 3NT and HNE levels are elevated in AD and MCI brains
(Butterfield, Drake et al., 2001; Butterfield and Lauderback, 2002; Castegna, Aksenov et
al., 2002a; Castegna, Thongboonkerd et al., 2003; Butterfield, 2004; Castegna,
Thongboonkerd et al., 2004; Butterfield, Poon et al., 2006; Butterfield, Reed et al., 2006;
Sultana, Poon et al., 2006a; Sultana, Poon et al., 2006b). HNE is a highly reactive product
of arachidonic acid metabolism that is believed to interfere with normal cellular functions
(Butterfield and Lauderback, 2002). During oxidative stress several lipid peroxidation
products are formed, including HNE, one of the most abundant and toxic lipid-derived
aldehydes, and which can induce oxidative stress (Esterbauer, Schaur et al., 1991;
Lauderback, Hackett et al., 2001). Lipid peroxidation products such as HNE and acrolein
are known to cause damage to biomembranes, proteins and other biomolecules in AD
brain (Sayre, Zelasko et al., 1997; Lovell, Xie et al., 1998; Lauderback, Hackett et al.,
2001). These alkenals form an immediate substrate for GSH (Xie, Lovell et al., 1998) and
these lipid peroxidation products are known to be involved in apoptosis, which can be
initiated as a consequence of GSH depletion (Mark, Lovell et al., 1997).
GSH is known to detoxify HNE and protect cultured neurons against oxidative
damage resulting from amyloid β-peptide, iron, and HNE (Mark, Lovell et al., 1997).
GSH can also protect brain from damage by peroxynitrite, hydroxyl free radicals, or
reactive alkenals (Koppal, Drake et al., 1999b; Pocernich, La Fontaine et al., 2000;
Pocernich, Cardin et al., 2001; Drake, Kanski et al., 2002; Drake, Sultana et al., 2003).
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D609 may binds to reactive alkenals formed due to peroxidation of lipids and detoxifies
their effects (Lauderback, Drake et al., 2003).
HNE can alter pyruvate dehydrogenase (PD) (Pocernich and Butterfield, 2003),
decrease cell survival (decrease MTT reduction) and cause inhibition of Na+K+ ATPase
(Mark, Lovell et al., 1997). The activity of the adenine nucleotide transporter in
mitochondria is inhibited by HNE, which directly results in ATP depletion (Chen,
Bertrand et al., 1995). Aβ increases lipid derived free radical production (Chen, Bertrand
et al., 1995; Mark, Lovell et al., 1997; Butterfield, Drake et al., 2001; Butterfield and
Lauderback, 2002; Boyd-Kimball, Mohmmad Abdul et al., 2004). HNE rapidly leads to
decline in multiple sites of the mitochondrial respiratory chain and modified specific
mitochondrial target proteins lead to apoptosis and cell death in AD (Picklo, Amarnath et
al., 1999).
Recently, we showed that the xanthate D609, a glutathione mimetic (Lauderback,
Drake et al., 2003), protects primary neuronal culture against Aβ (1-42)-induced
oxidative stress and neurotoxicity in vitro (Sultana, Newman et al., 2004) and against Aβ
(1-42) in vivo (Perluigi, Joshi et al., 2006). D609 has the ability to scavenge hydrogen
peroxide and hydroxyl free radicals (Lauderback, Drake et al., 2003). D609 can bind to
reactive alkenals and detoxify their effect, thereby preventing these alkenals from
damaging mitochondria (Lauderback, Drake et al., 2003; Joshi, Sultana et al., 2005a).
AAPH is known to induce protein carbonylation and nitration (Kanski, Lauderback et al.,
2001) in mitochondria. In the current study, we report that in vivo delivery of D609
inhibits the damage to brain mitochondria caused by production of hydroxyl free radicals,
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alkoxyl and peroxyl radicals and Aβ (1-42)-induced in vitro oxidative stress to decrease
protein oxidation and lipid peroxidation.
Aβ disrupts Ca2+ homeostasis in neurons (Mattson, Barger et al., 1993), and
increased intracellular Ca2+ level can increase sphingomylinase activity to produce
ceramide (Di Paola, Zaccagnino et al., 2004). Activation of the apoptogenic
sphingomyelin-dependent signaling pathway is mediated by ceramide (Di Paola,
Zaccagnino et al., 2004) during oxidative stress to play role in the pathogenesis of
neuronal disease (Michel, Lambeng et al., 1999). Apoptosis induced by the membranepermeable second messenger ceramide, followed by the release of cytochrome-c and Ca2+
from the mitochondria with the loss of mitochondrial transmembrane potential has been
observed (Michel, Lambeng et al., 1999). Both cytochrome-c release and rise of
intracellular Ca2+ cause caspase-3 activation and nuclear condensation (Michel, Lambeng
et al., 1999). ROS-dependent and independent pathways are initiated by caspase-8
activation and contribute to ceramide formation via the activation of both neutral and acid
sphingomyelinases (SMases) in TNF-alpha-induced apoptosis of human glioma cells
(Michel, Lambeng et al., 1999). In one study, D609 has also been shown to inhibit
sphingomyelin synthase in SV40-transformed human lung fibroblasts, but ceramide and
DAG levels evolved in opposite directions (Luberto and Hannun, 1998) and partially
protected against apoptosis (Denis, Lecomte et al., 2002).
In conclusion, this study has demonstrated that, similar to the case with elevated
cytosolic GSH protecting brain mitochondria (Drake, Kanski et al., 2002), i.p. injection
of D609 protects brain mitochondria (anti-apoptotic) against oxidative stress induced in
vitro by different oxidants, such as AAPH, Fe2+/H2O2 or Aβ(1–42). In vivo delivery of
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D609 showed significant protection against protein oxidation, lipid peroxidation and
cytochrome-c release in gerbil brain mitochondria. While a role for inhibition of PC-PLC
by D609 in the protection of brain mitochondria cannot be excluded, based on the data
from the present and previous studies (Joshi, Sultana et al., 2005a; Perluigi, Joshi et al.,
2006), the increment in the GSH level and the activity of its dependent enzymes (GST,
GPx and GR), are strong indications to suggest that D609 has neuroprotective effects to
brain mitochondria due in significant part to its antioxidant properties. Thus, in brain
mitochondria, the antioxidant properties of in vivo delivery of D609 conceivably could be
beneficial in the treatment of diseases related to oxidative stress that involve
mitochondria (AD, Huntington disease, Parkinson’s disease, for example). This xanthate
compound protects against in vitro treatment of Aβ (1-42); consequently, we suggest
D609 may be part of a promising therapeutic strategy for Alzheimer’s disease. Studies to
test this notion in rodent models of AD are in progress.

Copyright © Gururaj Joshi 2006
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Chapter 11
N-Acetyl cysteine-mediated protection against oxidative stress in APP/PS-1 mouse:
A pilot study towards therapeutic modulation of mild cognitive impairment (MCI)
11.1. Overview of the Study

N-acetyl cysteine (NAC) is a glutathione (GSH) precursor. It provides the limiting
substrate in GSH synthesis, cysteine. The mechanism by which is does is not very well
known. NAC is commonly used in treatment of acetaminophen poisoning. NAC is one
the most widely used in antioxidant therapy. Previously our laboratory showed an
increase in GSH levels post i.p. injection of NAC. NAC reduces the protein oxidation and
lipid peroxidation in synaptosomes treated with acrolein. The present study was
undertaken to test the hypothesis that NAC would provide in vivo neuroprotection against
free radical oxidative stress-mediated by Aβ (1-42) in APP/PS-1 mice, a model of
Alzheimer’s disease (AD). In the present study, NAC was administered orally (2mg/kg
body weight/day) in drinking water for 5 months beginning at 4 months of age for both
APP/PS-1 mice and wild type aged matched control. Another group of APP/PS-1 and
wild type mice were given normal drinking water. Brain isolated from APP/PS-1 mice
given NAC in water at 9 month of age showed significant reduction in the levels of
protein oxidation and lipid peroxidation when compared to the brain isolated from
APP/PS-1 mice given normal drinking water. Additionally, increased expression of a key
antioxidant enzymes expression levels, GPx, was also observed in brain isolated from
APP/PS-1 given NAC when compared to APP/PS-1 mice given normal drinking water.
We also observed an increased expression of Pin 1, a key cell cycle protein in brain
isolated from APP/PS-1 mice that were given NAC when compared to APP/PS-1 mice
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given normal drinking water. These results are discussed with reference to potential use
of this brain accessible glutathione precursor in the treatment of oxidative stress-mediated
AD.
11.2. Introduction

Oxidative stress has implication in various neurodegenerative disorders including
Alzheimer’s disease (AD) (Hensley, Hall et al., 1995; Markesbery and Lovell, 1998;
Butterfield, Drake et al., 2001; Butterfield and Lauderback, 2002). As described in
Chapter 1, AD affects more that 4 million Americans and is one of the leading causes of
death in US. There is no efficient therapy towards treatment of this dreaded disorder.
Pathological characteristics of AD includes the presence of senile plaques comprised of
aggregated Aβ, neurofibrillary tangles consisting of hyperphosphorylated tau, and
synapse loss (Katzman and Saitoh, 1991; Bosetti, Brizzi et al., 2002). Etiologically, a free
radical-mediated oxidative stress hypothesis in AD has gained considerable importance
(Butterfield, Drake et al., 2001). In AD brain, oxidative stress leads to significant protein
oxidation (Butterfield and Lauderback, 2002), DNA and RNA oxidation (Mecocci,
MacGarvey et al., 1993; Lovell, Gabbita et al., 1999; Nunomura, Perry et al., 1999;
Wang, Xiong et al., 2005), lipid peroxidation (Markesbery and Lovell, 1998; Lauderback,
Hackett et al., 2001), and neuronal dysfunction or death. Increased production of reactive
oxygen species (ROS) along with depletion in antioxidant capacity is observed in AD
(Beckman and Ames, 1998) and consistent with this observation α-tocopherol (vitamin
E) administration in AD patients delayed its progression when compared to placebo
treated control (Sano, Ernesto et al., 1997), suggesting that oxidative stress-mediated AD
progression may possibly be delayed by antioxidant therapy.
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Mild cognitive impairment (MCI) is generally referred as the transitional zone
between normal aging and early dementia or clinically probable Alzheimer's disease
(AD) (Winblad, Palmer et al., 2004). Most individuals with MCI eventually develop AD
or other forms of dementia, which may suggest that MCI could be the early phase in the
development of AD (Almkvist, Basun et al., 1998; Morris, Storandt et al., 2001). MCI is
a general term used to describe a slight but measurable memory disorder. A person with
MCI has memory problems greater than normally expected with aging, but does not show
other symptoms of dementia, such as impaired reasoning or judgment. A person with
MCI is at higher risk for developing AD. Although some of the MCI cases become stable
or become resolved, most persons with MCI develop AD. A direct relationship between
MCI and AD is yet to be established. Recently our laboratory showed an overlap in the
oxidized proteins in MCI and AD subjects (Butterfield, Poon et al., 2006). Oxidation of
these proteins may play a significant role in development of MCI to AD (Butterfield,
Poon et al., 2006). Oxidative stress has been implicated in MCI (Keller, Schmitt et al.,
2005; Butterfield, Reed et al., 2006). Our laboratory recently showed elevated proteinbound 4-hydroxy-2-nonenal (HNE) levels, a lipid peroxidation product, , in brain from
persons with mild cognitive impairment (Butterfield, Reed et al., 2006). By using redox
proteomics, our laboratory showed some key proteins to be oxidized in MCI brain,
suggesting oxidative stress play an important role in MCI and may be the reason for
progression of MCI to AD (Butterfield, Poon et al., 2006). Since MCI is potentially
reversible, and oxidative stress plays a key role in development and progression of this
disease, it is imperative to look at a potential therapeutic strategy involving antioxidants
to prevent MCI and eventually stop its progression to AD.
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Among the genetic risk factors for AD, includes mutations in the presenilin 1
(PS1) (Sherrington, Rogaev et al., 1995), presenilin 2 (PS2) (Rogaev, Sherrington et al.,
1995), or the APP gene (Chartier-Harlin, Crawford et al., 1991). Approximately 30%
familial Alzheimer’s disease (FAD) cases have mutations in PS1 (Schellenberg, 1995).
PS1 is a part of γ-secretase complex that cleaves APP to release Aβ(1-42). Mutation in
PS1 has been shown to alters APP processing to enhance the generation of Aβ(1–42)
peptides (Jarrett, Berger et al., 1993). Synaptosomal proteins from PS-1 mutant mice
showed increased oxidative stress and alteration in synaptosomal protein structure when
compared to wild type (LaFontaine, Mattson et al., 2002).
Several line of evidence shows that Aβ(1–42) plays a central role in AD
pathogenesis and is well documented. Our laboratory was instrumental in hypothesizing
Aβ(1–42)-mediated oxidative stress in AD brain (Butterfield, Drake et al., 2001). Based
on these studies a mouse model showing accelerated Aβ(1–42) deposition was used to
study the oxidative stress parameter and antioxidant therapeutic intervention towards
MCI or AD. As described in Chapter 2, this mouse model was developed by Borchelt et
al., which had FAD mutant human PS1-A246E and a chimeric mouse/human (Mo/Hu)
APP695 harboring a Hu Aβ domain and mutations (K595N, M596L) linked to Swedish
FAD (APP swe) coexpressed (APP/PS-1 human knock-in mouse) (Borchelt, Ratovitski et
al., 1997). The APP/PS-1 mice showed increased Aβ production and accelerated amyloid
deposition in the brain (Borchelt, Ratovitski et al., 1997). Previous studies from our
laboratory have shown that neurons from APP/PS1 mice have increased basal protein
oxidation and lipid peroxidation, and are more vulnerable to oxidation by various
exogenous oxidants when compared to wild type (Mohmmad Abdul, Sultana et al.,
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2006). All these studies suggest that APP/PS1 mice can be used as a model of FAD,
which is characterized by Aβ(1–42)-mediated oxidative stress.
Depletion of glutathione (GSH), an intracellular antioxidant, is known to be
involved in several neurodegenerative disorders (Benzi and Moretti, 1995b; Markesbery,
1997; Butterfield, Castegna et al., 2002a). Many attempts have been made to develop
antioxidant compounds that can act as precursor of GSH or mimic GSH as scavenger of
reactive oxygen species (ROS) and to maintain the intracellular redox state. Increase in
the endogenous GSH levels by dietary or pharmacological intake of GSH precursor or
GSH mimetic protects brain against oxidative stress (Anderson and Luo, 1998;
Butterfield, Drake et al., 2001; Halliwell, 2001). Considering the importance of
developing new antioxidant compounds and the relevance of their application in the
treatment of neurodegenerative diseases, we focused our attention on glutathione
precursor, N-acetyl cysteine (NAC).
NAC is an FDA-approved drug used in the treatment of acetaminophen-mediated
liver toxicity (Prescott, Park et al., 1977) or heavy metal poisoning. NAC acts as an
indirect precursor of GSH. It is thought to provide cysteine, a rate limiting substrate in
GSH synthesis (Dringen and Hamprecht, 1999). NAC acts as antioxidant by raising
intracellular levels of cysteine or by the scavenging ROS itself. NAC is also used in
treatment of HIV infection (Droge, 1993), and cancer chemotherapy (Holoye, Duelge et
al., 1983). Apart from its antioxidant properties, NAC is known to improve neuron
survival in the CA1 region of the hippocampus following ischemic-reperfusion injury
(Zhang, Tian et al., 2003). NAC can acts as transcription factor and can rescue neurons
from apoptotic death by activation of the Ras-ERK pathway (Yan and Greene, 1998).
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NAC reduces the inflammatory symptoms in brain by direct inhibition of NF-κB and
blocking iNOS from producing inflammatory cytokines (Pahan, Sheikh et al., 1998).
11.3. Purpose of the study

Previous studies from our laboratory have shown that NAC can partially protect
brain-derived membrane proteins against peroxynitrite-induced damage (Koppal, Drake
et al., 1999a). NAC significantly increased endogenous glutathione levels, in vivo, in
cortical synaptosome cytosol and prevented protein oxidation caused by hydroxyl
radicals (Pocernich, La Fontaine et al., 2000). NAC protected mitochondria against
oxidative damage induced by 3-nitropropionic acid and significantly reduce striatal lesion
volumes (La Fontaine, Geddes et al., 2000). We also showed that NAC protected
synaptosomal membranes against acrolein-induced protein damage by elevating GSH
levels, in vivo (Pocernich, Cardin et al., 2001). We recently showed reversal of memory
impairment and brain oxidative stress by NAC in aged SAMP8 mice (Farr, Poon et al.,
2003). The current study was designed to determine if in vivo NAC would protect brain
from APP/PS-1 mice against inherent Aβ(1–42)-mediated oxidative stress-induced
protein oxidation and lipid peroxidation.
11.4. Experimentals
11.4.1. Chemicals

All the chemicals were purchased from Sigma-Aldrich (St. Louis, MO), unless
stated otherwise. The OxyBlot kit used for protein carbonyl determination was purchased
from Intergen (Purchase, NY). The primary antibody for HNE was purchased from Alpha
Diagnostics (San Antonio, TX). The primary antibody for GPx was purchased from
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Chemicon International (Temecula, CA). Transfer membranes for western blot and slot
blot were purchased from Biorad (Hercules, CA).
11.4.2. Animals

For this study, male Wild type (WT) and APP/PS-1 mice, approximately 30 g in
size, housed in the University of Kentucky Central Animal Facility in 12-h light/dark
conditions and fed standard Purina rodent laboratory chow ad libitum, were used. The
animal protocols were approved by the University of Kentucky Animal Care and Use
Committee. The APP/PS-1 mice used are the APPNLh/APPNLh × PS-1P264L./PS-1P264L.
double mutant generated by using the Cre-loc© knock-in technology (Cephalon, Inc.,
Westchester, PA, USA) to humanize the mouse Aβ sequence and to create a PS-1
mutation identified in human AD (Reaume, Howland et al., 1996; Siman, Reaume et al.,
2000).
11.4.3. Treatments

Mice were divided into 4 groups. A group of WT and APP/PS-1 mice received
normal drinking water and another group of WT and APP/PS-1 mice received water
containing NAC (2mg/kg/day) for a period of 5 months. A 1% solution of NAC in water
(pH adjusted to 7.2 by NaOH) was prepared and given to mice. Water was changed every
alternate day for 5 months. Approximately 4 to 5 ml of water was consumed per mice per
day, which gives a cumulative dose of 2mg/kg per mice per day, not accounting for spills.
The NAC treatment was started at 4 month age. The dose of NAC was chosen based on
prior studies (Andreassen, Dedeoglu et al., 2000). Following 5 months of NAC treatment,
mice were sacrificed and brains were isolated and flash frozen in liquid nitrogen.
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11.4.4. Preparation of brain homogenate

Brains were thawed and placed in ice cold lysing buffer containing 4μg/ml
leupeptin, 4μg/ml pepstatin, 5 μg/ml aprotinin, 2mM ethylenediaminetetraacetic acid
(EDTA), 2mM ethylene glycol-bistetraacetic acid (EGTA) and 10mM 4-(2hydroxyethyl)-1-piperazine-ethanesulfonic acid (HEPES), pH 7.4. The brains were
homogenized by 20 passes of a Wheaton tissue homogenizer, and the resulting
homogenate was centrifuged at 20000g for 10 minutes. The pellet was suspended in 1ml
phosphate buffered saline (PBS) and the supernatant (cytosolic fraction) was retained for
fluorescence studies, GSH measurement and enzyme activities. All the fractions
suspended in PBS were washed twice with PBS at 32000g for 10 min. The resulting
fractions were assayed for protein concentration by the Pierce BCA method (Bradford,
1976).
11.4.5. Protein Carbonyls

Samples (5μl) of brain homogenate, 12% sodium dodecyl sulfate (SDS) (5μl), and
10μl of 10 times diluted 2,4-dinitrophenylhydrazine (DNPH) from 200mM stock were
incubated at room temperature for 20 min, followed by neutralization with 7.5μl
neutralization solution (2M Tris in 30% glycerol). Protein (250ng) was loaded in each
well on a nitrocellulose membrane under vacuum using a slot blot apparatus. The
membrane was blocked in blocking buffer (3% bovine serum albumin) in PBS 0.01%
(w/v) sodium azide and 0.2% (v/v) Tween 20 for 1h and incubated with a 1:100 dilution
of anti-DNP polyclonal antibody in PBS containing 0.01% (w/v) sodium azide and 0.2%
(v/v) Tween 20 for 1h. The membrane was washed in PBS following primary antibody
incubation three times at intervals of 5 min each. The membrane was incubated following
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washing with an anti-rabbit IgG alkaline phosphatase secondary antibody diluted in PBS
in a 1:8000 ratio for 1h. The membrane was washed three times in PBS for 5 min and
developed in Sigma fast tablets, [5-bromo-4-chloro-3-indolyl phosphate/Nitro blue
tetrazolium substrate (BCIP/NBT substrate)]. Blots were dried, scanned with Adobe
Photoshop, and quantified with Scion Image (PC version of Macintosh compatible NIH
image). No non-specific binding of antibody to the membrane was observed.
11.4.6. HNE

Sample (5μl) of brain homogenate, 12% SDS (5μl), and 5μl of modified Laemmli
buffer containing 0.125 M Tris base pH 6.8, 4% (v/v) SDS, and 20% (v/v) glycerol were
incubated for 20 min at room temperature and were loaded (250ng) in each well on a
nitrocellulose membrane in a slot blot apparatus under vacuum. The membrane was
treated as above and incubated with a 1: 5000 dilution of anti-HNE polyclonal antibody
in PBS for 1h 30min. The membranes were further developed and quantified as above. A
faint background staining due to the antibody alone was observed, but since each sample
had a control, this minor effect was controlled.
11.4.7. 3NT

Samples (5μl) of brain homogenate, 12% SDS (5μl), and 5μl of modified
Laemmli buffer containing 0.125 M Tris base pH 6.8, 4% (v/v) SDS, and 20% (v/v)
glycerol were incubated for 20 min at room temperature and were loaded (250ng) in each
well on a nitrocellulose membrane in slot blot apparatus under vacuum. The membrane
was treated as above and incubated with a 1: 2000 dilution of anti-3-nitrotyrosine (3NT)
polyclonal antibody in PBS for 1h 30min. The membranes were developed further and
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quantified as described above. No non-specific binding of antibody to the membrane was
observed.
11.4.8. Western blots

Samples (100 μg from cytosolic fraction) were incubated with sample loading
buffer, and protein samples were denatured and electrophoresed on a 12.5% SDSpolyacrylamide gel. Proteins were transferred to a nitrocellulose membrane at 90 mA/gel
for 2 h. The blots were blocked for 1h in fresh wash buffer (10 mM Tris-HCl, pH7.5),
150 mM NaCl, 0.05% Tween 20, pH 7.4, containing 3% bovine serum albumin) and
incubated with a 1:1000 dilution of GPx monoclonal antibody in PBS for 1h. The
membrane was washed three times in PBS and was incubated for 1 h with an anti-rabbit
IgG alkaline phosphatase secondary antibody diluted in PBS in 1:8000 ratio. The
membrane was washed for three times in PBS for 5 min and developed in Sigma fast
tablets (BCIP/NBT substrate).
In all cases non-specific background labeling by secondary antibody was
negligible.
11.4.9. Enzyme activity assay
11.4.9.1. Estimation of glutathione peroxidase activity

GPx (EC 1.11.1.9) was measured using a reaction mixture consisting of 0.2 mM
H2O2, 1.0 mM GSH, 0.14 U of glutathione reductase (GR), 1.5 mM NADPH, 1.0 mM
sodium azide and 0.1M phosphate buffer (pH 7.4) and 1mg/ml of supernatant protein
(Wheeler, Salzman et al., 1990). The changes in absorbance were recorded at 340 nm in a
96 well microtiter plate and enzyme activity was calculated as nmol of NADPH oxidized
min− 1 mg− 1 protein.
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11.5. Statistical analysis

Two-way ANOVA followed by a multiple comparisons test (Turkey HSD) was
used to assess statistical significance. P values <0.05 were considered significant for
comparison between control and experimental data sets.
11.6. Results

The reason for starting NAC treatment at the 4 month age was chosen based on
previous pathological studies. The Aβ(1-42) deposition starts at the age of 5-6 months.
These mice develop elevated levels of Aβ(1-42) at about 6 months of age (Borchelt,
Thinakaran et al., 1996; van Groen, Kiliaan et al., 2006). The Aβ(1-42) aggregation as in
senile plaques is seen at the age of 9 months (van Groen, Liu et al., 2003). The brain
pathology at 7-9 months age is reminiscent of that of an MCI or early AD brain. Based on
this observation we hypothesized that administration of NAC at an early age (4-5mo) for
a period of 5 months (time by which amyloid plaques are formed) can reduce the Aβ(142)-mediated oxidative stress in APP/PS-1 mice at later age (9 mo) and can prevent MCI
like pathology.
11.6.1. NAC protects APP/PS-1 mice brains against protein oxidation and
lipid peroxidation

Figures 11.1, 11.2 and 11.3 show the levels of protein carbonyls, 3-NT (markers
of protein oxidation) and protein-bound HNE (a lipid peroxidation product) levels,
respectively, in all the treatment groups. There was significant elevation in protein
carbonyl, 3-NT and protein bound HNE levels in brain isolated from 9 month-old
APP/PS-1 mice that were given normal water when compared to the levels in brain
isolated from 9 month-old WT mice given normal drinking water or NAC containing
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water (p < 0.05, n = 6). Administration of water containing NAC to APP/PS-1 mice
reduced the levels of protein carbonyls, 3-NT and protein-bound HNE significantly
compared to the levels in brain isolated from APP/PS-1 mice given normal drinking
water (p < 0.05, n = 6).
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Figure 11.1: Levels of protein carbonyl in all the treatment groups. There is a

significant increase in protein carbonyl level in brain isolated from APP/PS-1 mice that
were given normal drinking water when compared to WT groups (* p < 0.05, n = 6).
Administration of NAC in drinking water to APP/PS-1 mice decreases protein carbonyl
level significantly in brain. The brain isolated from APP/PS-1 mice treated with NAC in
water shows a significant decrease in protein carbonyl levels when compared to the levels
in brain isolated from APP/PS-1 mice that were given normal drinking water (* p < 0.05,
n = 6). The data are presented as mean ± SEM expressed as percentage of control.
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Figure 11.2: Levels of 3NT in all the treatment groups. There is a significant

increase in 3NT level in brain isolated from APP/PS-1 mice that were given normal
drinking water when compared to WT groups (* p < 0.05, n = 6). Administration of NAC
in drinking water to APP/PS-1 mice decreases 3NT level significantly in brain. The brain
isolated from APP/PS-1 mice treated with NAC in water shows a significant decrease in
3NT levels when compared to the levels in brain isolated from APP/PS-1 mice that were
given normal drinking water (* p < 0.05, n = 6). The data are presented as mean ± SEM
expressed as percentage of control.
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Figure 11.3: Levels of protein-bound HNE in all the treatment groups. There is a

significant increase in protein-bound HNE level in brain isolated from APP/PS-1 mice
that were given normal drinking water when compared to WT groups (* p < 0.05, n = 6).
Administration of NAC in drinking water to APP/PS-1 mice decreases protein-bound
HNE level significantly in brain. The brain isolated from APP/PS-1 mice treated with
NAC in water shows a significant decrease in protein-bound HNE levels when compared
to the levels in brain isolated from APP/PS-1 mice that were given normal drinking water
(* p < 0.05, n = 6). The data are presented as mean ± SEM expressed as percentage of
control.
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11.6.2. NAC increased GPx expression and activity in APP/PS-1 mice brain

Figure 11.4a, b and 11.5 shows the expression and activity of GPx in all the
treatment groups. There was significant reduction in GPx expression and activity in brain
isolated from 9 month-old APP/PS-1 mice that were given normal water when compared
to the GPx expression and activity in brain isolated from 9 month-old WT mice given
normal drinking water or NAC containing water (p < 0.05, n = 6). Administration of
water containing NAC to APP/PS-1 mice significantly increased the protein expression
and activity of GPx when compared to the levels in brain isolated from 9 month-old
APP/PS-1 mice given normal drinking water (p < 0.05, n = 6).
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Figure 11.4a: Levels of GPx in all the treatment groups. There is a significant

decrease in GPx level in brain isolated from APP/PS-1 mice that were given normal
drinking water when compared to WT groups (* p < 0.05, n = 3). Administration of NAC
in drinking water to APP/PS-1 mice increased GPx level significantly in brain. The brain
isolated from APP/PS-1 mice treated with NAC in water shows a significant increase in
GPx levels when compared to the levels in brain isolated from APP/PS-1 mice that were
given normal drinking water (* p < 0.05, n = 3). The data are presented as mean ± SEM
expressed as percentage of control.
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Figure 11.4b: A representative western blot showing levels of GPx in various

treatment groups. GAPDH was used as loading control.
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Figure 11.5: Activity of GPx in all the treatment groups. There is a significant

decrease in GPx activity in brain isolated from APP/PS-1 mice that were given normal
drinking water when compared to WT groups (* p < 0.05, n = 6). Administration of NAC
in drinking water to APP/PS-1 mice increased GPx activity significantly in brain. The
brain isolated from APP/PS-1 mice treated with NAC in water shows a significant
increase in GPx activity when compared to the activity in brain isolated from APP/PS-1
mice that were given normal drinking water (* p < 0.05, n = 6). The data are presented as
mean ± SEM expressed as percentage of control.
11.7. Discussion

Oxidative stress has been implicated in MCI and AD (Butterfield, Drake et al.,
2001; Keller, Schmitt et al., 2005; Butterfield, Poon et al., 2006; Butterfield, Reed et al.,
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2006). Previous studies from our laboratory and others have shown that Aβ(1-42) is
associated with free radical generation leading to proteins and lipids oxidation
(Varadarajan, Yatin et al., 2000; Butterfield, Drake et al., 2001; Butterfield and
Lauderback, 2002). A comprehensive model for neurodegeneration in AD combining two
established notions, viz., elevated oxidative stress in AD brain and centrality of Aβ in the
cause and consequences of this dementing disorder (Butterfield and Lauderback, 2002;
Castegna, Thongboonkerd et al., 2003) was developed by our laboratory. Based on these
and several other well documented notions that support that oxidative stress may be
central to the Aβ-driven neurodegeneration, treatment with brain accessible antioxidants
may be a promising approach for slowing disease progression and oxidative damage that
may be responsible for the cognitive and functional decline observed in MCI or AD.
The oxidation of proteins by free radicals-mediated protein oxidation may be
responsible for damaging enzymes critical in neuronal function (Varadarajan, Yatin et al.,
2000; Butterfield, Boyd-Kimball et al., 2003). By using proteomics, our laboratory
showed some of the critical proteins that are oxidized in AD and MCI (Castegna,
Aksenov et al., 2002a; Castegna, Aksenov et al., 2002b; Castegna, Thongboonkerd et al.,
2003; Butterfield, Poon et al., 2006). One such protein was peptidyl-prolyl cis/trans
isomerase (Pin 1). Pin 1 is oxidatively dysfunctional in AD (Sultana, Boyd-Kimball et al.,
2006a) and MCI (Butterfield, Poon et al., 2006) and is down-regulated in AD brain
(Sultana, Boyd-Kimball et al., 2006a). The present results demonstrate elevated levels of
Pin 1 n 9 month-old APP/PS-1 mice treated with NAC in drinking water compared to the
levels in 9 month-old APP/PS-1 mice given drinking water. The oxidative modification
of proteins either by introduction of carbonyl functionality or by nitration of tyrosine
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residues leads to formation of protein-protein cross-linked aggregates that often changes
the conformation, including protein unfolding of functional protein, thereby rendering a
protein inactive (Butterfield and Stadtman, 1997; Stadtman and Berlett, 1997). In the
present study, we showed the ability of in vivo NAC to provide neuroprotection against
protein oxidation as indexed by protein carbonyls and 3NT (Stadtman and Berlett, 1997),
in APP/PS-1 mice on subsequently isolated brain. There was a significant reduction in
protein oxidation in brain isolated from AAP/PS-1 mice that were given NAC in drinking
water when compared to the protein oxidation in brain isolated from APP/PS-1 mice that
were given normal drinking water. This implicate the efficacy of NAC in preventing
Aβ(1-42)-mediated protein oxidation in he model of MCI or early AD.
Elevated level of lipid peroxidation products, such as HNE and acrolein are
observed in AD and MCI brain and in a model of MCI (Sayre, Zelasko et al., 1997;
Lauderback, Hackett et al., 2001; Butterfield, Reed et al., 2006; Mohmmad Abdul,
Sultana et al., 2006). These reactive alkenals form the immediate substrate for GSH
(Lovell, Xie et al., 1998; Xie, Lovell et al., 1998). These lipid peroxidation products are
also known to be involved in apoptosis, which is seen as a consequence of GSH depletion
(Mark, Lovell et al., 1997). HNE and other reactive alkenals can bind to the functional
protein and render them inactive (Lauderback, Hackett et al., 2001). In the present study
we looked at the levels of protein-bound HNE in all the groups. There was a significant
reduction in protein-bound HNE levels in brain isolated from AAP/PS-1 mice that were
given NAC in drinking water when compared to the protein-bound HNE levels in brain
isolated from APP/PS-1 mice that were given normal drinking water (Figure 11.3). The
increase in endogenous GSH levels following in vivo administration of NAC (Pocernich,
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La Fontaine et al., 2000) may be the reason behind decreased HNE levels. Reduce the
level of lipid peroxidation product implicate less oxidative stress (Butterfield and
Lauderback, 2002).
Decreased levels of GSH are associated with aging and neurodegeneration (Liu
and Choi, 2000; Butterfield, Castegna et al., 2002a) and therapeutic interventions based
on elevation of GSH levels have been shown to be protective against oxidative stress
conditions of the brain (Koppal, Drake et al., 1999a; Pocernich, Cardin et al., 2001). A
variety of well established potential antioxidant compounds are under investigation to
prevent Aβ-induced toxic effects (Anderson and Luo, 1998; Behl, 2002; Grundman and
Delaney, 2002; Boyd-Kimball, Sultana et al., 2005c). Previously our laboratory showed
elevated GSH levels in NAC injected mice and its protective effect on protein and lipid
oxidation against hydroxyl radical and peroxynitrite-mediated oxidative stress (Koppal,
Drake et al., 1999a; Pocernich, La Fontaine et al., 2000). In the present study we
measured the expression and activity of one of the key GSH related enzyme, GPx. GPx
protects the neurons from oxidative stress by catalyzing the reduction of H2O2 at the
expense of GSH (Sies, 1999; Hansen, Go et al., 2006). There was a significant elevation
in protein expression levels of GPx in brain isolated from AAP/PS-1 mice that were
given NAC in drinking water when compared to the levels in brain isolated from
APP/PS-1 mice that were given normal drinking water. Consistent with the increased
GPx expression, we also observed an increased activity of GPx enzyme in brain isolated
from AAP/PS-1 mice that were given NAC in drinking water when compared to the GPx
activity in brain isolated from APP/PS-1 mice that were given normal drinking water. A
lower expression and activity of GPx in APP/PS-1 mice implicate less clearance of H2O2
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and increased ROS. NAC increases the activity and expression of GPx, in vivo, thereby
more clearance of H2O2 and less ROS-mediated protein oxidation and lipid peroxidation
as observed in this study.
The ability of in vivo NAC to prevent inherent oxidative stress, possibly due to
increased Aβ(1-42), in this APP/PS-1 mouse model of MCI and AD could also be related
to its other properties, such as its function as anti-inflammatory and as activator of
several other protective signaling pathways as discussed earlier. Thus, we suggest that
multiple biological functions of NAC could potentially contribute to counteract Aβdriven neurotoxicity in the APP/PS-1 mice brain. Preliminary result also suggest that
NAC increases the expression of Pin 1 (data not shown), a cell cycle protein, that is
known to be oxidatively modified and down-regulated in AD brain (Sultana, BoydKimball et al., 2006a). However, its potential antioxidant property and role as GSH
precursor is clear. Consistent with this notion, we showed decreased protein oxidation
and lipid peroxidation in APP/PS-1 mice administered NAC, in vivo (Figure 11.1-11.3).
The study also suggests that administration of lower concentration of NAC over a period
of time could act as a preventive measure towards oxidative stress-mediated
neurodegenerative disorders, such as MCI. In conclusion, the present study demonstrated
the ability of NAC to act as a potent antioxidant in vivo, thereby providing
neuroprotection against Aβ-induced inherent oxidative stress in model of MCI or AD,
although additional studies are required to determine if this notion has merit. Studies to
elucidate the mechanistic aspects of neuroprotection by NAC in APP/PS-1 mouse model
of AD are on progress.
Copyright © Gururaj Joshi 2006
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Chapter 12
Conclusion and future studies
12.1 Conclusions

The work in this dissertation examined antioxidant properties of a GSH mimetic
and GSH precursor against oxidative stress-mediated neurodegenerative disorders.
Specifically, the role of in vivo D609 protection against Fe2+/H2O2, AAPH and Aβ (142)-mediated oxidative stress in brain synaptosomes or mitochondria, the ability of in
vivo GCEE to reduce ADR-mediated oxidative stress in brain, and in vivo NAC-mediated

protection against oxidative stress in APP/PS-1 mouse model of AD were examined.
The protection of synaptosomes and mitochondria, in vivo, by D609 is arguably
due to presence of the thiol group in D609 that forms basis for its antioxidant property.
Our group previously showed that the methylated derivative of D609 is inactive against
oxidative stress-mediated by Aβ (1-42) in neuronal cultures (Sultana, Shelley et al.,
2004). The thiol group in D609 could react with lipid peroxidation products and form
Michael adducts and prevent these reactive lipid peroxidation products from causing
neurotoxicity. Intraperitoneal (i.p.) injection of D609 (50mg/kg) to gerbils, followed by
isolation of synaptosomes and mitochondria from brain showed protection against
oxidative stress-mediated by Fe2+/H2O2, AAPH and Aβ (1-42) when compared to their
respective control that were injected i.p. with saline. Furthermore, a significant alteration
of the GSH/GSSG ratio towards more oxidized form was observed in brain mitochondria
isolated from saline-injected gerbils that were subsequently treated with Fe2+/H2O2,
AAPH and Aβ (1-42). D609 maintained the GSH/GSSG ratio towards the more reduced
form in mitochondria isolated from D609-injected gerbils subsequently treated with
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Fe2+/H2O2, AAPH and Aβ (1-42) when compared to control. These studies on an animal
model could form the basis for eventual treatment strategies for oxidative stress related
neurodegenerative disorders.
GCEE, a GSH precursor, was used to study its antioxidant properties against
ADR-mediated oxidative stress. We observed that ADR, a cancer chemotherapeutic drug,
is involved in oxidative stress in brain. Injection (i.p.) of ADR (20 mg/kg) causes
significant protein oxidation and lipid peroxidation in brain. ADR also increases the
expression of detoxification enzyme and protein, GST and MRP-1, respectively, in brain
and alters GSH levels and GSH-dependent enzyme activities. By using redox proteomics
we identified several important proteins that were oxidized in brain isolated from ADRinjected mice when compared to control. In vivo GCEE (150 mg/kg) showed protection
against ADR-mediated alteration in GSH levels and significantly decreased protein
oxidation and lipid peroxidation in brain isolated from ADR-injected mice that were
previously injected with GCEE. The protection of brain against the oxidative damage
caused by in vivo ADR by GCEE is consistent with previous other studies in which
GCEE protected neurons in vitro AD-related amyloid beta-peptide (Boyd-Kimball,
Sultana et al., 2005c) or brain in vivo against peroxynitrite-induced oxidative stress
(Drake, Kanski et al., 2002). Further studies on an animal model could form the basis for
an eventual treatment strategy for preventing oxidative stress mediated by ADR. The
results shown in this dissertation research suggest that GCEE-mediated increment in
brain GSH levels and the activity of GST could be a potential therapeutic approach
towards modulating cognitive impairment in patients undergoing chemotherapy.
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Lastly, NAC, a GSH precursor, was examined in the APP/PS-1 mouse model of
AD. NAC was given to the mice in their drinking water (2mg/kg/day) over a period of
five months and oxidative stress parameters were studied. The results reported in this
dissertation research showed that NAC has ability to reduce brain protein oxidation and
lipid peroxidation in APP/PS-1 mice that our group had shown was due to Aβ (1-42)
(Mohmmad Abdul, Sultana et al., 2006). APP/PS-1 mice are known to show an
accelerated Aβ production in brain and have pathology reminiscent of that AD brain.
Apart from protecting brain from protein oxidation and lipid peroxidation, NAC also
increased the protein expression levels of several antioxidants and the key modulatory
protein, Pin 1, in brain isolated from APP/PS-1 mice when compared to wild type. NAC
is a FDA-approved drug and has been used in several studies involving
neurodegeneration, such as ALS, AD among others. The findings of this dissertation
study is particularly relevant to AD brain because of several lines of evidence involving
Aβ (1-42)-mediated oxidative stress in AD brain.
12.2 Future studies

Based on the findings in this dissertation, the following experiments may warrant
exploration:
1.

Because many neurodegenerative disorders involve mitochondrial

dysfunction and our study showed that D609 can protect brain mitochondria from various
oxidative stress inducers, it would be useful to look for its effect in mice models of
various neurodegenerative disorders, such as AD, PD and ALS. Further, using a redox
proteomics approach that can identify specifically oxidized protein, one can determine
the identity of proteins specifically protected by D609 in vivo.
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2.

It is now clear from studies described in this dissertation that ADR causes

oxidative stress in brain and GCEE protects against ADR-mediated oxidative stress. We
used proteomics to identify proteins that are specifically oxidized and differentially
expressed in brain isolated from ADR-injected mice. A similar kind of study can be
useful to determine if these ADR-mediated oxidized proteins are protected by in vivo
administration of GCEE. Further, compounds that can elevate the GSH level and have
similar action as GCEE should be examined in the mice injected with ADR.
3.

Preliminary studies described in this dissertation show that NAC can

reduce oxidative stress in the APP/PS-1 mouse model of AD. Further studies are required
to investigate the mechanistic aspects of the mode of action of NAC in its ability to
protect against oxidative stress. One of the key parameters that will be useful is to
examine is the levels of GSH and GSSG and their ratio in NAC-treated mice. GSH
elevation could be the important factor towards NAC’s ability towards protection against
oxidative stress in APP/PS-1 mice. Proteomics can be used to investigate the proteins that
are specifically protected from oxidation in these mouse models and should be correlated
with proteomics studies conducted on human AD samples already reported from our
laboratory.

Copyright © Gururaj Joshi 2006
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Appendix I
In Vivo Protection of Synaptosomes from Oxidative Stress Mediated by 2,2-Azobis
(2-amidino-propane) Dihydrochloride (AAPH) or Fe2+/H2O2 by Ferulic Acid Ethyl
Ester (FAEE): Insight into Mechanisms of Neuroprotection and Relevance to
Oxidative Stress Related neurodegenerative Disorders
A.1. Overview of the study

Ferulic acid ethyl ester (FAEE) is an ester derivative of ferulic acid, the latter
known for its anti-inflammatory and antioxidant properties. Previous studies from our
laboratory have shown that ferulic acid protects synaptosomal membrane system and
neuronal cell culture systems against hydroxyl and peroxyl radical oxidation. FAEE is
lipophilic and is able to penetrate lipid bilayer. Previous studies reported that FAEE
reduces Alzheimer’s amyloid β peptide Aβ (1-42)-induced oxidative stress and
cytotoxicity in neuronal cell culture by direct radical scavenging and by inducing certain
antioxidant proteins. In the present study we tested the hypothesis that FAEE would
provide neuroprotection against free radical oxidative stress in vivo. Synaptosomes were
isolated from the gerbils that were previously injected intraperitoneally (i.p.) with FAEE
or DMSO and were treated with oxidants, Fe2+/H2O2 or 2,2- Azobis (2-amidino-propane)
dihydrochloride (AAPH). Synaptosomes isolated from the gerbil previously injected i.p.
with FAEE and treated with Fe2+/H2O2 and AAPH showed significant reduction in
reactive oxygen species (ROS), levels of protein carbonyl, protein bound 4hydroxynonenal (HNE, a lipid peroxidation product), and 3-nitrotyrosine (3NT, another
marker of protein oxidation formed by reaction of tyrosine residues with peroxynitrite)
compared to Fe2+/H2O2 or AAPH induced oxidative stress in synaptosomes isolated from
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the brain of gerbils that were previously injected with DMSO. The synaptosomes isolated
from gerbil pre-injected with FAEE and subsequently treated with AAPH or Fe2+/H2O2
showed induction of heme oxygenase (HO-1) and heat shock protein 70 (HSP-70) but
reduced inducible nitric oxide synthase (iNOS) levels. These results are discussed with
reference to potential use of this lipophilic antioxidant phenolic compound in the
treatment of oxidative stress related neurodegenerative disorders.
A.2. Introduction

Alzheimer’s disease (AD), an age-associated dementing disorder, and many other
neurodegenerative disorders, are characterized by free radical mediated oxidative stress
in brain (Hensley, Hall et al., 1995; Markesbery, 1997; Stadtman and Berlett, 1997;
Butterfield, Drake et al., 2001; Kanski, Lauderback et al., 2001; Butterfield and
Lauderback, 2002). AD, characterized by the presence of senile plaques, neurofibrillary
tangles and loss of synapses, affects more than four million Americans and is one of the
leading causes of death in United States (Katzman and Saitoh, 1991). The free radicalmediated reactive oxygen species (ROS) and reactive nitrogen species (RNS) generated
in brain can lead to protein oxidation (Hensley, Hall et al., 1995; Stadtman and Berlett,
1997), DNA and RNA oxidation (Gabbita, Lovell et al., 1998; Lovell, Gabbita et al.,
1999; Butterfield, Drake et al., 2001), lipid peroxidation (Sayre, Zelasko et al., 1997;
Markesbery and Lovell, 1998; Butterfield and Lauderback, 2002) and neuronal
dysfunction or death. Increased production of ROS and RNS along with depletion in
antioxidant capacity is observed in AD and other neurodegenerative disorders
(Butterfield, 1997; McIntosh, Trush et al., 1997; Omar, Chyan et al., 1999; Varadarajan,
Yatin et al., 2000). Proteomics analysis of protein from AD brain and from models
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thereof, demonstrates oxidative modification of key proteins that are involved in
metabolism, exitotoxicity, proteosomal function, lipid asymmetry and redox balance in
brain (Castegna, Aksenov et al., 2002a; Castegna, Aksenov et al., 2002b; Calabrese,
Stella et al., 2004; Poon, Calabrese et al., 2004). Several lines of evidence show that in
models of AD, oxidative stress leads to lipid peroxidation, which releases reactive
alkenals that binds to proteins and cause their dysfunction (Mark, Lovell et al., 1997;
Sayre, Zelasko et al., 1997; Subramaniam, Roediger et al., 1997; Markesbery and Lovell,
1998; Butterfield and Lauderback, 2002). It has also been reported that ROS and RNS
mediated oxidative stress leads to apoptosis in neuronal cell cultures (Butterfield,
Castegna et al., 2002b; Butterfield and Lauderback, 2002). Hence, ROS and RNS
generation becomes important in understanding oxidative stress and oxidative stress
related disorders.
Antioxidant intervention is gaining significance as a promising therapeutic
strategy in treating neurological disorders, and many antioxidants and chemicals that
mimic antioxidants in the free radical scavenging properties are under investigation (Xie,
Lovell et al., 1998; Halliwell, 2001; Pocernich, Cardin et al., 2001; Drake, Kanski et al.,
2002; Boyd-Kimball, Sultana et al., 2005c; Joshi, Sultana et al., 2005a). Natural plant
products are been studied in great deal with reference to antioxidant therapy for
neurodegenerative disorders as they have minimal pathological and toxic side effects
associated with oxidative stress (Halliwell, 2001; Butterfield, Castegna et al., 2002a) in
contrast to side effects of a number of synthetic drugs.
Ferulic acid (4-hydroxy-3-methoxycinnamic acid) is a phenolic compound and a
component of fruits and vegetables, such as tomatoes. Ferulic acid has in vitro free
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radical scavenging properties toward hydroxyl radical, peroxynitrite and oxidized lowdensity lipoprotein (Yu, Hong et al., 1999; Kanski, Aksenova et al., 2002; Kikuzaki,
Hisamoto et al., 2002; Ogiwara, Satoh et al., 2002). In vivo protection against [Aβ (142)]-induced toxicity in brain and also suppression of [Aβ (1-42)]-mediated
immunoreactivities of the astrocyte marker glial fibrillary acidic protein (GFAP) and
interleukin-1 beta (IL-1 beta) in the hippocampus have been reported (Kim, Cho et al.,
2004). Studies from our lab showed protective effects of ferulic acid towards hydroxyl
and peroxyl free radical-mediated oxidative stress in synaptosomes and neuronal cell
culture (Kanski, Aksenova et al., 2002).
Ferulic acid ethyl ester (FAEE) (Ethyl 4-hydroxy-3-methoxycinnamate) (Figure
A.1) is the ethyl ester, derivative of ferulic acid, the latter known for its antiinflammatory and antioxidant properties as noted above (Yan, Cho et al., 2001; Kikuzaki,
Hisamoto et al., 2002). The ester group of FAEE make the compound more hydrophobic
and lipophilic when compared to ferulic acid and hence a better potential antioxidant with
respect to brain (Scapagnini, Butterfield et al., 2004). FAEE induces expression of heme
oxygenase (HO-1) in astrocytes at both the message and protein levels (Scapagnini,
Butterfield et al., 2004; Sultana, Ravagna et al., 2005)produces biliverdin and eventually
bilirubin, both known for their antioxidant activity (Scapagnini, Butterfield et al., 2004;
Sultana, Ravagna et al., 2005). Recently, our laboratory characterized the protective
effect of FAEE on the in vitro oxidative stress induced by Aβ (1-42) in rat primary
neuronal cell culture by inducing HO-1 and heat shock protein 72 (HSP-72) and by
suppressing inducible nitric oxide synthase (iNOS) (Sultana, Ravagna et al., 2005).
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A.3. Purpose of the study

The present study was designed to test the hypothesis that FAEE in vivo would
protect synaptosomes subsequently isolated from gerbils against oxidative stress induced
by Fe2+/H2O2 (hydroxyl radical formation) and AAPH (alkoxyl and peroxyl radical
formation). We examined whether the in vivo protective effect of FAEE on oxidative
damage in synaptosomes might be mediated by increased expression of HO-1 and HSP70 and decreased expression of iNOS, as is the case in vitro (Sultana, Ravagna et al.,
2005).

CH3CH2O

O

OCH3
OH

Figure A.1: Ethyl 4-hydroxy-3-methoxycinnamate or Ferulic acid ethyl ester

(FAEE)

A.4. Experimentals
A.4.1. Animals

For all the studies male Mongolian gerbils (2-3 months of age), approximately
80 g in size, housed in the University of Kentucky Central Animal Facility in 12-h
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light/dark conditions and fed standard Purina rodent laboratory chow ad libitum, were
used. The University of Kentucky Animal Care and Use Committee approved the animal
protocols. The animals were divided in three groups. One group was injected i.p. with
150-mg/kg bodyweight of FAEE (dissolved in dimethyl sulfoxide [DMSO]) one hour
prior to decapitation and the other groups were given equivalent amount of DMSO at the
same time. The concentration and time of FAEE were based on dose-dependent and timedependent responses (data not shown).
A.4.2. Chemicals

All chemicals, including FAEE, were purchased from Sigma-Aldrich (St. Louis,
MO), unless stated otherwise. Fresh 10 mM stock solution of 2,7-dichlorofluoroscin
diacetate (DCFH-DA) was prepared in ethanol for the DCF fluorescence assay. Fresh
FAEE was prepared in DMSO. The protein oxidation detection kit was purchased from
Intergen (Purchase, NY) and primary antibody for HNE and 3NT were purchased from
Chemicon International. Anti-HO-1, anti-iNOS, anti-HSP-70 and anti- -actin primary
antibodies and alkaline phosphatase-conjugated secondary antibodies were purchased
from Santa Cruz Biotechnology (Santa Cruz, CA).
A.4.3. Preparation of Synaptosomes

Synaptosomes were isolated from gerbils injected i.p. with DMSO (control) or
with FAEE (150mg/kg body weight), 1h after injection. The synaptosomal isolation
procedure has been described elsewhere (Whittaker, 1993). Briefly, the gerbils were
sacrificed by decapitation and the brain was isolated on a cold plate and placed in 0.32M
sucrose isolation buffer containing 4μg/ml leupeptin, 4μg/ml pepstatin, 5 μg/ml aprotinin,
2mM ethylenediaminetetraacetic acid (EDTA), 2mM ethylene glycol-bistetraacetic acid
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(EGTA) and 20mM 4-(2-hydroxyethyl)-1-piperazine-ethanesulfonic acid (HEPES),
trypsin inhibitor (20μg/ml), and 0.2mM phenylmethanesulfonyl fluoride (PMSF), pH 7.4.
The whole brain was homogenized by 20 passes with a Wheaton tissue homogenizer. The
homogenate was centrifuged at 1500 g for 10 min. The pellet was discarded and the
supernatant was retained and centrifuged at 20000 g for 10 min. The resulting pellet was
resuspended in approximately 1ml of 0.32M sucrose isolation buffer and layered over a
discontinuous sucrose gradient (0.85M pH 8.0, 1.0M pH8.0, 1.18M pH8.5 sucrose
solutions each containing 2mM EDTA, 2mM EGTA and 10mM HEPES) and spun at
82500 g for 1h at 4o C. The purified synaptosomes were collected from the sucrose
gradient interface at the 1.0/1.18M interface and twice washed with phosphate buffered
saline containing 0.01% (w/v) sodium azide and 0.2% (v/v) Tween 20 (PBS) and
centrifuged at 32000 g. The resulting synaptosomal membranes were assayed for protein
concentration by Pierce BCA method (Bradford, 1976). The synaptosomes obtained were
divided in two aliquots. One aliquot was incubated with 30 μM FeSO4 and 10 mM H2O2,
and the other aliquot was incubated with 1mM AAPH for 1h at 37o C. Both the
concentrations were based on prior studies (Joshi, Sultana et al., 2005a). The
synaptosomes isolated from DMSO-injected gerbils were treated with equal volume of
buffer. The synaptosomal samples were washed following incubation and suspended in
PBS for further studies.
A.4.4. DCF fluorescence

The DCF fluorescence procedure has been described elsewhere (Wang and
Joseph, 1999). Briefly, 10 μM DCFH-DA was incubated with synaptosomes (1mg/ml)
for 30 minutes at 37o C. Intracellular esterases convert DCFH-DA into anionic DCFH,
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which because of its negative charge is trapped in the synaptosomes. Upon oxidation with
ROS, the non-fluorescent DCFH is converted to fluorescent 2,7- dichlorofluoroscein
(DCF). Synaptosomes were spun at 3000 g in a tabletop Eppendorf centrifuge for 5
minutes at 4o C. Synaptosomes were suspended in 500 μl of PBS and loaded in triplicate
(100 μl per well) in a black microtiter plate and the fluorescence was measured in a
Spectramax microtiter plate reader (λex = 495nm, λem = 530nm) and quantified using
softPro max software. Similar studies were performed with an oxidation-insensitive dye
CDCF-DA (C369) to determine whether ester cleavage or efflux of the dye might
contribute to changes in fluorescence.
A.4.5. Protein carbonyls

Protein carbonyls are the markers of protein oxidation and were assessed by
following the standard protocol described elsewhere (Stadtman and Berlett, 1997).
Samples (5 μl), 12% sodium dodecyl sulfate (SDS) and 10 times diluted 2,4dinitrophenylhydrazine (DNPH) (10μl) from a 200 mM stock solutions, were incubated
at room temperature for 20 min. Samples were neutralized with 7.5μl neutralization
solution (2M Tris in 30% glycerol). The resulting solution was loaded in each well on a
nitrocellulose membrane under vacuum using a slot blot apparatus. The membrane was
blocked in blocking buffer (3% bovine serum albumin) for 1h and incubated with a 1:100
dilution of anti DNP polyclonal antibody in phosphate buffered saline containing 0.01%
(w/v) sodium azide and 0.2% (v/v) Tween 20 (PBS) for 1h. The membrane was washed
three times in PBS and was incubated for 1 h with an anti-rabbit IgG alkaline
phosphatase secondary antibody diluted in PBS in a 1:8000 ratio. The membrane was
washed for three times in PBS for 5 min and developed in Sigma Fast tablets (BCIP/NBT
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substrate). Blots were dried, scanned with Adobe Photoshop, and quantified with Scion
Image (PC version of Macintosh compatible NIH image).
A.4.6. HNE

Samples (5 μl) (normalized to 4mg/ml), 5μl of 12% sodium dodecyl sulfate (SDS)
and 5μl of modified Laemmli buffer containing 0.125 M Tris base pH 6.8, 4% (v/v) SDS,
and 20% (v/v) glycerol were incubated for 20 minutes at room temperature. Samples (250
ng) were loaded in each well on a nitrocellulose membrane in a slot blot apparatus under
vacuum. The membrane was blocked as above and incubated with a 1: 5000 dilution of
anti-HNE polyclonal antibody in PBS for 1 h 30 min. The membrane was developed as
described above.
A.4.7. 3NT

Sample (5 μl) (normalized to 4mg/ml), 5μl of 12% sodium dodecyl sulfate (SDS)
and 5μl of modified Laemmli buffer containing 0.125 M tris base pH 6.8, 4% (v/v) SDS,
and 20% (v/v) glycerol were incubated for 20 minutes at room temperature, and the
membranes were developed as described above except a 1:2000 dilution of anti-3-NT
polyclonal antibody was used.
A.4.8. Specificity of HNE and 3-NT antibodies

The specificity for both HNE and 3NT primary antibodies was checked as
described elsewhere (Scapagnini, Butterfield et al., 2004). For example, the samples were
treated with either the HNE or 3NT primary antibody reacted with free HNE or free 3NT, respectively. Very faint, non-specific binding was seen on the HNE blot (data not
shown) that was accounted in the background for each blot. No staining was seen on the
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3-NT blot, suggesting that there was no non-specific binding of the primary 3-NT
antibody (data not shown).
A.4.9. Western blots

Mixtures of loading buffer and synaptosome samples (100 μg) were denatured
and electrophoresed on a 10% SDS-polyacrylamide gel. Proteins were transferred to
nitrocellulose at 90 mA/gel for 2 h. The blots were blocked for 1h in fresh wash buffer
(10 mM tris-HCl [pH7.5], 150 mM NaCl, 0.05% Tween 20, pH 7.4, containing 5%
nonfat dried milk) and incubated with primary antibodies for 1 h (dilutions (1:1000) of
primary anti-HSP 70, iNOS, and HO-1 antibodies were made in wash buffer with 3%
nonfat dry milk). The membrane was washed three times in PBS and was incubated for 1
h with horse radish peroxidase-conjugated secondary antibodies in wash blot at room
temperature. The membrane was washed again for three times in PBS for 5 min and the
bands were visualized using an Amersham chemiluminiscence kit.
A.5. Statistical analysis

Analysis of variance (ANOVA) was used for comparison among the groups and
statistical evaluation. Results are presented as means ± SEM. P values < 0.05 were
considered significant.
A.6. Results
A.6.1. FAEE reduces ROS generation in synaptosomes

ROS generation was measured by using the DCF assay. DCF is formed by
reaction of DCFH with ROS (Wang and Joseph, 1999; Keller, Lauderback et al., 2000;
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Lauderback, Kanski et al., 2002). Figure A.2a shows the ROS levels in synaptosomes
isolated from DMSO-injected gerbils (control), synaptosomes isolated from DMSOinjected gerbils and subsequently treated with Fe2+/H2O2 or AAPH and synaptosomes
isolated from gerbils injected i.p. previously with FAEE and subsequently treated with
Fe2+/H2O2 or AAPH. As reported previously (Joshi, Sultana et al., 2005a), there was a
significant increase in ROS generation in synaptosomes isolated from control gerbils that
were treated with Fe2+/H2O2 or AAPH (p < 0.005) when compared to control.
Synaptosomes isolated from the FAEE-injected gerbils and subsequently treated with
Fe2+/H2O2 or AAPH showed a significant decrease in ROS levels when compared to
synaptosomes treated with Fe2+/H2O2 (p< 0.001) or AAPH (p < 0.005), which were
isolated from DMSO-injected gerbils.
The oxidation-insensitive dye, CDCF-DA (C369) was used in similar studies and
was used as a control experiment to ensure that ester cleavage or efflux of the DCFH was
not contributing to changes in fluorescence. Figure A.2b shows that there was no change
observed in the fluorescence in all the groups, confirming that changes in fluorescence
shown in Figure A.2a were due to oxidation of the dye and not because of drug efflux
changes or ester cleavage.
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Figure A.2a: Significant increase in ROS in synaptosomes isolated from DMSO-

injected gerbils and subsequently treated with Fe2+/H2O2 or AAPH compared to ROS in
synaptosomes isolated from DMSO-injected gerbils. Decreased ROS in synaptosomes
isolated from gerbils injected i.p. with FAEE subsequently treated with Fe2+/H2O2 or
AAPH relative to ROS in synaptosomes isolated from gerbils injected with DMSO and
subsequently treated with Fe2+/H2O2 or AAPH, * p < 0. 005, and ** P < 0.001; the data
are the mean ± SEM expressed as percentage of control values, (n = 6).
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Figure A.2b: Measurement of ROS generation using the oxidation-insensitive

probe C369. The oxidation-insensitive fluorescence probe C369 was used as control to
demonstrate the results of Figure 2a are due to oxidation of DCFH and not due to drug
efflux of DCFH-DA with reaction outside the synaptosomes.
A.6.2. FAEE in vivo inhibits protein oxidation

Protein carbonylation is one of the markers of protein oxidation (Butterfield and
Stadtman, 1997). Protein carbonyl levels in synaptosomes isolated from brains of
DMSO-injected gerbils (control), synaptosomes isolated from control gerbils and
subsequently treated with Fe2+/H2O2 or AAPH, and Fe2+/H2O2 - or AAPH-treated
synaptosomes isolated from brains of gerbils previously injected i.p. with FAEE are
shown in Figure A.3a. A significant increase in protein carbonyl levels is observed in
synaptosomes isolated from control gerbils and subsequently treated with Fe2+/H2O2 or
AAPH (p < 0.005) when compared to untreated control. Synaptosomes isolated from
FAEE-injected gerbils and subsequently treated with Fe2+/H2O2 and AAPH showed
significantly decreased protein carbonyl levels when compared to synaptosomes isolated
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from DMSO-injected gerbils and subsequently treated with Fe2+/H2O2 or AAPH (p <
0.005).
A.6.3. FAEE in vivo prevents nitration of tyrosine residues

3-nitrotyrosine (3-NT) is another marker of protein oxidation (Butterfield and
Stadtman, 1997; Castegna, Thongboonkerd et al., 2003). Levels of 3-NT in synaptosomes
isolated from the brains of DMSO-injected gerbils (control), synaptosomes isolated from
control gerbils and then treated with Fe2+/H2O2 or AAPH and Fe2+/H2O2- and AAPHtreated synaptosomes isolated from gerbils previously injected i.p. with FAEE is shown
in Figure A.3b. There was a significant increase in 3-NT levels in synaptosomes isolated
from DMSO-injected gerbils and subsequently treated with Fe2+/H2O2 or AAPH (p <
0.005) when compared to those of control. Synaptosomes isolated from FAEE-injected
gerbils and subsequently treated with Fe2+/H2O2 or AAPH showed a significant decrease
in 3-NT levels when compared to synaptosomes isolated from DMSO-injected gerbils
and then treated with Fe2+/H2O2 or AAPH (p < 0.005).
A.6.4. FAEE in vivo inhibits HNE formation

Free radical attack on arachidonic acid produces reactive alkenals, such as 4hydroxynonenal (HNE). HNE binds to proteins by Michael addition (Butterfield and
Stadtman, 1997), altering their conformation, and thereby reducing there activity
(Subramaniam, Roediger et al., 1997; Lauderback, Hackett et al., 2001; Zhou,
Lauderback et al., 2001). Figure A.3c shows the protein-bound HNE levels in
synaptosomes isolated from DMSO-injected gerbils (control), synaptosomes isolated
from control gerbils and subsequently treated with Fe2+/H2O2 or AAPH, and Fe2+/H2O2or AAPH- treated synaptosomes isolated from gerbils previously injected i.p. with FAEE.
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A significant increase in protein-bound HNE levels is observed in synaptosomes isolated
from control gerbil brains treated with Fe2+/H2O2 or AAPH (p < 0.005) when compared
to control. Synaptosomes isolated from FAEE-injected gerbils and subsequently treated
with Fe2+/H2O2 or AAPH showed a significant decrease in protein bound HNE levels
when compared to synaptosomes isolated from DMSO-injected gerbils subsequently
treated with Fe2+/H2O2 or AAPH (p < 0.005).

254

180

*

160

*

*

*

%control

140

120

100

80

60

40
Con

tro l

Fe2+

2
EE
/H 2 O
2+FA
H 2O
/
+
2
Fe

AAP

H

AAP

H+FA

EE

Figure A.3a: Significant increase in protein carbonyl levels in synaptosomes

isolated from DMSO-injected gerbils and subsequently treated with Fe2+/H2O2 or AAPH
compared to protein carbonyls in synaptosomes isolated from DMSO-injected gerbils.
Decreased protein carbonyl level in synaptosomes isolated from gerbils injected i.p. with
FAEE and subsequently treated with Fe2+/H2O2 or AAPH relative to protein carbonyl
level in synaptosomes isolated from gerbils, injected i.p with DMSO and subsequently
treated with Fe2+/H2O2 or AAPH, * p < 0. 005; the data are the mean ± SEM expressed as
percentage of control values, (n = 6).
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Figure A.3b: Significant increase in 3-NT levels in synaptosomes isolated from

DMSO-injected gerbils and subsequently treated with Fe2+/H2O2 or AAPH compared to
3-NT in synaptosomes isolated from DMSO-injected gerbils. Decreased 3-NT level in
synaptosomes isolated from gerbils injected i.p. with FAEE and subsequently treated
with Fe2+/H2O2 or AAPH relative to 3-NT level in synaptosomes isolated from gerbils,
injected i.p with DMSO and subsequently treated with Fe2+/H2O2 or AAPH, * p < 0. 005;
the data are the mean ± SEM expressed as percentage of control values, (n = 6).
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Figure A.3c: A significant increase in protein bound HNE levels in synaptosomes

isolated from DMSO-injected gerbils and subsequently treated with Fe2+/H2O2 or AAPH
compared to protein bound HNE in synaptosomes isolated from DMSO-injected gerbils.
Decreased protein bound HNE level in synaptosomes isolated from gerbils injected i.p.
with FAEE and subsequently treated with Fe2+/H2O2 or AAPH relative to protein bound
HNE level in synaptosomes isolated from gerbils, injected i.p with DMSO and
subsequently treated with Fe2+/H2O2 or AAPH, * p < 0. 005; the data are the mean ± SEM
expressed as percentage of control values, (n = 6).
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A.6.5. FAEE in vivo induces HO-1 and HSP-70 expression

Previous studies from our laboratory and those of others have shown induction of
HO-1 and HSP-72 at both the gene and protein levels in cell culture as a protective
response to oxidative challenge (Calabrese, Stella et al., 2004; Scapagnini, Butterfield et
al., 2004; Sultana, Ravagna et al., 2005). In the current study we demonstrated an
increase in expression of HO-1 (Figure A.4a and b) and HSP-70 (Figure A.4c and d) in
synaptosomes isolated from FAEE-injected gerbils, extending the previous in vitro
studies. We also observed a significant increase in HO-1 and HSP-70 expression levels in
synaptosomes isolated from FAEE-injected gerbils and subsequently treated with
Fe2+/H2O2 or AAPH (p < 0.005) when compared to synaptosomes isolated from control
gerbils and compared to synaptosomes isolated from DMSO-injected gerbils
subsequently treated with Fe2+/H2O2 or AAPH, consistent with the observation that both
oxidative stress and FAEE synergistically increased HO-1 expression.
A.6.6. FAEE in vivo suppresses iNOS expression

Several lines of evidence show that iNOS expression increases with oxidative
stress and several antioxidants suppresses its expression either at gene level or at protein
level (Luth, Munch et al., 2002; Ayasolla, Khan et al., 2004). We previously showed that
FAEE suppresses the expression of iNOS in neuronal cell culture exposed to Aβ (1-42)induced oxidative stress (Sultana, Ravagna et al., 2005). Figure A.6 show a decrease in
expression of iNOS in synaptosomes isolated from FAEE-injected gerbils, extending the
in vitro studies. There was a significant increase in iNOS expression levels in

synaptosomes isolated from DMSO-injected gerbils subsequently treated with AAPH (p
< 0.005) when compared to control. In contrast, synaptosomes isolated from FAEE-
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injected gerbils subsequently treated with AAPH showed a significant decrease in iNOS
expression levels when compared to synaptosomes isolated from DMSO-injected gerbils
and then treated with AAPH (p < 0.005). A decreased iNOS expression was observed in
synaptosomes isolated from FAEE-injected gerbils subsequently treated with Fe2+/H2O2
when compared to synaptosomes isolated from DMSO-injected gerbils subsequently
treated with the same oxidant. However the difference was not statistically significant
(data not shown). This is likely due to a larger scatter of the data.
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Figure A.4a and b: Representative Western blot and plot showing a significant

increase in HO-1 expression in synaptosomes isolated from gerbils injected i.p with
FAEE and then treated with AAPH or Fe2+/H2O2 compared with untreated synaptosomes
isolated from DMSO-injected gerbils (control) and control synaptosomes treated with
AAPH or Fe2+/H2O2 respectively, * p < 0.005 Vs Control, (n = 5).
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Figure A.4c and d: Representative western blot and plot showing a significant

increase in HSP-70 expression in synaptosomes isolated from gerbils injected i.p with
FAEE and then treated with AAPH and Fe2+/H2O2 respectively compared with untreated
synaptosomes isolated from DMSO-injected gerbils (control) and control synaptosomes
treated with AAPH or Fe2+/H2O2 respectively * p < 0.005 Vs Control, (n = 5).
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Figure A.5: Representative Western blot and plot showing a significant decrease

in iNOS expression in synaptosomes isolated from gerbils injected i.p with FAEE and
then treated with AAPH compared with control synaptosomes treated with AAPH. There
was a significant increase in iNOS expression in control synaptosomes treated with
AAPH when compared with control showing induction of iNOS in response to oxidative
stress, * p < 0.005 Vs Control, ** p < 0.005 Vs AAPH alone, (n = 5).

A.7. Discussion

High content of polyunsaturated fatty acids, significant oxygen utilization, and
relatively poor antioxidant capacity make the brain particularly vulnerable towards
oxidative stress (Halliwell, 2001; Butterfield and Lauderback, 2002). Due to an
imbalance in the antioxidant system and generation of oxidants such as free radicalmediated ROS and RNS, there is oxidative stress (Yu, 1994; Butterfield, 2002;
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Butterfield and Lauderback, 2002). In AD brain, synaptic membranes in particular are
vulnerable to oxidative damage (Lauderback, Kanski et al., 2002). Receptors for
glutamate are concentrated in synaptic membranes and these receptors mediate increase
in intracellular Ca2+ and exitotoxicity, both of which cause ROS and RNS generation that
lead to subsequent protein oxidation (Hensley, Carney et al., 1994; Hensley, Hall et al.,
1995; Mattson, 1996). Mitochondrial potential change due to increased Ca2+ levels lead
to release of superoxide ion radicals. Since mitochondria are concentrated in the synaptic
region of neurons because of high-energy usage (Mattson, 1996), the synaptic region of
neurons becomes particularly more vulnerable to oxidative stress. Therefore,
synaptosomes were chosen for our studies to evaluate oxidative stress parameters and
investigate likely mechanisms of action of FAEE in vivo.
ROS generation and oxidative stress has been implicated in many
neurodegenerative disorders including AD (Butterfield, Drake et al., 2001). DCF
fluorescence is a useful and reliable technique in quantifying overall oxidative stress in
cells. This method can also be used to evaluate the efficacy of antioxidants against
oxidative stress in cells (Wang and Joseph, 1999). Previously, our lab showed that ferulic
acid scavenges hydroxyl and peroxyl radical in synaptosomes (Kanski, Aksenova et al.,
2002). Ferulic acid can form a resonance-stabilized phenoxy radical with free radicals,
which accounts for its potent antioxidant activity. Recently, we also showed that FAEE
scavenges hydroxyl and peroxyl radical generated in neuronal cultures in response to Aβ
(1-42)-induced oxidative stress (Sultana, Ravagna et al., 2005).
The results shown in Figure A.2a suggest that FAEE has radical scavenging
property. There was a decrease in fluorescence intensity in synaptosomes that were
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isolated from FAEE-injected gerbils and subsequently treated with Fe2+/H2O2 or AAPH
when compared to synaptosomes that were isolated from DMSO-injected gerbils and
subsequently treated with Fe2+/H2O2 or AAPH. Use of an oxidation insensitive dye C369
(Figure A.2b) demonstrated that the fluorescence observed in Figure A.2a is due to ROS
only. FAEE has conjugated double bonds in its structure, which makes it a good
electrophile (Figure A.1). In response to a free radical it can form a resonance-stabilized
phenoxy radical (Lauderback, Kanski et al., 2002). Because of its ester group, FAEE is
more lipophilic than ferulic acid (Scapagnini, Butterfield et al., 2004) and can hence cross
the membrane and trap electrons. This could be the reason for low intracellular ROS in
FAEE-treated rodents, as observed in the DCF assay of this study.
As noted above, free radical mediated oxidative stress leads to protein oxidation
in many neurodegenerative disorders (Butterfield and Stadtman, 1997; Butterfield, Drake
et al., 2001), and protein carbonyls are one of the chief biomarkers for protein oxidation
(Stadtman and Berlett, 1997). Studies from our lab and those of others have shown that
oxidative stress leads to oxidative modification of key protein and enzymes that are
critical for proper biological functions (Castegna, Aksenov et al., 2002a; Castegna,
Aksenov et al., 2002b; Poon, Calabrese et al., 2004). AAPH or Fe2+/H2O2 induce protein
oxidation by increasing protein carbonyl levels (Kanski, Lauderback et al., 2001;
Pocernich, Cardin et al., 2001). Ferulic acid was shown to reduce protein oxidation by
reducing protein carbonyl formation in synaptosomes and cultured neurons (Lauderback,
Kanski et al., 2002). Supporting the hypothesis of the current study, in vivo protection of
synaptosomes from Fe2+/H2O2 or AAPH- mediated oxidative stress was demonstrated by
FAEE. There was a significant reduction in protein carbonyl levels (Figure A.3a) in
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synaptosomes isolated from FAEE-injected gerbils and subsequently treated with
Fe2+/H2O2 or AAPH when compared to synaptosomes isolated from DMSO-injected
gerbils and subsequently treated with Fe2+/H2O2 or AAPH. Attack of free radicals on
some amino acid residues leads to carbonyl formation (Butterfield and Stadtman, 1997).
Other direct reactions to produce protein carbonyls include cleavage of the protein
polypeptide chain or reaction with sugars (glycation) or their glyoxidation products
(Butterfield and Stadtman, 1997). HNE and other lipid peroxidation products such as
malondialdehyde and acrolein bind to proteins by Michael addition and introduce
carbonyl groups in proteins, leading to oxidative modification of proteins (Butterfield and
Stadtman, 1997). As demonstrated in our current study, FAEE in vivo can reduce free
radical generation by scavenging ROS and RNS and thereby reduce the chance of free
radical attack on proteins and hence preventing there oxidative modification.
As in the case of protein oxidation, elevated lipid peroxidation products such as
HNE and acrolein have been observed in many neurodegenerative disorders (Sayre,
Zelasko et al., 1997; Markesbery and Lovell, 1998; Butterfield and Lauderback, 2002;
Zarkovic, 2003; Simpson, Henry et al., 2004). HNE alters the conformation of cortical
synaptosomal membrane proteins and reduces there activity (Subramaniam, Roediger et
al., 1997; Lauderback, Hackett et al., 2001) following binding to proteins by Michael
addition (Butterfield and Stadtman, 1997). Ferulic acid has been shown to modulate the
lipid peroxidation in neuronal cultures and synaptosomes (Lauderback, Kanski et al.,
2002). As noted, we recently reported that FAEE reduces HNE levels in neuronal cell
cultures treated with Aβ (1-42) (Sultana, Ravagna et al., 2005). In the present study we
demonstrated that FAEE in vivo reduces the HNE levels produced by Fe2+/H2O2 or
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AAPH. HNE and other lipid peroxidation products are involved in apoptosis and protein
dysregulation (Subramaniam, Roediger et al., 1997; Butterfield and Lauderback, 2002;
Awasthi, Sharma et al., 2003; Zarkovic, 2003). Several studies have demonstrated that
reducing HNE levels may reduce cytotoxicity (Butterfield, Castegna et al., 2002a; Joshi,
Sultana et al., 2005a; Sultana, Ravagna et al., 2005). In biological systems, several
enzymes are involved in scavenging or removing HNE (Xie, Lovell et al., 1998; Sultana
and Butterfield, 2004) and the proteasomal systems in neurons are responsible for the
removal of HNE-bound oxidized cytosolic and nuclear proteins (Grune and Davies,
2003). The reduced levels of HNE by FAEE in vivo might implicate reduced cytotoxicity
in synaptosomes caused by hydroxyl or alkoxyl free radicals.
Nitration of tyrosine residues on peptides by RNS has been studied as a biomarker
for protein oxidation in many neurodegenerative disorders (Stadtman and Berlett, 1997;
Castegna, Thongboonkerd et al., 2003). Nitric oxide (NO) is poorly reactive with most
biomolecules (except Fe) but reacts vigorously with free radicals such as superoxide
radicals to form peroxynitrite. Peroxynitrite can be protonated to peroxynitrous acid
(ONOOH) and subsequently reacts with CO2 and decompose to nitrogen dioxide radical
(*NO2) and hydroxyl radical (*OH), which posses potent free radical characteristic (Hall,
Detloff et al., 2004). These radicals react with biomolecules resulting in tyrosine nitration
and DNA damage (Beckman, Beckman et al., 1990). One possible cause of oxidative
stress is excessive generation of NO from L-arginine and nitric oxide synthase (NOS)
(Park, Krishna et al., 2000). Synthesis of NO from inducible NOS (iNOS) has been
correlated with a cytotoxic or inflammatory response in the immune system (Park,
Krishna et al., 2000). iNOS is specifically expressed as a response to immunological
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stimulus during certain pathophysiological conditions (Bredt, 1999). Hence, study of
iNOS expression might provide an insight into the effect of pharmacological agents in
response to inflammation. We previously showed increased 3NT levels and iNOS
expression in cultured neurons treated with Aβ (1-42), an expression that was attenuated
by FAEE treatment (Sultana, Ravagna et al., 2005). Consistent with our in vitro data,
here we demonstrated in vivo reduction in 3NT levels in synaptosomes isolated from
FAEE-injected gerbils and subsequently treated with AAPH or Fe2+/H2O2 when
compared to synaptosomes isolated from DMSO-injected gerbils and subsequently
treated with AAPH or Fe2+/H2O2 (Figure A.3b). We also demonstrated reduced iNOS
expression in synaptosomes isolated from FAEE-injected gerbils and subsequently
treated with AAPH compared to that in synaptosomes isolated from DMSO-injected
gerbils and subsequently treated with AAPH (Figure A.5). FAEE is known for its antiinflammatory properties. The data obtained suggest that FAEE may be able to reduce NO
production by reducing the expression of iNOS reflecting lower inflammation and
nitration of tyrosine residues on proteins.
The involvement of heme oxygenase (HO) or heat shock protein (HSP) responses
in oxidative stress-related disorders, including AD, has gained considerable importance in
recent years (Poon, Calabrese et al., 2004). The expression of HO-1, an inducible isoform
of HO, has been closely related to that of amyloid precursor protein (APP) (Dore, 2002).
During various pathophysiological conditions, induction of HO-1 (also called HSP-32)
catabolizes heme and generates carbon monoxide (CO) and biliverdin (and subsequently
bilirubin), a potent antioxidant and anti-inflammatory agent (Calabrese, Stella et al.,
2004). The expression of HO-1 is also reported to be upregulated during oxidative stress,
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as well as by GSH depletion (Tyrrell, 1999; Calabrese, Stella et al., 2004). The HO
pathway has been shown as an important defense system in neurons under oxidative
stress (Le, Xie et al., 1999; Chen, Gunter et al., 2000) and expression of HO-1 is altered
at the gene and protein levels in AD and other neurodegenerative disorders seen in some
neurodegenerative disorders including AD (Pappolla, Chyan et al., 1998; Schipper, 2000;
Takahashi, Dore et al., 2000; Takeda, Perry et al., 2000). Previously we demonstrated
that FAEE protects rat neuronal culture against oxidative damage and increases cell
viability by inducing HO-1 expression both at m-RNA and protein level (Scapagnini,
Butterfield et al., 2004; Sultana, Ravagna et al., 2005). This protective effect was
attenuated in the presence of Zinc protoporphyrin IX, an inhibitor of HO activity
(Scapagnini, Butterfield et al., 2004; Sultana, Ravagna et al., 2005). Similarly, in the
current in vivo study we demonstrated protection of synaptosomes isolated from FAEEinjected gerbils against oxidative stress by inducing HO-1 and HSP-70 expression
(Figure A.4a, b, c, and d, respectively). Although there was an increase in the expression
of HO-1 and HSP-70 in synaptosomes isolated from DMSO-injected gerbils,
subsequently subjected to oxidative insult when compared to untreated controls, the
further increased expression of HO-1 and HSP-70 in synaptosomes isolated from FAEEinjected gerbils subsequently exposed to oxidative stress is likely due to FAEE in the
system (Scapagnini, Butterfield et al., 2004; Sultana, Ravagna et al., 2005), suggesting
FAEE acts in vivo as a neuroprotective agent against oxidative insult by further inducing
expression of heat shock proteins in brain.
FAEE has been used previously as an antioxidant agent that has protective effects
in in vitro models. We extended these results to an in vivo model and validated some of
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our previous in vitro studies. The probable multifunctional mechanism of action of FAEE
involves direct scavenging of radicals, up-regulation of HO-1 and HSP 70 and downregulation of iNOS (Figure A.6). These in vivo studies on an animal model of oxidative
stress could form the basis for an eventual therapeutic approach towards oxidative stressrelated disorders, although further studies are required to establish merit in this notion.
Studies on the effect of FAEE on genetically derived animal models of oxidative stressrelated disorders are in progress.
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Figure A.6: Schematic representation of proposed mechanisms of

neuroprotection for FAEE. (+), induction; (-), inhibition; HSP 70, heat shock protein 70;
HO-1, heme oxygenase-1; iNOS, inducible nitric oxide synthase.
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